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Abstract 
Introduction: Chronic lower limb oedema (CLLO) is a common but often 
unrecognised problem amongst people with multiple sclerosis (pwMS), for which 
treatment is rarely provided. The prevalence of CLLO in pwMS has been 
examined in some countries such as Italy and the UK, however, due to the 
scarcity of evidence it is very difficult to approximate how common the problem 
is in developing countries. Added to this, research conducted to date on the 
management of chronic oedema and lymphoedema has focussed primarily on 
patients with cancer. CLLO related to other aetiologies warrants further 
investigation. 
Methodology: This mixed methods study aimed to gain an improved 
understanding of the prevalence and impact of CLLO in pwMS and the 
contribution of progressive resistance exercise on its remediation. The study was 
undertaken in two hospitals in Riyadh city, in the Kingdom of Saudi Arabia. 
Phase one of this study aimed to evaluate the prevalence of CLLO in pwMS who 
are resident in the Kingdom of Saudi Arabia and attends one of the two hospitals 
and to determine the main characteristics of those at increased risk of developing 
CLLO. This study screened 269 pwMS for CLLO. Data were analysed using 
univariate and bivariate analysis using SPSS software version 26. Continuous 
and categorical variables were examined using the Students t and Chi-square 
tests. 
Phase two of the study aimed to assess the effectiveness of Progressive 
Resistance Exercise (PRE) in the management of CLLO in pwMS who are 
resident in the Kingdom of Saudi Arabia and to determine the impact of CLLO on 
pain and quality of life.  Those who were found to have CLLO during phase one 
screening were invited to participate in phase two. Fifteen participants with 
bilateral CLLO agreed to participate in this phase. They performed a biweekly 
PRE programme for 12-weeks. The participants were assessed before and 
following the intervention to determine if any changes occurred in lower limb 
circumference, Quality of Life (QoL) or pain.  Limb circumference was measured 
at 4 cm intervals. QoL and pain were measured using the Quality of Life Measure 
for Limb Lymphoedema (LYMQOL) tool and the Short form of the McGill Pain 
Questionnaire (SF-MPQ). 
XIV 
 
Phase three of the study aimed to identify and explore factors that contribute to 
successful or unsuccessful use of PRE from the perspectives of participants.  
During this phase, the knowledge and understanding developed by 
physiotherapists of CLLO in pwMS was explored together with their knowledge 
of current practice in terms of exercise therapy.  Ten pwMS and CLLO and five 
specialist lymphoedema physiotherapists were interviewed. Data were analysed 
using the Framework Method.      
Results: Out of 269 pwMS screened during phase one, 21 (8%) were found to 
have bilateral CLLO. The bivariate analysis between two groups (with CLLO and 
without CLLO) shows statistically significant differences were found in CLLO 
group for all variables (namely: age, weight, BMI, MS duration, EDSS, 
categorical: MS type) except for gender. In phase two, fourteen participants 
completed the intervention with mean age of 44±7.11 years, EDSS 5.6±0.96, BMI 
29.08±7.91 and disease onset 12.92±3.7 years. The result shows no statistically 
significant change in overall legs volume but there was a decrease in some 
segments. A reduction was reported in the SF-MPQ tool in both visual analog 
scale (VAS) and present pain intensity (PPI) domains. Moreover, statistical 
significance increase was found in the LYMQOL tool in the overall QoL domain. 
Three themes emerged from the CLLO participants’ data in phase three: life 
experience before receiving the PRE intervention; participants’ experiences after 
having PRE intervention, and “little changes but they matter”. Data from 
physiotherapists emerged with two themes: awareness about CLLO in pwMS and 
current lymphoedema practice.      
Conclusion: This study concluded that although PRE had no effect on CLLO in 
pwMS, QoL and pain improved significantly after the intervention. The qualitative 
data also showed improvements in physical and psychological well-being. There 
was lack of awareness of CLLO in pwMS among health care providers suggesting 
that this specific gap in knowledge needs to be addressed in order to provide a 
meaningful treatment plan. 
The twelve-week PRE programme may have a secondary impact on some 
aspects of life and there is some evidence of changes in the legs. However, limb 
volume did not change overall.  
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Chapter 1 Introduction and Background  
1.1  Demography of the Kingdom of Saudi Arabia  
In the Gulf Cooperation Council (GCC), the Kingdom of Saudi Arabia (KSA) has 
the largest and fastest growing population (Ram, 2014). According to the KSA 
General Authority for Statistics in 2019, the total KSA population reached 33,400 
million with a 2.52% population growth rate in 2017. More than 55% of the 
population are under 30 years old (‘General Authority for Statistic’, 2019). This 
fast-growing population will place a financial pressure and will increase the 
demand for many services and supporting infrastructure such as educational and 
health care services. 
As the majority of the population are young, the Ministry of Health (MOH) 
launched the National Transformation Program (NTP) 2020 and the Saudi Vision 
2030 to meet the future needs of the population. In the last year, 14 new hospitals 
have been built  leading to a 3% increase in the number of hospital beds available, 
with Riyadh city (the capital) and Makkah seeing the largest increase in capacity 
relative to the population (‘Annual Report of the Ministry of Health’, 2017). Twenty 
six percent of MOH hospitals are based in Riyadh city. As few hospital facilities 
are available in nearby cities, most people with chronic conditions (such as 
multiple sclerosis [MS]) are referred to Riyadh hospitals.  
Multiple sclerosis is an autoimmune long-lasting and recurrent disorder that 
affects people during their most productive years of their life which results in   
many physical, psychological and social consequences (Hudaif, Bwardi and 
Kojan, 2014; Alamri and Al-Busaidi, 2016). This disease group has received 
attention from health care providers over the last two decades in Saudi Arabia 
due to the fast-growing number of young people presenting with the condition 
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and concern about the pressures this will create for the health care system, both 
now and in the future.         
1.2  Multiple Sclerosis in the Kingdom of Saudi Arabia 
Around the world, approximately 2.1 million people in 2008 have been diagnosed 
with MS and by 2013 this number had increased to 2.3 million (Multiple Sclerosis 
International Federation, 2013). Moreover, according to the Atlas of MS, the 
global average prevalence of MS has risen from 30 to 33 per 100,000 individuals 
(ibid).  In 1988, the first paper about MS in the kingdom of Saudi Arabia was 
published by Yaqub and Daif which indicated that there is an increase in the 
incidence of MS in KSA but that it was still considered an uncommon condition 
(Yaqub and Daif, 1988). Ten years later, another paper by Daif et al. about the 
pattern of presentation of MS in KSA, stated that the prevalence rate was 20 per 
100,000 individuals and this  resembled the Western presentation of the type of 
MS (Daif et al., 1998). However, with the gradual increase of incidence  every 
year, it is now believed to be a substantial health care problem (Alshanqiti et al., 
2016). This point is supported by many studies which show an increase in the 
number of people with Multiple Sclerosis (pwMS) has  doubled  that reported two 
decades previously, when it was  reported to affect around 35-40 per 10,000 
individuals (Aljumah et al., 2013; Bohlega et al., 2013; Mohammed, 2016). This 
global increase indicates that there are no signs of levelling off in the prevalence 
of MS.  
In Saudi Arabia, relapsing-remitting MS (RRMS) is the commonest clinical type 
at the onset of the disease  affecting (85%), followed by primary progressive MS 
(PPMS) affecting  10 to 15% of the cases, then progressive relapsing MS (PRMS) 
with 5%  (Aljumah et al., 2013). Secondary progressive MS (SPMS) represents 
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a stage following RRMS where people with RRMS convert to SPMS with time 
and show progressive decline in their neurological condition (ibid). The common 
primary presenting clinical symptoms in KSA residents is  limb weakness (Daif et 
al., 1998). Other frequent physical deficits can be chronic pain, difficulty in 
executing  activities of daily living (ADL), impaired mobility, fatigue, sensory and 
visual disorders (Al Wutayd et al., 2018). These types of dysfunctions can be 
temporary, permanent or progressive for pwMS.   
In 2013, a very valuable report from the World Health Organization and Multiple 
Sclerosis International Federation emphasised the importance of the subject as 
people can experience the consequences of MS for more than 20 years. The 
report (Multiple Sclerosis International Federation, 2013, p.3) stated that: 
“Some people with MS experience little disability during their lifetime, as 
many as 60% may be unable to walk without assistance 20 years after onset. 
This has major implications for the quality of life of people with MS and their 
families and friends, and for the cost to society if their condition is not 
managed adequately.” 
This point is a significant message and must grab the attention of stakeholders in 
the health care system globally, as the long period of immobilization could lead 
to unpleasant and life-threatening consequences.   
1.3  Potential Consequences of Immobilization in people with Multiple 
Sclerosis (pwMS) 
The underlying mechanisms of impaired functional capacity in pwMS could be 
related to neural or muscular deficit or a combination of both (Dalgas et al., 2010). 
In terms of muscular deficit (irrespective of the type and severity of MS), the 
muscle fibres characteristics show changes. Some studies have pointed out a 
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loss in muscle mass along with a shift in the proportion of fibre types from type I 
to type IIa in the lower limb which is similar to results found in immobilized healthy 
controls individuals (Kent-Braun et al., 1997; Dalgas et al., 2010; Wens et al., 
2014). Furthermore, as reported in the Wens et al cross sectional study, the type 
IIa muscle fibre not only has a greater proportion in pwMS but also tends to  
atrophy (Wens et al., 2014). The type IIa muscle fibre is a fast twitch oxidative 
fibre which is ideal for power activities, but they fatigue easily. This could explain 
the reduction in muscle strength seen amongst  pwMS, since the patient cannot 
tolerate activity for a long time (Kjolhede, Vissing and Dalgas, 2012) and as a 
result of these changes, low physical activity may develop  over time (Solaro et 
al., 2006). Therefore, tailoring a rehabilitation program for pwMS must 
concentrate more on preservation and rebuilding muscle strength and consider 
the changes that occur in muscle fibres. 
On the other hand, up to 80% of pwMS show a degree of somatosensory 
impairment and proprioception problems in the lower extremities (Jamali et al., 
2017). This neural deficit as reported in the Jamali et al. prospective cross-
sectional study is associated with limited balance and postural control problems. 
Furthermore, a reduction in plantar sensation was also reported which leads to a 
cautious walking pattern in which speed of walking is reduced (ibid). It should 
also be emphasized that, Fear of Fall (FOF) behaviours can also develop in 
pwMS which is one of the contributing factors that curtail physical activity. This 
was spotted in  cross-sectional data from telephone interviews with 1064 pwMS 
which showed that 63.5% of participants reported FOF and 82.6%  had curtailed 
physical activity (Peterson, Cho and Finlayson, 2007).  
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When the movement capacity of pwMS decreases, the physiological 
mechanisms of calf muscles will be hindered or absent and, as a result, the 
pumping pressure of the calf muscles on the veins and lymphatic vessels will also 
decrease (Faett et al., 2012, 2013). Over time, fluid may accumulate in the 
interstitial space (Faett et al., 2012) which can lead to an inflammatory response, 
causing fibrotic changes in the subcutaneous tissue and hypertrophy of adipose 
tissue (Mayrovitz, 2009). Delays in identifying this issue at an early stage may 
lead to unpleasant outcomes.  
Recent published studies have found a correlation between immobility and 
chronic oedema (CO). One of these studies, a cross-sectional study of 
community nursing services by Moffatt et al. (2019a) aimed to determine the 
number of people with CO and the impact on health services. The study indicated 
that the prevalence of CO was high amongst people with reduced mobility and 
obesity (71.6%, 61.9%), respectively. Similar results were found in a point-
prevalence study of hospital inpatients by Quéré et al. (2019) which reported that 
CO is prevalent in less moblile patients (41.5%) compared to those with heart 
failure (34.7%). Another study in Denmark used the same methods and revealed 
that 44% of in-patients  had secondary lymphoedema as a  result of immobility 
(Nøerregaard et al., 2019).     
Given the neurological and muscular changes that can occur in pwMS and their 
effects on mobility, there is a risk for this population of developing chronic 
oedema.  Limited evidence from the literature has shown the prevalence of CO 
in pwMs (Solaro et al., 2006; Arpaia et al., 2010; Keeley et al., 2017). More in 
depth understanding about the prevalence rate and main characteristics of those 
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at high risk of developing CO in pwMS is systematically reviewed in the next 
chapter.       
1.4  Definition of Chronic Oedema 
There is some confusion regarding the terminology used to describe patients with 
leg swelling.  In some instances, the term ‘chronic oedema’ and ‘lymphoedema’ 
are used interchangeably. Traditionally, the term lymphoedema is a very narrow 
and limited term that is linked to a specific population. It is called primary 
lymphoedema when a congenital abnormality has occurred in the lymphatic 
system but when it is linked to lymphatic damage it is called acquired or 
secondary lymphoedema. Common causes include treatment for cancer and 
other diseases or trauma that adversely affect the lymphatics including damage 
to the venous system through issues such as deep vein thrombosis. Currently 
professionals knowledge is poor and many do not understand the complex 
mechanisms that give rise to both primary and secondary lymphoedema (Moffatt, 
Keeley and Quéré, 2019b).  
In recent years, the understanding of the pathophysiology of the venous and 
lymphatic system  has supported the idea that the lymphatics are involved in all 
forms of chronic oedema  (Bianchi, Vowden and Whitaker, 2012). Chronic 
oedema is the broad term that is used to describe oedema that exists for three 
months or more. The term incorporates the traditional understanding of 
lymphoedema and also chronic swelling that arises from another  more complex 
aetiology (Moffatt, Keeley and Quéré, 2019b). It can occur in one  or more parts 
of the body such as: the upper or lower limbs, upper or lower body, neck and face 
(Moffatt et al., 2003). The causes of chronic oedema are summarized in Table 
1.1. Neglecting this condition may lead to fluid imbalance and accumulation of 
 
8 
 
Chapter 1 Introduction and Background  
protein-rich extracellular fluid in the interstitial spaces as a result of damage or 
failure to lymphatic drainage (Bianchi, Vowden, and Whitaker, 2012; Faett et al., 
2013). The term chronic oedema is therefore a public health term not a diagnostic 
category. 
 
Table 1. 1:  Causes of Chronic Oedema 
 
Vascular: 
• Severe varicose veins 
• Trauma  
• Chronic venous insufficiency 
• Venous hypertension 
• History of deep vein thrombosis 
• Lack of calf muscle and plantar foot pump 
• Phlebitis 
Lymphatic: 
• Congenital abnormality (primary lymphoedema) 
• Burns or orthopaedic surgery (secondary lymphoedema)   
• Cancer treatment (e.g., Radiotherapy) 
Other:  
• Renal or cardiac diseases 
• Obesity  
• Immobility  
• Limb dependency  
• Late stage lipoedema with concurrent lymphoedema  
• Some medications  
 
Unclear nomenclature can impede recognition of this condition and the 
development of clinical services. Added to this, it might limit the understanding of 
the underlying factors that cause the swelling which influence negatively on 
treatment options. Chronic oedema is a more inclusive term, yet it is not a 
diagnosis and the underlying causes should be identified (Moffatt, Keeley and 
Quéré, 2019b). Studies have shown that poor understanding among health care 
professionals about lymphoedema can delay appropriate treatment and this may 
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lead to progression of the condition and deterioration of  Quality of Life (QoL) 
(Morgan, Franks and Moffatt, 2005; Bogan, Powell and Dudgeon, 2007).        
1.5  Economic and Psychosocial Impact of Chronic Oedema 
Chronic oedema and its potential progression to more complicated problems 
such as lymphovenous oedema or lymphoedema can create enormous 
pressures for health care system (Lawrance, 2009). In addition, facing  life-long 
physical, psychological and social difficulties generate  personal  pressures for  
patients which lead to reductions in QoL (Greene and Meskell, 2017). This 
condition can debilitate a person if it is combined with another physical illness 
such as multiple sclerosis (MS). 
 As disability increases, the cost of health care also increases steeply 
(Patwardhan, 2005). Treatment that is related to MS cost the US health care 
system  $47,000 and €18,000 to €31,000 in Europe per annum (Beer, Khan and 
Kesselring, 2012). The one related to chronic oedema cost the health care 
system in the UK for a mean length of 12 days’ hospital stay an estimated mean 
of £2300 when the patient admitted for intravenous antibiotics as a result of acute 
infection (cellulitis) in the affected area (Moffatt et al., 2003). Bills for health care 
systems could increase if pwMS develop chronic lower limb oedema (CLLO) and 
the scenario can be more damaging if the condition is not recognised and treated 
early.  Unfortunately, undetected and/or untreated CLLO in pwMS and non-
oncology related lymphoedema (NORL) is commonly reported in the literature. In 
the Faett et al (2013) prospective longitudinal single cohort study, the 
demographic data shows that all the pwMS who have CLLO for 2 to 7 years had 
not received any treatment for  oedema (Faett et al., 2013). Similarly, a Canadian 
qualitative study of 108 participants identified that limited or no access to 
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treatment was one of the main issues that face the NORL and children with 
lymphoedema (Hodgson et al., 2011).  Unluckily, the consequence of neglect 
through non recognition of CLLO will not only affect the patient physically (e.g. 
Pain, increase swelling and infection, decrease mobility) but it will also affect their 
quality of life (Keast et al., 2015). 
Social isolation, work absenteeism, dependence in  activities of daily living (ADL) 
and low self-esteem relating to body image are all forms of psychosocial 
disabilities that may have  socio-economic implications for patients  (Williams, 
Moffatt and Franks, 2004). In 2003, a study conducted in the UK aimed to 
determine the magnitude of the problem of chronic oedema in the community, 
and the likely impact of oedema on use of health resources, employment and 
patient quality of life by carrying out a questionnaire-based survey supported by 
clinical evaluation and interview. The study reported that 823 patients had CO 
and 80% out of them had taken time off work and 8% had given up work.  
Furthermore, quality of life was reported to below normal and 56% were taking 
regular prescribed analgesia to control pain. The results of this study reflect the 
indirect costs of this condition and the consequences if diagnosis and treatment 
are delayed.  
Other associated impairments to patients QoL have been reported in the literature 
including choosing clothes, footwear, adverse effects on relationships, sexual 
functioning, anxiety, depression and functional impairment (Atkin, 2014; Mercier 
et al., 2019). In Greene & Meskell’s study, a condition-specific tool was used to 
explore the impacts of CLLO on QoL. Ninety participants completed the 
Lymphoedema Quality of Life (LYMQOL) questionnaire and over half of the 
sample had experienced difficulties in finding clothes, footwear, socks and tights 
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to fit the oedematous limb and indicated that CLLO affected their ability to engage 
in leisure activity (Greene and Meskell, 2017).  
In the last decade, the focus of the literature on the negative impacts of CO on 
patients QoL has   increased substantially. However, much of the evidence 
focuses on upper limb oedema or lymphoedema due to breast cancer  with 
scarce attention to  lower limb CO and the broad concept of CO (Greene and 
Meskell, 2017).  
1.6  Current Treatments for Chronic Oedema  
Some people with Multiple Sclerosis (pwMS) face pain, a reduction in muscle 
strength, mobility and somatosensory function (Rejdak, Jackson and Giovannoni, 
2010; Beer, Khan and Kesselring, 2012) which over  a  long-term period could 
promote  development of  CLLO. However, because the prevalence and impact 
of the problem for this population remains unclear (Keeley et al., 2017)  provision 
of care  is rarely considered a priority and services are often limited in whether 
they exist or the range of treatments that are offered.  
Currently, health care delivery is based on controlling, managing and preventing 
the recurrence of lymphoedema symptoms in those with a cancer related 
lymphoedema, and  those with other causes are denied access to care (Moffatt 
et al., 2003).  As a result, there is poor recognition of  chronic condition at an early 
stage which might aggravate the symptoms and lead to potential consequences 
such as acute infection in the affected area (Moffatt et al., 2016). Poor 
understanding about the prevalence of CLLO in pwMS, assessment tools or 
measurements, treatment and best practice among health care providers 
generate this lack of knowledge and skills that they need to improve  quality of 
life and better outcomes (Tiwari, Myint and Hamilton, 2006; Keen, 2008).  
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In the literature, the “gold” standard of  treatment for chronic oedema or 
lymphoedema is a range of components that grouped together under the term 
complete decongestive therapy (CDT) (Lasinski et al., 2012). The treatment 
consists of manual lymphatic drainage (MLD), compression therapy with 
garments or bandages, skin care, exercise, and education in self-care. The 
treatment is provided in two phases: reductive or intensive CDT (phase 1) and 
maintenance CDT (phase 2). The aims of  CDT are to improve  QoL, functioning 
mobility, control and reduce swelling, prevent infections and reduce risk of 
recurrence (Rodrick et al., 2014). The success of this treatment is affected by a 
number of factors, including well-trained and high skilled practitioners (Faett et 
al., 2013), Insurance providers also need to  recognize that compression supplies  
are required for treatment (Moffatt, Keeley and Quéré, 2019b).      
Although compression is considered a standard element of care for 
lymphoedema, the effectiveness of the CDT is often questioned for a variety of 
reasons. First, the importance of each individual component is not clear in the 
literature. It is not known which components of CDT are most effective at reducing 
oedema and what would be the implications if one component of CDT was not 
applied. In addition, as the individual components of CDT are delivered in 
different ways, it is possible this also affects outcomes and interpretation of the 
results. Second, the focus of this treatment is mainly on breast cancer related 
lymphoedema (BCRL) and widening the sample to non-oncology related 
population is not well researched. Third, some components such as exercise and 
self-care education are not well defined in the literature in terms of their 
frequency, intensity, and duration. 
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In 2005, a systematic review by McCallin et al investigated the effectiveness of 
physical therapy treatment for BCRL. The study appraised 20 studies and sought 
to evaluate the strength of evidence in support of CDT and its individual 
components. They found that evidence of the effectiveness of CDT was available 
but the contribution of each component in limb volume reduction was not clear 
(McCallin, Johnston and Bassett, 2005). Similar results were found in 2012 by 
Lasinski et al when they conducted a systematic review of the evidence 
underpinning CDT and individual components in the treatment of lymphoedema. 
Twenty-two articles met inclusion criteria and they concluded that CDT is an 
effective treatment but it was difficult to agree which components were effective 
as the treatment intervention was often bundled and the  interactions between 
each element were difficult to ascertain (Lasinski et al., 2012).  
Although there is an abundance of studies that seek to break down CDT into  
specific components such as MLD or remedial exercise (Schmitz et al., 2009; 
Williams, 2010; Brown et al., 2013), compression therapy is always used in 
conjunction with other  treatment regimen. Compression therapy has strong 
effects on both the lymphatic and venous system (Özdemir et al., 2016). Exertion 
of pressure prevents capillary filtration and helps moving the fluid centrally and 
into areas with functioning lymphatics. The overall skin condition can be improved 
and shape distortion improved allowing increased patient functionality (Lee and 
Wigg, 2012). However, in order to maintain reduction in  limb volume, patients 
need to wear compression bandaging and garments (or equivalent) on a daily 
basis and for the rest of their life as  rebound oedema forms quickly after  removal 
of compression  (Moffatt, 2004; Elwell, 2017). Issues of concordance have not 
been well researched. Non-concordance with compression methods will have a 
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negative influence on the effectiveness of the compression and also on wound 
and could rebound oedema rapidly healing (Moffatt et al., 2009).  
The reasons for non-concordance with compression are complex and lie outside 
the scope of this thesis. It is thought that patients who tend to be less committed 
to using compression therapy have a lack of awareness that compression therapy 
is the primary treatment (Hodgson et al., 2011) or they cannot wear 
garments/bandages because they are uncomfortable or they  have acute cellulitis 
(Brennan and Miller, 1998; Kunimoto et al., 2001). In 2006, a survey study by 
Lam et al. aimed to obtain an overview of patients’ experience with lymphoedema 
(Lam et al., 2006). From the 1,449 patients who responded they concluded that 
those with complicated oedema involving more than one limb were less likely to 
use compression garments. Moreover, pain and discomfort were the main reason 
for ceasing to wear garments (26%) and 15% experienced a problem with the 
fitting of garments. Other factors were intolerance to the material, especially in 
hot weather and swelling around the garment. However, it must be noted that this 
is a biased sample as they were recruited via a patient support group. Therefore, 
they may not represent other sub-sets in the wider population of patients. 
Bearing in mind the weather while tailoring treatment for pwMS who have CO is 
very important especially in hot countries such as Saudi Arabia where the 
temperature can reach 55°C during the summer months. Clinically, heat 
sensitivity was reported in pwMS between 60% to 80% and  the increasing body 
temperature found to be in correlated with worsening MS symptoms (Syndulko et 
al., 1996; Frohman et al., 2011; Beer, Khan and Kesselring, 2012). In agreement 
with these findings Simmons and colleagues found in a multinational internet-
based survey that 70% (n= 2,529) of pwMS reported they were sensitive to heat 
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and this symptom was correlated with fatigue (Simmons et al., 2004). Together 
with the fatigue, also muscle weakness, concentration difficulties and pain was 
correlated with heat sensitivity which reported as predictors of accidental falls 
(Davis et al., 2010; Flensner et al., 2011).   
These physiological changes were reported over 130 years ago, when Professor 
Wilhelm Uhthoff in 1890s - the founder of neuro-ophthalmology - reported a visual 
deterioration in pwMS after having a hot bath. His conclusion helped to shape the 
design of the rehabilitation strategies for the management of MS and restrictions 
in the use of thermal treatments emerged. Explanations of the “Uhthoff 
phenomenon” (UP) and the exact mechanisms of temperature dependency and 
its relationship with worsening the signs and symptoms are complicated and was 
not well known until 2004. In 2004 Humm et al. sought to evaluate UP for the first 
time by using motor evoked potentials to evaluate conduction velocity (Humm et 
al., 2004). The team found that demyelinated nerve fibres have slow nerve 
conduction velocity which tends to have a negative effect on the duration of action 
potentials, and this was reported when the temperature is between 36 - 40°C.  
Other possibility that linked to heat sensitivity is the brain lesions as a result of 
MS that is responsible for controlling core temperature (Frohman et al., 2011) 
and side effects of some medication such as beta-interferon which produce flu 
like symptoms (Flensner et al., 2011). Therefore, recommendations for easing 
the effects of  heat include wearing less, lightweight and breathable clothing and 
to conduct exercise in cool environments (Davis et al., 2010). Despite these 
recommendations,   agreement on wearing compression garments to decrease  
oedema in pwMS have emerged in literature with a suggested starting pressure 
between with 8-12 or 15-20mm Hg (Frohman et al., 2011). Precautions while 
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using compression therapy and starting with light pressure must be considered, 
as over time pwMS can also develop sensory impairments beside the autonomic 
dysfunction which occurs with  disease progression (Huang, Jay and Davis, 
2015). Wheelchair dependency, mobility restrictions and incontinence, are  
common amongst  some pwMS and are factors that should influence garment 
selection (Elwell, 2017). It is also important that personnel are trained to fit 
compression garments as pressure sores can develop if garments are poorly 
fitting. Due to the specific characteristics and complications of MS alternative 
treatment options may be required for CLLO if compression therapy cannot be 
applied. 
1.7  Exercise Therapy  
Although there are some favourable results regrading compression therapy for 
people with venous leg ulcers (VLUs), cancer related lymphoedema and 
dependency oedema, there is a scarcity of little literature on those with 
dependency oedema arising from a neurological disorder. In pwMS the reduction 
in muscle performance during both isometric strength and dynamic power 
production occur secondary to low physical activities which make them at an 
increased risk of developing CLLO (Charles, 2013;  Solaro et al., 2006). Since 
the origin of dependency oedema is caused by impairment in the calf muscles 
pumping mechanism (Faett et al., 2012), wearing compression might not help in 
preservation and rebuilding muscle strength to overcome the muscle weakness. 
Therefore, well-designed interventional studies that involve the musculoskeletal 
system need to be conducted. It is important to evaluate each single treatment 
modality carefully without adding all the other aspects of treatment that are 
currently used in combination. This will allow clinicians to understand the relative 
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contribution that single components of treatment can play and then in further 
research complex programmes of care involving two or more elements can be 
evaluated.  Studies of exercise interventions alone are needed, as these could 
provide new treatment strategies for those who cannot wear compression 
garments or bandages.  Exercise may also have beneficial consequences for the 
condition overall.  
Treating CO with exercise has received some attention in the scientific literature 
during the last two decades and more specifically in BCRL. Prior to that, the use 
of exercise has been controversial in this area due to the assumption that it may 
contribute to the development of   lymphoedema  for those at risk or it could 
increase limb volume through overexertion for those with established 
lymphoedema (Cooper, 2016). These claims have been rejected for a wide 
spectrum of exercise therapies examined since the 1990s. The types of exercise 
examined are non-specific and have ranged from hydrotherapy, deep breathing 
exercises and yoga. This leaves clinicians with an extensive and complex 
evidence base that can be difficult to understand and apply correctly in clinical 
practice.  
 Kwan et al have tried to identify the what contributes ‘best exercise practice’  by 
conducting a systematic review  of studies involving patients with lymphoedema 
(Kwan et al., 2011). The review included 19 studies, of which seven had 
examined the impact of resistance exercise, a further seven evaluated aerobic 
and resistance exercise; and five addressed other exercise modalities. The 
conclusion indicated that there is a strong evidence base for the safety of 
resistance exercise without an increased risk of lymphedema for breast cancer 
patients. Furthermore, they reported that combined aerobic and resistance 
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exercise appeared safe, but larger and more rigorous studies are required for 
confirmation of the results. Screening all of the studies included in the Kwan et al 
review indicated that in each instance compression therapy had been applied in 
combined with an exercise intervention. Such evidence does not enable 
substantive conclusions to be drawn about the relative effectiveness of each 
treatment modality. 
Very few studies have examined this question and those that are available are 
methodologically weak. One study by Johansson and colleagues sought to 
examine the effects of resistance exercise with and without a compression sleeve 
on BCRL patients (Johansson et al., 2005). For five days, 31 participants were 
treated with controlled low intensity arm exercise with weights on two non-
consecutive days that were interspersed with one day of rest during one session, 
the exercise was given with a compression sleeve and on the second session it 
was provided without a sleeve. Two weeks prior to the exercise intervention 
commencing all participants were asked to wear a compression sleeve. Water 
displacement was measured before, directly following and 24 hours after 
exercise. The results showed that limb volume was increased in both conditions 
immediately after exercise but after 24 hours there was no increase in limb 
volume compared to baseline. Perceived exertion when exercising with a sleeve 
was significantly higher than when exercising without one.  Perceived exertion is 
defined as “the feeling of how heavy, strenuous and laborious exercise is” and is 
measured using a psychophysical scale (Pageaux, 2016). In this study, the Borg 
rating scale was used which rates exertion on a scale from 6 (minimum) to 20 
(maximum) and every step was provided with verbal statement from “very very 
light” to “very very Hard”.  Although this study is one of a few studies that has 
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aimed to examine individual components of treatment, the methods are weak.  
One of these weaknesses concerns the ‘dose of treatment’. One session of 
exercise is not likely to stimulate the physiological changes that are expected to 
accompany reductions in limb volume. In addition, wearing a compression sleeve 
for two weeks prior to the intervention could have an impact on the results.   
Another study compared the effectiveness of exercise and compression 
garments in BCRL patients by conducting a randomized control trial (Irdesel, 
2007). Nineteen participants were included, one group with home exercise only 
and the second group conducted home exercises and wore compression 
garments. The participants were recruited from outpatient clinics in Uludag 
University, Turkey. The results show reduction in lymphoedema volume in the 
second group in compared to the other one after a six-month follow-up period. 
Although the second group showed a significant improvement, the study methods 
used to determine efficacy are arguable. The first contention is the credibility and 
accuracy of self-reported accounts of exercise conducted at home. The therapist 
relied on participant feedback about home exercise activity and encouraged them 
to do so if they had not. Secondly, accuracy in performing exercises at home 
without close supervision may have been limited as understanding and 
interpretation of the instructions could vary greatly from one person to another 
which may affect the accuracy and validity of the results. The final contention is 
the small sample size which make limits the degree to which results can be 
generalized.     
In short, the systematic reviews include studies with mixed interventions where 
the effects of exercise are eventually not as what have been assumed, either 
because the compression therapy was used prior to intervention or due to 
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methodological limitations. To our knowledge, no previous study has been carried 
out without compression therapy being used in conjunction with exercise at some 
point which creates an important gap in the evidence that needs to be addressed.   
Carrying out studies of a single intervention can help to clarify the potential 
benefits and constraints of the modality providing a solid foundation for delivery 
and commissioning of clinical services. 
The primary objective of this programme of research was to find an intervention 
that can decrease the volume of CO in neurological patients.  It is challenging to 
tailor interventions that are safe, acceptable, and effective for both MS and CLLO. 
Until the 1990s, exercises were prescribed with extreme caution for people with 
MS because it was believed that they may exacerbate symptoms of fatigue and 
that patients would have less energy available to conduct their activities of daily 
living (Kjolhede, Vissing and Dalgas 2012). This perception has been challenged 
during the last two decades and exercise is a well-researched and often favoured 
intervention in the field of MS. Many effective exercises are described in the 
literature highlight the importance of tailoring exercise to meet the needs of each 
patient relative to the type, severity, and nature of the condition. 
Recommendations from the American College of Sports Medicine (ACSM) on 
one hand are given toward low (30 – 39% Heart Rate Reserve [HRR]) to 
moderate (40 – 59% HRR) intensity with progression based on the patient’s ability 
(American College of Sports Medicine, 2018). On the other hand, high intensity 
exercises (60 – 89% HRR) are not suggested as they can lead  exhaustion and 
reduce the effectiveness of treatment (Dalgas, Stenager and Ingemann-Hansen, 
2008; Beer, Khan and Kesselring, 2012; American College of Sports Medicine, 
2018). This is related to the Uhthoff’s phenomenon where core body temperature 
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tends to increase during physical training which may interfere with a person’s 
activities of daily living.  
Progressive resistance and endurance exercises are two forms of training that 
are both popular in MS rehabilitation programs.  Both are tolerated and effective 
but in contrast to endurance training, resistance exercise has little  impact on core 
temperature (Dalgas, Stenager and Ingemann-Hansen, 2008). This vital point 
was a determining factor for the choice of exercise examined in this research, 
particularly as the participants reside in a country with very hot weather and the 
issue of not causing their physical health to deteriorate was a critical ethical issue. 
Added to this, this type of exercise also shows it was safe and effective on CO 
as highlighted in the previous studies with BCRL group, which added favour to 
this choice. As this study involved tailoring an intervention for neurological 
patients, chapter 4 will systematically review the literature on the positive and 
negative effects of resistance exercise and will outline how this influenced the 
intervention undertaken in this thesis.   
1.8  Thesis Rationale 
When the clinical signs of CO become visible, that indicates that the condition 
may have been  present for a long time (Keast et al., 2015).  Research conducted 
to date on the prevalence and nature of risk factors associated with CO and 
lymphoedema focus on those related to oncology but with different aetiology the 
needs for further research still remain. However, the new LIMPRINT 
(Lymphoedema Impact and Prevalence project) epidemiology is seeking to 
redress this balance and is focussing on those with all forms of Lymphoedema 
both primary and secondary (Moffatt, Keeley and Quéré, 2019b). This gap must 
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be addressed in order to recognize those who are not correctly diagnosed and 
consequently do not receive appropriate care.  
As a symptom, CO is frequently recognized, but health care providers must 
understand the underlying causes of this symptom and treat the oedema from its 
origin. Management of CO amongst people with MS is challenging as 
impairments arise in many body systems and are not limited to the vascular or 
lymphatic system. The evidence underpinning  best practice for the treatment  CO 
is amassing especially in oncology related lymphoedema and more specifically 
breast cancer (Kwan et al., 2011; Chang, 2013; Keilani et al., 2016). Treatment 
in the form of CDT and compression therapy has been shown to be effective. 
However, the outcomes do not  provide clear conclusions to be reached as in-
depth interpretation of each component of treatment in the bundle remain poor  
(Wigg and Lee, 2014). Therefore, a scientific option appraisal is needed of each 
therapy to support patients who cannot undertake one component of the CDT 
such as compression therapy.      
The advantages and disadvantages of compression therapy should be 
considered especially if the target group is having a neurological and autonomic 
dysfunction issues.  Exercise therapy as a treatment option and more specifically 
resistance exercise shows its effectiveness, safety, and suitability in treating both 
conditions (chronic oedema and MS) separately. Yet, none had been found in the 
literature about treat CLLO in pwMS. Consequently, this thesis is a first stage and 
that the results from this study will be then evaluated within larger randomized 
controlled trials (RCTs) that will include a control group.  In view of limited 
evidence and the gaps in this area this study is intended:  
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1. To evaluate the prevalence of Chronic Lower Limb Oedema (CLLO) in 
people with MS (pwMS) who are resident in the Kingdom of Saudi Arabia 
and attendees one of the two hospitals. 
2. To determine the main characteristics of those at high risk of developing 
CLLO. 
3. To assess the effectiveness of Progressive Resistance Exercise (PRE) in 
the management of CLLO in pwMS who are resident in the Kingdom of 
Saudi Arabia. 
4. To determine the impact of CLLO on pain and Quality of Life (QoL). 
5. To identify and explore the factors that contribute to successful or 
unsuccessful PRE from the perspectives of the participants. 
6. To explore the physiotherapists knowledge and understanding of CLLO 
in pwMS and the current practice in terms of exercise therapy. 
1.9  Organisation of this Thesis 
In this chapter, the researcher presented the study’s aim and objectives. Potential 
consequences of immobilisation in pwMS and economic and psychosocial 
impacts of CO have been provided. Current treatments for CO were explored as 
well as exercise therapy and the rationale behind this thesis.  
Chapter 2 presents the study methods and describe the mixed method approach 
that was used to collect and analyse the study data. Study ethical approval 
process, data protection, inclusion and exclusion criteria and study regime also 
were explained.  
In chapter 3, the researcher presents a systematic review related to prevalence 
rate of CLLO in pwMS. It provides the supporting evidence about the rate of CLLO 
in pwMS and the common characteristics of those who develop CLLO. Chapter 
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4 represents a systematic review study related to progressive resistance exercise 
and determine its effects on pwMS muscle performance and QoL. It highlights 
the effects of the intervention on disability progression, functional capacity, 
fatigue and QoL, and muscle performance and endurance.     
Chapter 5, 6, and 7 presents phase one, two and three of this study. In Chapter 
5, the researcher presents the findings of screening data through t-test (to 
compare the continuous variables and the Chi-square test for categorical 
variables) and Logistic regression test (to predicate values of an input and the 
probability of the variables in developing CLLO). Moreover, the researcher 
discusses this in relation to the existing literature. In chapter 6, the researcher 
presents the intervention programme and the findings of the quantitative analysis 
using Paired t-test to compare between pre and post intervention when the data 
were normally distributed and with Wilcoxon Signed-Rank test when it is not 
normally distributed. In chapter 7, she identifies and explores the factors that 
contribute to the successful or unsuccessful use of PRE from the perspective of 
pwMS which was obtained through individual interviews and used the framework 
analysis to identify three themes and seven sub-themes. For the 
physiotherapists’ participants, the individual interviews identified two themes and 
two sub-themes regarding the type and range of exercise therapies adopted 
routinely by neuro-physiotherapists who are practising in the KSA. 
In the final chapter 8, the researcher presents the overall discussion and 
conclusion of the thesis from the results of phase one, two and three. Overall 
strengths and limitations of the thesis as well as the implications to clinical 
practice and research, and recommendations was discussed.     
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1.10  Summary  
Within chapter 1, an overview introduction to the Kingdom of Saudi Arabia 
demographic information and the multiple sclerosis disease condition in the area. 
Explaining the potential consequences of immobilization in pwMS and what 
economic and psychological impacts could be generating if the patients 
developed CLLO. This chapter also highlighted the current clinical practice in 
treating chronic oedema and what other opportunities we do have if this practice 
is difficult to be delivered in some special cases. Thesis rational have been 
introduced with the overarching research aim and objectives. Lastly, how this 
thesis is organised from chapters 1 to 8 was highlighted. 
In the next chapter, research design, ethical approvals, data protection, study 
criteria and study regime will be presented in detail. 
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2.1   Introduction 
In this chapter, the primary aims of the research are outlined and the methods 
adopted in each component of the work are described. The rationale for 
adopting a mixed methods approach is also explained. The chapter concludes 
with a description of the procedures followed to ensure ethical and legal 
requirements were met. 
2.2   Research Aims and Objectives 
As highlighted in chapter 1, although the effectiveness of treatments for chronic 
oedema have been examined in many previous studies, there are limitations. 
Some of the gaps in the literature that remain concern the: (a) limited scope of 
the targeted group (i.e., the majority of participants are oncology related and 
more specifically they are breast cancer patients), (b) composition of the 
treatment intervention (Compression therapy has traditionally been used in 
conjunction with another component, therefore, it is difficult to define the 
contribution of each treatment element or combination of treatments, and (c) 
the robustness of the studies in which a single treatment has been applied.  
By bridging some of these gaps in knowledge, this research seeks to   provide 
an improved evidence base for clinical practice and improve patient outcomes.  
For pwMS who have developed CLLO, to our knowledge this is the first research 
study that tackles this problem and takes a step forward to help shape improved 
health services. Identifying the effects of exercise on CLLO for pwMS may 
identify unmet needs and offer an alternative treatment option treatment if 
compression therapy cannot be used. Furthermore, exploring the relationship 
between QoL and limb volume reduction in pwMS undergoing PRE will provide 
a new and valuable insight on this topic. Ultimately, understanding and 
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exploring the effects of an intervention from the perspective of both participants 
and clinicians will help to inform health care services in this field and allow the 
benefits and limitations of the intervention to be understood from a multi-
dimensional perspective. 
2.2.1 Research aims 
The aim of this programme of work was to gain an improved understanding of 
the prevalence and impact of CLLO in people with multiple sclerosis and the 
contribution of progressive resistance exercise on its remediation.    
2.2.2 Research objectives 
1) To evaluate the prevalence of Chronic Lower Limb Oedema (CLLO) in 
people with MS (pwMS) who are resident in the Kingdom of Saudi Arabia 
and attendees one of the two hospitals (Chapter 5). 
2) To determine the main characteristics of those at high risk of developing 
CLLO (Chapter 5). 
3) To assess the effectiveness of progressive resistance exercise (PRE) in 
the management of CLLO) in pwMS who are resident in the Kingdom of 
Saudi Arabia (Chapter 6).  
4) To determine the impact of CLLO on pain and Quality of Life (QoL) 
(Chapter 6).  
5) To identify and explore the factors that contribute to the successful or 
unsuccessful use of PRE from the perspective of pwMS (Chapter 7).  
6) To explore the knowledge and understanding of neuro-physiotherapists 
practising in the Kingdom of Saudi Arabia of CLLO amongst pwMS 
(Chapter 7). 
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7) To explore the type and range of exercise therapies adopted routinely by 
neuro-physiotherapists who are practising in the KSA (Chapter 7). 
2.3   Research Design  
In order to bridge some of the gaps identified in the literature and to deliver the 
research objectives listed above, a ‘mixed methods interventional design’ was 
selected in which both quantitative and qualitative data were gathered (Creswell 
& Plano Clark, 2017. p.108) 
Utilising a mixed methods approach, helps to ensure that the potential  
limitations of one method can be neutralized by the other (Creswell and 
Creswell, 2018). The concept of the supplemented qualitative strand occurring 
during the primary interventional stand was first introduced in 1996 by 
Sandelowski’s paper (Sandelowski, 1996). Implementing a qualitative strand 
before, during or after a quantitative study is based on the study aims and 
objectives (see Figure 2.1). By applying a mixed method design the effects of 
progressive resistance exercise on CLLO in pwMS can then be understood and 
identified from different aspects and perspectives. 
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Figure 2. 1:  Adding Qualitative Data Into a Study 
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2.4   Mixed Methods Approach  
Mixed methods approach is not a new concept of research but which was 
introduced  in the 1980s (Creswell and Creswell, 2018). An early definition of 
mixed methods was by Greene et al., (1989) when they said: 
Mixed method designs as those that include at least one quantitative 
method (designed to collect number) and one qualitative method 
(designed to collect words), where neither type of method is inherently 
linked to any particular inquiry paradigm. (p. 256)  
The rationale and purpose of using a mixed methods approach vary from one 
study to another. Collins et al. in 2006 have reviewed a range of mixed methods 
studies and identify four broad reasons behind using them, (a) to improve the 
accuracy of the data, (b) to provide a complete picture of the problem, (c) to 
avoid biases and weakness in one single method, and (d) to develop the 
analysis and build on initial findings by using a contrast method (Collins, 
Onwuegbuzie, and Sutton, 2006). Therefore, expanding the research to include 
more than one method can make it more comprehensive and help to enhance 
the information obtained. However, studies which utilise a mixed methods 
approach can also have limitations since it can be challenging to present and 
analyse data from convergent methods in a clear way (Creswell and Creswell, 
2018).  
Within this mixed method, each method functioned in parallel in order to 
understand and explore the subjective experiences toward the intervention 
which include barriers and facilitators experiences during the study. This study 
was conducted in two phases including one quantitative (phase two) and one 
qualitative (phase three). The primary outcomes of the study were the 
quantitative (CHAPTER 6:  EFFECTS OF PROGRESSIVE RESISTANCE 
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EXERCISE ON ….) phase where reduction in leg volume and improvements in 
QoL and pain were the objectives. However, before recruit the participants to 
phase two, phase one was undertaken to identification and screening for CLLO 
in pwMS. The objectives of this phase were to measure the prevalence of CLLO 
in pwMS who are resident in the Kingdom of Saudi Arabia and attendees one 
of the two hospitals and to determine the main characteristics of those at high 
risk of developing CLLO. The qualitative phase was used to explore the 
experiences of the participants. Figure 2.2 demonstrates how and when both 
phases (two and three) of the mixed methods design were adopted and how 
the results were analysed and inter-related.  
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Figure 2. 2:  Summary of the Mixed Methods Study Design  
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2.5   Ethical Approvals and Regulatory Aspects 
This study was carried out in accordance with the guidelines determined by the 
Ministry of Health National Centre in Saudi Arabia (2015) (MOH, 2015) and 
General Data Protection Regulation (GDPR) (Information Commissioner’s Office, 
2018). The moral principles have been considered to protect participants’ rights 
and safety, which include justice, autonomy, beneficence and non-maleficence 
(Ebbesen, 2011). Ethical approval was granted for all phases by the Research 
Ethics Committee (REC) in King Khaled University Hospital (KKUH) (Reference 
Number:  E-17-2733) on December 2017 (Appendix 1) and King Faisal Specialist 
Hospital and Research Centre (KFSH&RC) (Reference Number: ORA/0247/39) 
in March 2018 (Appendix 2).  
2.6  Data Protection  
Data collection was limited to the minimum required for the purposes of the study 
(MOH, 2018). Participant details and case report forms (CRFs) were held 
securely, in a locked room and cupboard.  Access to the information was limited 
to the study staff, principal investigator (PI) and relevant regulatory authorities. 
Electronic data that included study database for all study phases was held 
securely by password protected and access was restricted by user identifiers and 
passwords. Information about the study in the participant’s medical records / 
hospital notes was treated confidentially in the same way as all other confidential 
medical information. Data confidentiality was ensured by using an identification 
code numbers in the computer files for each participant. Medical information was 
shared with the participant’s medical team and medical personnel responsible for 
the participant’s health and safety. The PI asked the participants to keep an 
updated contact details in their study file so that they can be contacted when 
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needed. 
2.7 Record Retention and Archiving 
The aim of record-keeping and handling of data is to record, store and transfer 
the information gathered on each study participant into data that can be used in 
the report. In the event of electronic data handling, confidentiality of database 
was secured by safety procedures such as passwords. The PI held overall 
responsibility for ensuring the accuracy and completeness of data entry.  
As required by national regulations and in compliance with the General Clinical 
Practice (GCP) guidelines, the PI was arranging for the retention of the subject 
identification codes for a sufficient period of time to permit any medical follow-up 
which may be warranted, including follow-up for delayed treatment reactions. The 
sponsors (in this case are the hospitals) made appropriate arrangements for the 
retention of all other essential documentation pertaining to the clinical trial in a 
form which can be retrieved for future reference. Archived data was kept on 
electronic record (e.g., external hard disc) and a hard copy was made available 
on request. The results of this study can be available for inspection on request by 
the University of Nottingham (UoN) representatives, the representatives in the 
King Saud University (KSU) in Riyadh, the KKUH, the KFSH&RC and the 
participating physicians. 
2.8   Informed Consent and Patient Information Sheet 
The process for obtaining participant informed consent was in accordance with 
the KKUH and KFSH&RC guidance. Consent forms (CF) and participant 
information sheet (PIS) were distributed when patients attended an appointment 
and all patients who expressed an interest in participating provided informed 
written consent (Appendix 3 & 4). The PI and participants signed and dated the 
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CF before any assessments or interventions commenced. The PI explained the 
purpose of the study and ensured that potential participants had an enough time 
to consider participating. In Saudi Arabia, there are no written guidelines about 
the minimum time period required for people to decide if they wish to participate. 
Therefore, this research study  followed the UK National Research Ethical 
Service (NRES) guideline which stated that there are no fixed guidelines and 
each study should consider its own merits (National Patient Safety Agency 
(NHS), 2011). Therefore, this study considered the full understanding of study 
aims, PIS and given enough time to answer all potential participant’s questions 
as criteria for the time allowed to consider participation. The potential participant 
was able to ask questions and reflect without rushing into decisions to take part 
in the study. For those who have decided to take their time to consider 
participation, 48 hours was given followed by SMS or phone call (based on 
preference) to have their final decision.  
Each participant who returned a signed consent form received a copy of the 
signed and dated form and a second copy was filed in each participant’s medical 
notes where the original was retained in the study file. A unique study number 
had been given for each signed consent form to identify all data in the study. 
The decision regarding participation in the study was entirely voluntary and the 
PI emphasized to potential participants that they can withdraw at any time without 
penalty or affecting the quality or quantity of their future medical care, or loss of 
benefits to which participant is otherwise entitled.  
2.9   Study Design and Location   
This was a two-centre and one arm mixed methods study managed by the School 
of Medicine, University of Nottingham. The study was carried out in Riyadh city 
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(central region of the Kingdom of Saudi Arabia) where around 6 million people 
reside (Riyadh Chamber of Commerce, 2016). Two hospitals were chosen as the 
setting for this study, namely: King Khaled University Hospital (KKUH) and King 
Faisal Specialist Hospital and Research Centre (KFSH&RC). The rationale 
behind choosing these hospitals was based on several factors: first, the 
availability of a lymphoedema clinic in the hospitals. Second, these hospitals have 
an advance database system which makes access to patient files relatively easy. 
Third, those hospitals are at the highest level of specialized medical treatment 
and technologies available.   
2.10 Involvement of People Affected by MS 
Patients and public involvement (PPI) in research refers to a partnership between 
researchers and service users (National Institute for Health Research, 2013). The 
potential benefit of PPI is to designing relevant intervention that is in favour to 
patients and/or carers needs (Brett et al., 2014; Bagley et al., 2016). Therefore, 
in order to have insight that can help in designing applicable intervention, five 
people with multiple sclerosis (pwMS) had been asked to comment independently 
on the purpose and methods of this study. The purpose and the methods of the 
study was written in both Arabic and English language, with a simple and brief 
texts. People’s involvement results had not been used in the study analysis, 
however, their valuable comments on the study purpose and methods were 
considered for better study protocol.       
2.10.1  PPI method 
1) The first step was by identifying which platform can help to reach and 
involve a wider range of pwMS from different region, gender, and MS type. 
In the KSA, there are two MS societies: Arfa with 20,000 followers and 
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Saed with 4,630. These societies are mainly communicating with their 
audience either by social network platforms or website. According to the 
GMI (Global Media Insight) organization report in 2019, the total KSA 
population who are active internet user are 89.39% and 67.95% are active 
user of social network platform (GMI, 2017). However, from all the social 
network platform available, twitter is one of the top 5 most used in KSA 
after YouTube, Facebook, and Instagram, where you can have a formal 
communication with your audiences. Therefore, to reach people very fast 
and easily, approval was obtained from both societies to announce in their 
twitter account about the participating in PPI.  
2) After the approval, a message was posted through societies’ twitter calling 
for those who finds themselves interested in giving their feedback about 
the study purpose and methods.     
3) Ultimately, from the replies, five pwMS were selected based on their 
similarity to study inclusion criteria.  
4) A phone call was given for each participant explained their role as a PPI 
participant and also to arrange for the convenient way of sending PDF files 
that included the study purpose and methods in simple preferable 
language (either Arabic or English). 
5) Two days after sending the PDF files, the study principal investigator (PI) 
contacted the participants to have their comments/feedback.  
6)  The received feedback indicates that people are interested in the project 
and no amendment was made to the study.  
 
39 
 
Chapter 2 Research Design and Methods  
 
2.10.2  Costs of PPI 
Communications between PI and participants were through free call or chat 
application (WhatsApp or Telegram or Line based on what the participant have). 
By using this procedure there were no cost to other parties.  
2.11 Patients Inclusion and Exclusion Criteria  
Inclusion criteria  
• Male and female patients in both KKUH and KFS&RC with a confirmed 
diagnosis of multiple sclerosis (MS) 
• Willing and capable of giving informed consent. 
• Comprehension of Arabic or English language. 
• Patients with an Expanded Disability Status Scale (EDSS) between 3 and 
6.5.  
• Having chronic lower limb oedema as indicated by a positive pitting 
oedema test. 
• Live in Riyadh city or able to come to treatment sessions if he/she is not 
living in Riyadh. 
Exclusion criteria: 
• History of clinical renal, liver or heart condition. 
• Participation in any other study which could affect the outcomes of this 
study. 
• Current diagnosis or treatment of cancer. 
• Any other condition that could prohibit participation and affects muscle 
function such as recent lower limb fractures, osteoarthritis or rheumatoid 
arthritis that limit the normal range of movements in lower extremities.  
 
40 
 
Chapter 2 Research Design and Methods  
 
• Involvement in other structured physical or recreational fitness programs 
within the last 12 weeks. 
2.12  Study Regime  
The overall duration of the data collection period from recruitment step to the 
intervention was 6 months, started from 1st of January 2018 and ended on the 
30th of June 2018. Because the researcher had a permission from the SACB to 
leave the UK for data collection for only 6 months, the recruitment process was 
taken place from 1st of January 2018 until 31st of March 2018. After this date, no 
recruitment was undertaken because each participant must participate for 12 
weeks (3 months) with two sessions per week (24 sessions) and their 
participation was commenced upon signing the consent form. Therefore, time 
management was important to ensure that the research plan is completed and 
accurate.  
The intervention was started for each participant once he/she was recruited. The 
last session with the last participant was the end of data collection period. During 
this period, the study was conducted in three phases as can be seen in Figure 
2.3: 
• Phase one, which was the identification and screening step. The aim of 
this phase is to provide a preliminary data on the prevalence of CLLO on 
the pwMS who are residence in Riyadh city, Saudi Arabia. The 
recruitment of the participants was in this phase and once the participant 
was agreeing to participate then phase two was started. More in-depth 
exploration about this phase will be in the chapter 5.    
• Phase two, is the quantitative part where the intervention was taken place 
and chapter 6 will give a comprehensive discussion about this phase.    
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• Phase three, is the qualitative part where uncovering information that may 
not been exposed in phase two can be discovered in this phase by 
interviewing the participants and therapist. Chapter 7 will cover this part.  
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Figure 2. 3:  A Flowchart Shows the Steps from Identification to  
                     Recruitment of the Participants 
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2.13 Summary  
In this chapter, the research aims, objectives and methods have been described 
and the justification for a mixed methods approach has been explained. Lastly, 
the study setting, PPI procedures and participant selection criteria have been 
explained.  
Available evidence concerning the prevalence rate of CLLO in pwMS are 
presented in Chapter 3 in which the results of a systematic review are presented.    
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3.1  Introduction   
Although chronic oedema (CO) arises in many conditions, (Moffatt et al., 2019a) 
and has potentially serious consequences, many previous studies have 
examined the prevalence and impact of CO in specific rather than heterogeneous 
populations (Quéré et al., 2019). As a result, estimates of the prevalence of CO 
in the community may not reflect the scale of the problem accurately. The 
assessment and treatment need of many patients are not identified or 
underestimated.  
One recent cross-sectional study found that the prevalence of CO in community 
nursing services is high amongst patients with reduced mobility and obesity 
(71.6%, 61.9% respectively) (Moffatt et al., 2019a). Similarly, a point-prevalence 
study by Quéré et al. (2019) reported that CO occurred more frequenly in less 
moblile patients (41.5%) compared to those with heart failure (34.7%) (Quéré et 
al., 2019). These findings support the idea that immobility can lead to CO and  
therefore pwMS and other conditions that limit mobility are likely to develop CO.  
The aims of this systematic literature review were to: 
1. Determine the prevalence rate of CLLO in patients with multiple sclerosis. 
2. Identify the main characteristics of those at risk of developing CLLO.  
3.2  Methods   
3.2.1  Search strategy and data sources  
Relevant studies were searched online using the following electronic databases:  
AMED, BNI, CINAHL, COCHRANE, EMBASE, HBE, HMIC, Medline, PubMed, 
PsycINFO and Pedro.  In addition, searches of grey literature were carried out 
including: conference proceedings, governmental websites (Saudi Arabian 
Ministry of Health and the Saudi Arabian General Authority for Statistics), theses 
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and dissertations. The bibliographies and reference lists of included studies were 
also examined for potentially relevant studies. Principal authors were also 
contacted for additional information if it was not possible to evaluate the relevance 
of study from the abstract or full text. Records of search strategies in the 
Healthcare Databases Advanced Search (NICE) were saved at each stage 
detailing when and how the search was undertaken and a monthly alert was set 
for updates on the search terms used. Saving the results from this platform was 
helpful in freeing the results from duplication.    
The search strategy included a combination of subject terms that were joined with 
the ‘AND’ operator. The following search terms were used:    
• lower limb oedema AND multiple sclerosis  
• chronic lower limb oedema AND multiple sclerosis  
• chronic oedema AND multiple sclerosis  
• lymphoedema AND multiple sclerosis 
• prevalence of lower limb oedema AND multiple sclerosis  
• prevalence of chronic lower limb oedema AND multiple sclerosis 
• prevalence of chronic oedema AND multiple sclerosis 
• prevalence of lymphoedema AND multiple sclerosis  
In all search terms, the United States of America (USA) spelling of oedema 
(edema) and lymphoedema (lymphedema) was searched and the words multiple 
sclerosis was also searched in its abbreviation (MS) form. The initial search was 
carried in November 2017 with no restriction on the years included and this was 
updated in May 2020.  
 
47 
 
Chapter 3 Systematic Review on Prevalence of CLLO in pwMS 
3.2.2  Review criteria 
This review is not restricted to a specific clinical study design and all studies were 
included due to lack of research in this area. However, only studies written in 
English were included in the review. The studies included participants of either 
gender, all ages and with a clinical diagnosis of MS (for varying lengths of time). 
All studies reporting primary and secondary outcomes that measure lower limb 
oedema were included.  
3.2.3  Data acquisition  
The results of the search showed the scarcity of studies in this field. Therefore, 
the reviewer intended to include even not full-text studies (if relevant) and contact 
the primary author for more details. The reviewer screened studies titles and 
abstracts that are saved after removed duplication in order to identify relevant 
publications and to create a list of eligible studies. Studies that did not meet the 
review criteria were excluded as shown in Appendix 5. The remaining studies 
were retrieved in full text (if possible) and reviewed. This process was conducted 
using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) (Moher et al., 2012) as depicted in Figure 3.1. 
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Figure 3. 1:  PRISMA Flow Chart of Study Selection Process. 
 
A systematic data-extraction form was developed based on this review which 
aimed to extract data to scrutinise information from the included studies. 
Information extracted   included:  
1. Author names and year of publication 
2. Study design 
3. Study setting and geographic location  
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4. Sample size 
5. Gender  
6. CLLO prevalence rate 
7. Disease duration (number of years) mean  
8. MS course 
9. Extended Disability Status Scale score (EDSS) (±SD) 
10. Oedema outcome measures.   
The data were analysed based on study geographic location and setting, 
participant characteristics, outcomes measures, and quality. Prevalence in all 
studies is provided as the number of cases per 100,000 population.  
3.3  Quality Assessment and Analysis 
In this systematic review, the quality and risk of bias of each study were evaluated 
in order to report qualifying results, which is a fundamental step in any systematic 
review study. It is important to determine the quality of published evidence in 
order to determine the validity, and reliability of the results. Although many tools 
have been developed to assess the quality of experimental studies, those related 
to observational studies and estimates of prevalence considered to be 
unsatisfactory (Mallen, Peat and Croft, 2006) due to limited information about 
reliability; and internal and external validation (Hoy et al., 2012). 
During the last decade, there has been an increase in the number of prevalence 
related systematic reviews published and it is necessary to identify a suitable 
critical appraisals checklist. Several critical appraisal tools were identified as 
shown in Table 3.1.  Many of these tools share similar criteria including sample 
representation, recruitment, and measurement tool reliability.  
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Table 3. 1: Existing Critical Appraisal Tools on Prevalence Studies 
 
Authors (year of publication) Tool Name The number 
of items 
included in 
the tool 
Vandenbroucke et al., (2007) Strengthening the reporting of 
observational studies in 
epidemiology (STROBE) 
checklist  
22 
Loney et al., (1998) Critical appraisal tool for 
prevalence  
8 
Hoy et al., (2012) Risk of bias tool  10 
JBI (2014) Joanna Briggs Institute 
prevalence critical appraisal tool  
10 
 
However, Joanna Briggs Institute (JBI) prevalence critical appraisal tool has the 
advantage of being simple, has clear guidelines and can be administered quickly 
(Munn et al., 2014).The JBI tool was selected for use in this study based on the 
simplicity and inclusiveness of the instrument. The JBI tool measures both 
internal and external validity and has 10 scoring questions: 
1.  Was the sample representative of the target population? 
2.  Were study participants recruited appropriately?  
3.  Was the sample size adequate? 
4.  Were the study subjects and the setting described in detail? 
5.  Was the data analysis conducted with sufficient coverage of the identified 
       sample? 
6. Were objective, standardised criteria used for the measurement of the 
condition? 
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7.  Was the condition measured reliably? 
8.  Was there appropriate statistical analysis? 
9. Have all important confounding factors/subgroups/differences been 
identified and accounted for? 
10. Were sub-populations identified using objective criteria?  
All questions are scored yes, no, unclear or not applicable according to the 
information provided, allowing a positive maximum score of 10 points by giving 
equal weight to all questions (Munn et al., 2014).  
The method for analysing the quality of the studies depended on the critical 
appraisal of each study. When the answer was “Yes”, one point was given and if 
the answer “No”, “Unclear” or “Not applicable” then no points were given. 
However, in order to consider the relevance of the study, the JBI guidelines 
highlight that reviewers can make the decision whether or not to include a study 
based on meeting a pre-determined proportion of all criteria, or on certain criteria 
such as sample size or measuring reliability. It is also possible to weigh the 
different criteria differently (JBI, 2014). The pre-determined proportion or 
weighting each criterion differently relies on the researcher’s subjective appraisal 
based on their study aims (ibid). 
Therefore, decisions about the scoring system and the cut-off for inclusion of a 
study were based upon the guidelines, where the question numbers 3, 4, 6, 7 and 
8 of the methodological quality score must be rated “Yes” in order for a study to 
be included in the review.   
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3.4  Results  
Out of the 32 studies identified from the electronic and manual searches, 8 
studies were removed due to duplication. The remaining 24 studies were 
screened for eligibility using the inclusion criteria for titles and abstracts. Out of 
the 24 studies remaining, the search strategy revealed 3 prevalence related 
studies (Solaro et al., 2006; Arpaia et al., 2010; Keeley et al., 2017). By manual 
search in the included studies reference list, no more related data were found. A 
summary of the data extracted from the included studies is presented in Table 
3.2.  
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Table 3. 2: Study Characteristics 
Author (Year) Study design Study setting 
and location  
Sample 
size 
Gender CLLO 
prevalence 
rate (%) 
Disease 
duration (year) 
mean (±SD)  
MS 
course 
type 
EDSS 
(±SD) 
Oedema 
assessment 
3 Solaro, C. 
(2006) 
Cross-
sectional 
study  
MS center of 
the university of 
Genoa and the 
regional center 
of Italian 
multiple 
sclerosis 
society; Italy.   
205 F: 130 
M: 75 
  pwO: 93 
(45%) 
pwtO: 112 
(55%) 
pwO: 20.5 
(±11.3) 
pwtO: 13.7 
(±9.2) 
RR: 20 
pwO, 51 
pwtO 
SP: 49 
pwO, 36 
pwtO 
PP: 24 
pwO, 25 
pwtO 
Mean 
EDSS 
5.227 
(±2.11) 
 
Instrument 
evaluation: venous 
Doppler CW, 
lymphoscintigraphy 
(deep & superficial) 
Classification of 
oedema: Fovea’s 
sign (+ in venous 
oedema) & CEAP 
scale used, 
Stemmer’s sign (+ in 
lymphatic oedema) & 
5-point scale used. 
Screening 
assessment: 
neurologic status & 
reported presence of 
oedema.  
4 Arpaia, G. 
(2010) 
Prospective 
cohort study 
Don Gnocchi 
neurological 
rehabilitation 
center in Milan; 
Italy 
132 F: 87 
M: 45 
pwO: 113 
(86%), 58 
(43.9%) of 
them had 
DVT and 40 
(69%) out of 
them 
pwO: 18.0 
(±8.3) 
pwtO: 18.5 
(±8.0) 
Advanced 
MS (did 
not 
specified)   
EDSS 
>6.5 
Oedema test was 
recorded (but not 
identified how), 
asked the patient if 
they had any 
previous VTE. 
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Abbreviation: MS= Multiple Sclerosis, CLLO= Chronic Lower Limb Oedema, pwO= patient with Oedema, pwtO= patient without Oedema, RR= Relapsing Remitting, SP= 
Secondary Progressive, PP= Primary Progressive, EDSS= Expanded Disability Status Scale,  DVT= Deep Vein Thrombosis, VTE=Venous Thromboembolism
developed 
CO. 36 (48%) 
out of 74 of 
those who did 
not have 
DVT, had a 
CO.  
pwtO: 19 
(14%) 
Bilateral 
compression 
ultrasonography 
(CUS) used for DVT 
diagnosis.  
Plasma D-dimer test. 
5 Keeley, V. 
(2017) 
(unpublished 
study, only 
conference 
abstract)  
Cohort 
observation 
and 
questionnaire 
study 
Derby 
hospital; UK.  
Phase 1: 
235 
returned 
questionnai
res out of 
607. 
Phase 2: 
160 
random 
participants 
were 
assessed 
for CLLO. 
F:73.5% 
M:26.5
%  
Phase 1: 
101/235 
(42.4%) self-
reported to 
have CLLO. 
Phase 2: 
99/160 (62%) 
have CLLO 
Not identified All MS 
course 
was 
included 
EDSS 
from 3 
to 6 
Phase 1: self-
reporting 
questionnaire. 
Phase 2: pitting 
oedema test, limb 
circumference 
measurement, 
bioimpedance 
measurement for 
bilateral oedema, 
non-invasive 
moisture meter to 
assess water content 
of tissues, Duplex 
scan for DVT 
assessment.   
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3.4.1  Description of studies geographic location and setting  
All of the included studies were written in English and published between 2006 
and 2017. Studies were conducted in different countries: two in Italy (Solaro et 
al., 2006; Arpaia et al., 2010) and one in the UK (Keeley et al., 2017). One study 
was a prospective cohort study (Arpaia et al., 2010), one was a cross-sectional 
study (Solaro et al., 2006) and one was both a cohort observation and 
questionnaire study (Keeley et al., 2017). One study examined prevalence of 
CLLO in pwMS in a large geopolitical region in Italy (Milano), one examined in 
small region in South Italy (Genoa) and regional centre of Italian MS patient 
society (AISM), and one examined the prevalence in patients recruited from a 
large hospital in Derbyshire in the UK from rehabilitation and neurological 
department. Cases were obtained in a similar manner in all included studies 
which were through MS national society documents, MS clinic checklist and 
neurology and rehabilitation medicine files. In terms of MS diagnosis, one study 
(Keeley et al., 2017) was reported that their participants were recruited when 
they fulfil the 2010 revision to the McDonald criteria of MS, while the other two 
studies did not define diagnostic criteria.         
3.4.2  Participant characteristics 
The number of total participants assessed in the included studies ranged from 
132 to 235. The presence of CLLO in pwMS has been estimated to be 45%, 
85% and 62% respectively (Solaro et al., 2006; Arpaia et al., 2010; Keeley et 
al., 2017). Patients that were more disabled were found to be more susceptible 
to CLLO than those who were less disabled.  
In the Solaro et al. (2006) study, statistical significance was found between the 
mean EDSS 5.227 (±2.11) and mean age 55.4 (±2.11), meaning that older 
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participants who were more disabled were more likely to have oedema. More 
than 50% (49 out of 93) of patients had the secondary progressive (SP) type of 
MS with the mean disease duration was 20.5 years (±11.3). Similar findings 
were reported in Arpaia et al., (2010) as the study shows that less mobile 
patients with a mean EDSS of 8.1 (±1.15), a mean age of 58 (±11) years old 
and a mean disease duration 18.7 (±8.4) had developed CLLO. The MS course 
type was not labelled in the study. In Keeley et al. (2017) study, there was a 
relationship between Multiple Sclerosis Walking Scale (MSWS-12) and CLLO. 
The MSWS-12 scores were significantly higher in the CLLO group than in the 
non-CLLO group which supports the previous results. Moreover, those with 
CLLO were older with a mean age of 59 years, a mean EDSS of 6.5 and the 
disease durations were over 10 years. In addition, it was found that the quality 
of life in the CLLO group was lower than the other group.  
3.4.3  Outcome measures  
Although these studies measured the same domains (the CLLO), however, 
different test protocols were used based on study aims. Evaluating the type of 
oedema was the main aim of the Solaro et al. (2006) study, while the 
relationship between the presence of CLLO and immobility was the main aim in 
Keeley et al. (2017) study. In the Arpaia et al., (2010) study, the method used 
was to assess the frequency of deep vein thrombosis (DVT) in pwMS. However, 
the procedure to assess the CLLO was not described.     
In the Solaro et al. (2006) study, 69 out of 93 oedema participants had vascular 
examinations. Forty-five participants (65.2%) had a clinical-etiological-
anatomical-pathophysiological (CEAP) score of 3 (representing oedema) and 
34% had a score of 4 (representing skin changes).  According to the 5-point 
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scale of lymphatic oedema, 73.1% had scores of 1 (no oedema), 13.4% had 
scores of 2 (persistent oedema) and 13.5% had scores of 3 (ingravescent 
oedema) (Solaro, 2006).  Doppler evaluation was 78 (±4.7) in patients with 
CEAP stage 4 which indicated vein flow impairment.  
In the Keeley et al. (2017) study, the presence of oedema was assessed in two 
phases. Firstly, by self-report using questionnaires and secondly by clinical 
examination using the pitting oedema test, Bioimpedance Spectroscopy, Tissue 
Dielectric constant and ISL classification of stage of lymphoedema. From the 
first phase, 101 (42%) out of 235 returned questionnaires responded that they 
have CLLO while from the second phase 99 out of 160 participants (62%) 
examined clinically were found to have CLLO. In terms of mobility level, MSWS-
12 scores were high 77.8 (95% confidence interval (CI) 71.5 84.1) in the CLLO 
group.  A venous duplex scan was used to determine the presence of DVT. 
Only one participant with CLLO was shown to have deep venous incompetence.  
This finding does not correspond to the Arpaia et al., (2010) results, where 44% 
(58) of those who had CLLO were found to have a DVT which was confirmed 
by Duplex Ultrasonography. However, the participants characteristics were 
more severe and disabled (EDSS 8.1) than those included in the Keeley et al. 
(2017) study (EDSS 6.5) and participants were confined to a bed or wheelchair.      
3.4.4  Risk of bias in the included studies  
The Joanna Briggs Institute (JBI) prevalence critical appraisal tool was used to 
determine the quality of the studies.  Initially, the risk of bias score for the Keeley 
et al. (2017) study could not be obtained because only an abstract was available 
however, following a personal communication with the first author, additional 
information was gathered. The reviewer assessed the risk of bias of the 
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included studies as presented in Appendix 6. Only one of the studies included 
(Arpaia et al., 2010) did not fulfil the required criteria (question 4 with answer 
“NO”, 6 & 7 with “Unclear”).  
Since the findings of this systematic review study were limited (due to the 
inclusion of only two studies), a meta-analysis was not possible.  
3.5  Discussion  
This systematic review is presented to determine the prevalence rate of chronic 
lower limb oedema in patients with MS and the main characteristics of those at 
high risk of developing CLLO. Published studies on the prevalence rate of CLLO 
in MS patients up to May 2020 were identified and summarised. The key issue 
was the lack of relevant studies. Unfortunately, it was not possible to perform a 
meta-analysis due to different outcome measurements and the small number 
of studies included. Consequently, a narrative analysis was performed, which 
showed that the prevalence rate of CLLO was relatively high for some people 
with MS. The critical appraisal of the included studies was assessed by JBI 
prevalence tool which was based on the study characteristics, measuring 
outcomes, quality, and credibility of the results.     
With regard to the methodologies used in the studies, employed data were from 
a single-centre source, except Solaro et al., (2006), which added limitations as 
the findings cannot be generalised easily or applied to a wider population. In 
addition, the diversity associated with the participants characteristics such as 
EDSS, disease duration, age and disease course type may account for the 
differences observed in prevalence rates i.e., 45%, 85% and 62% respectively 
(Solaro et al., 2006; Arpaia et al., 2010a; Keeley et al., 2017). For example, the 
mean EDSS score in Arpaia study was 8.1, whereas in the Keeley study the 
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mean EDSS score was 6 which indicates that the sample in Arpaia study was 
more disabled. However, all participants recruited in the studies had a high 
EDSS score, meaning that their physical activity is limited which effects 
negatively on the calf muscle pumping mechanism. This suggest that further 
work is needed to include people with less severe MS to overcome the patient 
selection bias and to label those who would be at high risk of developing CLLO. 
The relationship between different characteristics such as disease duration, 
age, and disease course with the risk of developing CLLO found to be significant 
in pwMS.  The Solaro et al. (2006) study showed a significant relationship 
between age and the presence of CLLO. Similar findings have been highlighted 
in Keeley and colleagues (2017) where the prevalence of CLLO was high in 
older participants and when age was adjusted to the UK MS population, the 
prevalence of CLLO dropped to 46% instead of 62%. The age, EDSS and 
MSWS-12 was found to correlate with developing CLLO, indicating that those 
who are older with more disability were more likely to develop CLLO. Added to 
this, the disease duration was correlated with EDSS scores which support the 
results described earlier.  
Arpaia (2010) study found that 69% (40 out of 58 participants) of those who had 
leg oedema had evidence of DVT. In Solaro (2006) study, 24 (34%) out of 69 
had a clinical stage CEAP 4 with venous pressure 78 (±4.7) mmHg (normal 
pressure is 57 mmHg) which flag the need for specialized care. Only one person 
out of 63 who undertake venous duplex scans in Keeley (2017) study found to 
have deep venous incompetence. This suggested that future studies to identify 
the risk factors that place pwMS in high risk of DVT and differentiate 
lymphoedema from oedema of other origin are needed.  
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The Keeley study raises a vital point which other studies have not highlighted 
namely patient self-recognition of CLLO. Around forty-two percent of 
participants recognized that they have CLLO but when clinical assessments 
were undertaken 62% were found to have CLLO. This may suggest that with 
mild/moderate symptoms, patients do not recognise the signs of swelling. This 
may also apply to health care providers which can result in delays in treatment 
provision and development of cellulitis.  Further research is required to examine 
the occurrence and implications of poor awareness. Enabling detection of 
oedema at an early stage could improve clinical outcomes and reduce treatment 
costs (Stout et al., 2013). 
This review is limited by the heterogeneity of the included studies. The variety 
of outcome measures used also highlights the importance of securing a 
consensus nationally and internationally about the selection, relative 
contribution, and importance of alternative measures. Once these agreements 
are reached, it will be possible to assess and predict the characteristics of CLLO 
in MS and other patient groups as needed. 
3.6  Conclusion  
In summary, previous research shows that in some people with MS, the 
prevalence of CLLO has been confirmed clinically in 45%, 85% and 62% of 
patients respectively  (Solaro et al., 2006; Arpaia et al., 2010; Keeley et al., 
2017). The prevalence of CLLO is significant in those who are more disabled 
(EDSS ≥5.27) and with a disease duration above 10 years. Moreover, a 
statistical association was found between age and EDSS scores, where older 
patients with more disability were more likely to have chronic oedema. 
Increasing awareness of CLLO among pwMS and health care providers can 
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help to improve identification of the condition and enable provision of treatment 
at an earlier stage. 
However, due to lack of evidence in this area, it is difficult to draw firm 
conclusions about the prevalence rate of CLLO in pwMS. There is an urgent 
need for well-designed cross-sectional studies to address this gap in the 
evidence Studies should not be restricted to a single site or specific course of 
MS. In addition, an international consensus regarding standard outcome 
measures of CLLO would enable correct classification and early detection. This 
could highlight the unrecognized problem that may develop in this group of 
patients, help improve the efficiency of health care systems and introduce an 
early intervention for these patients. 
3.7  Summary  
This chapter examined the literature on the prevalence of CLLO on pwMS. The 
review aims, search strategy, data analysis and quality assessment have been 
highlighted. The results found that CLLO in pwMS is a common, un-recognized 
and under-treated problem. Since autonomic dysfunction, thermal sensitivity, 
and physical weakness (as discussed in chapter 1) are common impairments 
in pwMS, developing vascular problems will add challenges when trying to tailor 
interventions. The next chapter (4) will review the literature concerning the use 
and effectiveness of resistance exercise. This intervention is thought to be safe 
and is tolerated by patients.          
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4.1   Introduction 
Until the 1990s, exercise was not prescribed for pwMS. Fearing that this would 
exacerbate fatigue and MS symptoms which might cause deterioration in the 
patient’s general health (Kjolhede, Vissing and Dalgas, 2012). This argument, 
however, has been challenged in recent years and motor rehabilitation requires 
the performance of several rehabilitation exercises (White and Dressendorfer, 
2004). A large body of research has considered the effects of exercise on MS 
patients, however, the diversity in the protocols used leaves the health care 
practitioners confused with what is currently best practice and the clinical 
protocols they should follow with their patients.  
Several reviews have emerged in the literature evaluating the different aspects 
of exercise in people suffering from MS. In 2008, Dalgas and colleagues 
reviewed studies on resistance, endurance, and combined training for MS 
patients. They concluded that resistance training with moderate intensity had 
beneficial effects on such patients through improvement of the patients’ physical 
activity levels and fatigue, where mood and quality of life diverge. In addition, 
the interventions were well tolerated by patients. However, because the 
methodological quality of the resistance training studies included were low, 
three years later (in 2012) the same group performed another review including 
new randomised controlled trials (RCTs) and non-RCTs studies (Dalgas, 
Stenager and Ingemann-Hansen, 2008). The focus of their new study in 2012 
was on the literature that evaluates the effects of progressive resistance 
exercise (PRE) in pwMS up to March 2011. The results consistently reported 
that PRE has a positive effect on patient’s muscle strength and fatigue.  
Furthermore, mood and quality of life improved but diverse results exist due to 
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differences in programme protocol, sample size and outcome measures 
(Kjolhede, Vissing and Dalgas, 2012). However, 50% (8/16) of the studies 
included were non-RCT, which scored lower (between 3 and 4 of total 11 points) 
than RCT studies on PEDro methodological quality scale. This suggest that 
future studies need to consider some aspects such as blinding of assessors, 
therapist, and participants to improve internal and external validity as well as to 
evaluate whether sufficient statistical information was introduced to make the 
results interpretable.  
Despite the previous knowledge on PRE in pwMS, an updated systematic 
review including studies with well defined PRE programme are still warranted. 
Therefore, this review was intended to include studies regarding pwMS and 
progressive resistance exercise, published up to August 2020 in order to:   
1. Determine the effects of Progressive Resistance Exercise (PRE) on 
muscle performance (strength, endurance, and fatigue) for patients with 
multiple sclerosis. 
2. Determine the effects of Progressive Resistance Exercise on patients’ 
Quality of Life (QoL).  
4.2  Method 
4.2.1  Review criteria 
I) Types of studies 
This review was restricted to English language, in a full text and RCTs study 
design. The RCT study is defined as a trial in which the study investigators 
allocate eligible participants to intervention or control groups based on random 
selection (Kabisch et al., 2011, p.664).  
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II) Types of participants 
Patients of either gender, of all ages and clinically diagnosed of multiple 
sclerosis (for any length of time) will be included. 
III) Types of intervention and outcomes measures   
According to the American College of Sports Medicine (ACSM), the progressive 
resistance training protocols are defined as “dynamic muscle contractions with 
the use of concentric (CON), eccentric (ECC), and isometric muscle actions 
against an external load. This load can be increased whenever the subject can 
perform the required number of repetitions” (American College of Sports 
Medicine, 2018). Based on this, all papers that fitted this definition were 
included. Any studies that focused on improving physical function but in 
association with equipment or body weight such as HIIT or electrical therapy or 
transcutaneous electrical nerve stimulation (TENS), technology such as visual 
reality (VR) were excluded.  
In terms of outcomes measures, studies that used outcomes to measure 
aspects of muscle strength, activity limitation, chronic lower limb oedema 
(CLLO) and patients’ quality of life were included.  
4.2.2  Search strategy and data sources  
The search strategy identified relevant studies by online literature searches 
using the following electronic databases: AMED, BNI, CINAHL, COCHRANE, 
EMBASE, HBE, HMIC, Medline, PubMed, PsycINFO and Pedro. In addition, 
manual searches were performed. References in relevant publications were 
examined. MS sociate website and abstracts published in conferences were 
also searched and personal communication with the principal author was 
conducted whenever more information was needed. The records of the search 
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strategy in the Healthcare Databases Advanced Search (NICE) were saved at 
each stage detailing when and how the search was undertaken and a monthly 
alert was set for update on the same search terms used. 
The search strategy included a combination of subject terms that joint with 
‘AND’ operator. The following search terms were used:  
• Multiple sclerosis and progressive resistance exercise  
• Multiple sclerosis and resistance exercise  
• Multiple sclerosis and resistance training  
• Multiple sclerosis resistance training  
• Multiple sclerosis and weight training  
In all search terms, the words multiple sclerosis was altered to its abbreviation 
(MS) and plural word of exercise was also searched. The initial search was 
taken place in December 2017 with no restriction on the years included and this 
was updated in March 2020. 
4.2.3  Data acquisition  
All publication results from the search strategy were saved in the Healthcare 
Databases Advanced Search (NICE) and the duplicate results were removed. 
The reviewer independently screened the updated list of study titles and 
abstracts, in order to identify relevant publications and create a list of eligible 
studies. Studies that did not meet the review criteria were excluded as shown 
in Appendix 7. The remaining studies were retrieved in full text and reviewed. 
This process was reported in Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement (Moher et al., 2009) as can be seen 
in Figure 4.1. 
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Figure 4. 1:  PRISMA Flow Chart of Study Selection Process. 
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A systematic data-extraction sheet was developed, and the following 
characteristics were included:  
1. Authors and year of publication 
2. Study design and study setting 
3. Sample size, dropouts, and adherence 
4. Gender  
5. EDSS scale and MS disease course 
6. Description of study and control protocol  
7. Duration and frequency of intervention 
8. Outcome measures 
For the studies where the required information was missing (for example: the 
full text was not identified and only the abstract was available), a personal 
communication with the main author was made. 
4.3  Quality Assessment and Analysis  
A fundamental step of a systematic review study is to provide the most reliable 
evidence about the effects of intervention in RCT studies. In order to address 
this, a risk of bias assessment is used to report qualified results. It is important 
to consider whether the research has been conducted to the highest possible 
standards and to determine the extent to which the results can be believed. 
Many RCT assessment tools are available, which include scales or checklists. 
The most widely used scale in systematic reviews of RCT is the Cochrane 
Collaboration’s tool which assesses the risk of bias in such studies (Munn et al., 
2014). The tool contains both internal validity and descriptive criteria. Six 
domains of bias are included in this tool: selection bias, performance bias, 
detection bias, attrition bias, reporting bias and other sources of bias (Higgins 
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et al., 2011). Assessment of one or more items can be made within each 
domain, which may cover various aspects or outcomes of the domain. For each 
item in the tool, the assessment was in two parts. First part was “reviewer’s 
judgment”, where three potential answers, “high”, “low” or “unclear” risk of bias, 
for each item must be given. The second part was “Support for judgment”, in 
which a descriptive text is provided to ensure transparency in how decisions 
were made. 
The reviewer independently evaluated the quality of included studies by using 
the following criteria:  
1. Checking for selection bias: for each included study, the following was 
evaluated:  
• Random sequence generation. 
❖ Low risk of bias (truly random process). For example: 
random number table or computer random number 
generator. 
❖ High risk of bias (non-random process). For example: odd, 
hospital or clinic record numbers. 
❖ Unclear. 
• Allocation concealment.  
❖ Low risk of bias. For example: telephone randomisation, 
central randomisation, or sequentially numbered sealed 
envelopes. 
❖ High risk of bias. For example: open random allocation, 
unsealed envelopes or alternate dates of birth. 
❖  Unclear.  
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2. Checking for performance bias: for each study, blinding of participants 
and personnel were assessed as the following: 
❖ Low risk of bias. For example, the participants and personnel 
had no knowledge of which intervention was received.  
❖ High risk of bias. 
❖ Unclear.  
3. Checking for detection bias: for each study, blinding for outcome 
assessment was assessed as the following: 
❖ Low risk of bias. For example, the participants and personnel 
had no knowledge of which outcome assessment was received.  
❖ High risk of bias. 
❖ Unclear.  
4.  Checking for attrition bias: for each study, incomplete outcome data 
such as withdrawals or drop-outs must be explained. For each attrition 
and exclusion, the reason must be explicit. It should be clear if it was 
included in the analysis of the study as which of the following: 
❖ Low risk of bias: if less than 10% was missing. 
❖ High risk of bias:  if more than 10% was missing.  
❖ Unclear.  
5. Checking for reporting bias: for each study, selective reporting must be 
described as the following:  
❖ Low risk of bias: when all of the study’s pre-specified outcomes 
and expected outcomes were reported. 
❖ High risk of bias: when not all of the study’s pre-specified 
outcomes were reported. 
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❖ Unclear. 
6. Checking for other sources of bias: for each study, other problems, such 
as: was there any potential source of bias related to specific study 
design? Was there any bias in the selection of the study participants (for 
example, only male or female participants were included, only mild cases 
were included, or a specific type of MS was included).  
❖ Low risk of bias: meaning that there are no other problems. 
❖ High risk of bias: meaning that there are other problems. 
❖ Unclear. 
4.3.1  Analysis  
The method for analysing the quality of the studies depends on the critical 
appraisal of each individual study. The answers to the above tool were either 
low risk of bias, high risk of bias or unclear. The decision about the scoring 
system and the cut-off for inclusion of a study were based upon the guidelines 
in the Cochrane Collaboration’s tool for assessing risk of bias in randomised 
trials (2011).  
The guidelines highlighted that reviewers could make the decision whether or 
not to include a study, based on whether the study met key domains. The 
reviewers should decide which domains are most important in the context, 
ideally when they are writing the protocol (Higgins et al., 2011, p.3).  
In this review, the reviewer considered the potentially included study as “high 
quality” if all key domains were at low risk of bias. If one or more from the key 
domains was at high risk of bias, the study was considered as “low quality”.  
There were four key domains in this review: “selection bias, attrition bias, 
reporting bias and other sources of bias”. In the last domain, study restriction to 
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one gender were considered as source of bias. Unclear risk of bias was 
considered when a low or unclear risk of bias was given for all key domains. In 
addition to the risk of bias evaluation tables for each study included, a 
summarise judgements figures was used to illustrate the overall analysis (see 
figure 4.2 and 4.3). 
4.4  Results     
Out of the 922 studies identified from the electronic and manual searches, 709 
studies were removed due to duplication. The remaining 213 studies were 
screened from titles and abstracts. Out of the 213 studies, 179 were excluded 
due to: irrelevant titles (not MS patients or not exercise intervention: n=127), 
written language was not English (n=14), pilot studies (n=6), case studies (n=2), 
the intervention was combined (n=29), and non-human participants (n= 1). The 
remaining 34 studies were screened for eligibility using the inclusion criteria for 
this review. Out of 34, 27 studies were excluded, details are outlined in 
Appendix 7.  
The search strategy revealed seven RCT studies  (Dalgas et al., 2009, 2010; 
Dodd et al., 2011; Medina-Perez et al., 2014, 2016; Kjølhede et al., 2015; 
Moradi et al., 2015). Details of the seven studies are presented in Table 4.1. 
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Table 4. 1:  Studies’ Characteristics 
Author (Year) Study 
design & 
setting 
Sample size, 
drop-outs & 
adherence 
Gender EDSS (±SD) 
and MS 
course 
Description of 
study and 
control protocol 
Duration & 
frequency of 
intervention 
Measuring outcomes  
After 
intervention 
Follow-up 
period 
1. Dalgas et 
al. (2009) 
RCT in 
Denmark  
SS: 38 (PRT=19, 
CG=19). 
Total dropout: 
7/38=18% (4RT, 
3CG) 
Adherence: 99% 
F=20  
M=11 
(after drop-
out)  
EDSS: 3.0-5.5 
MS course: RR 
only 
PRT: weight 
machines were 
used for 5 leg 
exercises.  
3-4 sets, 8-12 rep. 
at 8-15 RM, 2-3 
minutes rest 
between sets.  
CG: normal 
physical activity 
took place. 
*Follow-up: un-
supervised 
training for PRT.     
12 weeks 
2 sessions/week 
Week-12: 
KE MVC, KF-
MVC, 1 RM leg 
press, FS, SCT, 
CST, 10-MWT, 6-
MWT: all 
improved in PRT 
but there were no 
changes in CG.  
Week-24: 
In PRT: only KE-
MVC and FS 
were maintained. 
In CG: the 
effects of PRE 
after the trial 
were similar to 
what was gained 
in the PRT during 
the trial. 
2. Dalgas et 
al. (2010) 
RCT in 
Denmark 
SS: 38 (PRT=19, 
CG=19). 
Total dropout: 
7/38=18% (4RT, 
3CG) 
Adherence: 99% 
F=20  
M=11 
(after drop-
out) 
EDSS: 3.0-5.5 
MS course: RR 
only 
PRT: weight 
machines were 
used for 5 leg 
exercises.  
3-4 sets, 8-12 rep. 
at 8-15 RM, 2-3 
minutes rest 
between sets.  
12 weeks 
2 sessions/week 
Week-12: 
FSS, MFI-20, 
MDI, SF-36 
(physical & 
mental): all 
improved in PRT 
but there were no 
changes in CG. 
Week-24: 
In PRT: there 
were no 
improvements 
after week-12 but 
there were no 
deteriorations 
lower than the 
baseline score. 
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CG: normal 
physical activity 
took place. 
*Follow-up: un-
supervised 
training for PRT.   
In CG: there 
were 
improvements in 
fatigue and SF-
36 for quality of 
life (mental 
component) only.  
3. Dodd et al. 
(2011) 
RCT 
in 
Australia  
SS: 76 (PRT=39, 
CG=37). 
Total dropout: 
5/76=7% (3PRT, 
2CG) 
Adherence: 92% 
(22.9±1.5 out of 
24) 
F & M Ambulation 
Index score: 2-
4 
MS course: RR 
only 
PRT: weight 
machines were 
used for 5 leg 
exercises.  
2 sets, 10-12 rep. 
at 10-12 RM, 2 
minutes rest 
between sets.  
CG: normal 
physical activity 
habits & social 
program: 1 
hour/week. 
*Follow-up: both 
groups were 
advised not to do 
any PRE, only 
normal activity.   
10 weeks 
2 sessions/week 
Week-10: 
MP: 
PRT=increased, 
CG= no changes 
ME: 
PRT=increased, 
CG= no changes 
Fatigue: 
PRT=decreased, 
CG= no changes 
QoL: 
PRT=increased, 
CG= no changes 
Week-22: 
PRT: no 
increase, but the 
level did not 
reach baseline 
level. 
CG: no changes.  
4. Kjolhede 
et al. 
(2015) 
RCT, two 
centres in 
Denmark  
SS: 35 (PRT=18, 
CG=17) 
Total dropouts: 
6/35=17% (1 in 
PRT during 
intervention 
period, 5 in 
F & M EDSS: 2.0 to 
5.5 (mean of 3) 
MS course: RR 
only 
PRT: weight 
machines were 
used for 4 leg 
exercises & 2 
upper limb 
exercises.  
24 weeks 
2 sessions/week 
Week-24: 
Functional 
capacity: all 
T25FWT, 2MWT, 
5STS, MSWS-12, 
and ascending 
stairs-climb 
Week-48: 
Functional 
capacity: all the 
tests were 
maintained in 
follow-up, except 
MSWS-12 which 
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CG=2 during 
intervention 
period & 3 at 
follow-up) 
Adherence: 
93±5% (44.7±2.2 
out of 48)  
3-5 sets, 6-10 rep. 
at 6-15 RM, 2-3 
minutes rest 
between sets.  
CG: normal 
physical activity 
took place. 
*Follow-up:  
PRT: continued 
self-guided 
training for 
another 24 weeks. 
CG: underwent 
the same PRE for 
24 weeks.  
improved in the 
PRT.  
No changes in 
the CG.  
declined to 
baseline level in 
the PRT.  
In the CG: only 
T25FWT, 5STS 
and stair climb 
were improved.  
5. Medina-
Perez et 
al. (2014) 
RCT, 
multi-
centre in 
Spain.  
SS: 42 (PRT=30, 
CG=12). 
Total dropouts: 0 
Adherence: 90% 
(22.9±1.5 out of 
24) 
F=23 
M=19 
EDSS: 1-6 
MS course: RR 
only 
PRT: weight stack 
machines were 
used for bilateral 
seated knee 
extensions. 
3 sets, 8-12 rep., 
progressive 
increased load 35-
70% of MVIC, 3 
minutes rest 
between sets.  
CG: normal 
physical activity 
took place.   
*Follow-up: both 
groups were 
12 weeks 
2 sessions/week 
Week-12: 
MVIC:  
PRT= increased, 
CG= decreased 
Maximal torque: 
PRT= increased, 
CG= decreased  
Average muscle 
power:  
PRT= increased, 
CG= decreased  
Muscle 
endurance:  
PRT= increased, 
CG= increased 
Week-24 (de-
training period):  
In PRT: all 
variables 
decreased, 
except muscle 
power which was 
higher than 
baseline level.  
In CG: all 
variables 
decreased.   
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advised not to do 
any PRE, only 
normal activity.   
6. Medina-
Perez et 
al. (2016) 
RCT, 
multi-
centre in 
Spain. 
SS: 77 (PRT=38, 
CG=39). 
Final data 
included and 
analysed: 40 
participants 
(PRT=20, 
CG=20) 
Total dropouts: 
37/77=48%  
Adherence: 95% 
(22.8 out of 24) 
F=20 
M=20 
(after drop-
out) 
EDSS: 3-6 
MS course: RR 
only 
PRT: weight stack 
machines were 
used for bilateral 
knee extensors. 
3-4 sets, 4-10 
rep., progressive 
increased load 40-
70% of MVIC, 3 
minutes rest 
between sets.  
CG: normal 
physical activity 
took place.   
12 weeks 
2 sessions/week 
Week-12: 
MWIC:  
PRT= increased, 
CG= no changes 
Maximal torque: 
PRT= increased, 
CG= no changes  
Peak muscle 
power:  
PRT= increased, 
CG= no changes 
N/A 
7. Moradi et 
al. (2015) 
RCT in 
Iran 
SS: 20 (PRT=10, 
CG=10) 
Total dropouts: 
4/20=20%, 
(PRT=2/10 & 
CG=2/10) 
Adherence: 
100% 
Only male 
participants 
EDSS: 1.0-6.0 
MS course: 
RR/SP 
PRT: conventional 
weight machines 
were used for 
seated rowing, 
chest presses, leg 
extensions & 
presses. 
1 set, 6-10 rep. at 
50% 1-RM & 10-
15 rep. at 60-80% 
1-RM  
CG: normal 
physical activity 
took place. 
8 weeks 
3 sessions/week 
10-metre timed 
walk test: 
PRT= decreased, 
CG= no changes 
Three-minute 
step test:  
PRT= increased, 
CG= decreased 
Time up & go 
test:  
PRT= decreased, 
CG= no changes 
Flamingo stand 
test:  
PRT= increased, 
CG= no changes 
N/A 
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Seated rowing, 
chest presses, 
leg extensions & 
presses:  
PRT= increased, 
CG= decreased 
EDSS:  
PRT= decreased, 
CG= increased 
 
Abbreviation: 10-MWT= 10 Minute Walking Test  
2MWT= Two Minute Walk Test 
5STS= 5-Time Sit-To-Stand Test 
6-MWT= 6 Minute Walking Test 
CG= Control Group 
CST= Chair Stand Test  
EDSS= Expanded Disability Status Scale  
F= Female  
FS= Functional System scale  
FSS= Fatigue Severity Scale  
KE MVC= Knee Extensor Maximum Voluntary 
Contraction  
 
KF-MVC= Knee Flexor Maximum Voluntary 
Contraction  
M= Male 
MDI= Major Depression Inventory      
ME= Muscle Endurance 
MFI-20= Multidimensional Fatigue Inventory  
MP= Muscle Power  
MSWS-12= 12-item MS Walking Scale 
MVIC= Maximal Voluntary Isometric Contraction 
MWIC= 
N/A= Not Available  
PRE= Progressive Resistance Exercise  
 
PRT= Progressive Resistance 
Training 
QoL= Quality of life 
RCT= Randomized Controlled Trials 
rep.= repetitions 
RM= Repetition Maximum  
RR= Relapsing Remitting 
SCT= Stair Climbing Test  
SF-36= Short Form 36  
SP= Secondary Progressive  
SS= Sample Size  
T25FWT= Time 25 ft Walk Test 
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4.4.1  Description of studies  
All included studies were written in English and published between 2009 and 
2016. Moreover, these studies were conducted in different countries: two in 
Spain (Medina-Perez et al., 2014; Medina-Perez et al., 2016), one in Iran 
(Moradi et al., 2015), one in Australia (Dodd et al., 2011) and three in Denmark 
(Dalgas et al., 2009; Dalgas et al., 2010; Kjolhede et al., 2014).  
The included studies consisted of 326 participants with 173 enrolled in the 
interventional group and 153 enrolled in control group (normal physical 
activities). Two studies contained 76 and 77 participants respectively (Dodd et 
al., 2011; Medina-Perez et al., 2016), but the rest had between 20 and 42 
participants (Medina-Perez et al., 2014; Dalgas et al., 2009; Dalgas et al., 2010; 
Kjolhede et al., 2014; Moradi et al., 2015).  
4.4.2  Risk of bias in included studies 
The methodological quality scoring for the included studies was based on the 
Cochrane Collaboration’s tool for RCTs. The reviewer independently assessed 
the risk of bias in the included studies as presented in Appendix 8. Five studies 
were classified as high quality studies (Medina-Perez et al., 2014; Dalgas et al., 
2009; Dalgas et al., 2010; Kjolhede et al., 2014; Dodd et al., 2011) and two were 
classified as low quality studies (Moradi et al., 2015; Medina-Perez et al., 2016). 
As can be seen in Figure 4.2 and Figure 4.3 risk of bias in some individual 
studies was higher in some domains than others. For all studies, a summary of 
key domains is highlighted below: 
• Random sequence generation and allocation concealment (selection 
bias): all studies presented some information about the method used for 
randomisation and the way concealed or randomisation lists were 
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generated. Three studies (Kjolhede et al., 2014; Dodd et al., 2011; 
Moradi et al., 2015) provided detailed information about the process.  
• Incomplete outcome data (attrition bias): all of the studies, except two 
(Moradi et al., 2015; Medina-Perez et al., 2016) included all data in the 
final analysis. In the other two studies, the data from the participants 
who had dropped-out during the intervention period had not been 
included in the final analysis and no further information was given about 
the reasons.  
• Selective report (reporting bias): the study protocol was available in 
most studies; however in three studies (Moradi et al., 2015; Medina-
Perez et al., 2016; Medina-Perez et al., 2014), it was difficult to know if 
there were any deviations from the original protocol or not.   
• Restriction to one gender (other bias): one study was found to have a 
restriction to one gender, male only (Moradi et al., 2015), whereas the 
rest of the studies included both genders.  
All studies provided information about ethical approval and patient consent 
before the interventions started.       
 
Figure 4. 2: Risk of bias item graph presented as percentages across all included studies. 
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Figure 4. 3: Risk of bias summary: reviewer’s judgments about each risk of bias item for each 
included study. 
 
4.4.3  Effects of intervention  
I) Participant characteristics 
All participants in the included studies were clinically diagnosed with multiple 
sclerosis by a neurologist. Between 50% and 62.5% of participants were 
females. The severity of disease expressed by EDSS ranged between 1 and 
6.5 in all studies. All studies only included the relapsing-remitting (RR) MS 
course, except Moradi et al. (2015) which also included secondary-progressive 
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(SP). The mean disease duration and participant age group ranged between 5 
and 12.2 years, and 34 and 50.4 years, respectively. 
II) Disability progression, intervention adherence and drop-out rate 
The most common and validated tool to measure the disease progression in the 
studies was EDSS. In all studies, PRE had no effects on the score except in 
Moradi et al. (2015), where the score decreased in the exercise group after 8 
weeks of intervention. However, no studies reported any deterioration or any 
symptom exacerbations. The level of adherence in all studies was high 
(between 90% and 100%), while the drop-out rates ranged between 0% to 20%. 
Only Medina-Perez et al. (2016) reported a drop-out rate of 48% (37/77 
participants).  
In summary, as a long-term intervention ranging between 8 and 24 weeks, there 
was a good adherence to PRE in the experimental group. However, there was 
no indication about the effects of PRE on disease progression.  
III) Muscle performance and endurance  
Improvement in muscle strength was consistently reported in the high-quality 
studies. Lower extremity strength significantly increased in maximum voluntary 
isometric contractions (MVIC), or isotonic voluntary contractions (which are 
measured in 1RM, 1 repetition maximum). The MIVC and 1RM of the lower limb 
at baseline in the experimental group was improve after PRE intervention. The 
MVIC at the knee extensor, knee flexor and ankle plantar flexion increased 
between ~7% to 11% (Dalgas et al., 2009; Dalgas et al., 2010; Medina-Perez 
et al., 2014; Kjolhede et al., 2014) and the 1RM increased 16.8% in leg press 
and 29.8% in reverse leg press (Dodd et al. 2011). In addition, the peak torque 
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was measured isokinetically in Medina-Perez et al. (2014) and a slight 
improvement was found in the knee extension (7.7% increase).  
In terms of muscle endurance, the results in the included studies were 
consistent as well. Slight improvement in muscle endurance was found in 
Medina-Perez et al. (2014) and Dodd et al. (2011).    
In summary, there is strong evidence that PRE can increase MS patients’ lower 
extremity strength. However, no change occurred in the endurance. In general, 
there is a need for future studies that measure cardiovascular, neural adaptation 
and morphological and evaluate it relation to different PRE protocol.  
IV) Functional capacity 
Functional capacity has been measured by different outcome measurements in 
the included studies. However, the results show consistent improvement in the 
targeted group. The functional capacity score (FS) in Dalgas et al. (2009 and 
2010) improved by 21.5% after 12 weeks of PRE. The patients’ ability to walk 
also showed improvement, the effects of walking performance distance in the 
2- or 6-minute walking tests (2MWT, 6MWT) were increase by 3-10% (Dalgas 
et al., 2009; Kjolhede et al., 2014). The maximum walking velocity, measured 
by a timed 25-foot walk test (T25FWT) or 10-meter walk test (10MWT) improved 
by ~12.4% (Dodd et al., 2009; Kjolhede et al., 2014).  
Other measurements were also used to evaluate the functional capacity. The 
stair climb test (SCT), 5-time sit to stand test (5STS) and chair stand test (CST) 
were all included. In two studies (Dodd et al., 2009; Kjolhede et al., 2014), the 
SCT improved by 12.3% and 13.5% improvement was reported in the 5STS 
and CST.  
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In summary, PRE can improve the functional capacity in the MS patients, along 
with muscle strength, however more studies are needed to strengthen the 
recommendations for this intervention. 
V) Fatigue and quality of life  
Two high quality included studies evaluated the effects of PRE on fatigue and 
patients’ quality of life (Dalgas et al., 2010; Dodd et al., 2011). Dodd et al. (2011) 
compared the modified fatigue impact scale (MFIS) in experimental (EG) and 
control groups (CG), finding that all scale categories (physical, cognitive, and 
psychosocial) improved after 10 weeks in the EG. In addition, the improvement 
was correlated with their improvement in the 2MWT. Similar findings were 
reported in Dalgas et al. (2010) by utilizing the fatigue severity scale (FSS) and 
multidimensional fatigue inventory (MFI-20) to quantify fatigue. In the last scale, 
different components were measured, and the improvement was significant 
overall, with the highest scores reported in the physical fatigue and reduced 
activity components. 
In terms of QoL in MS patients, the results of the above studies were in 
agreement with each other. In Dodd et al. (2011), the World Health Organization 
Quality of life scale (WHOQOL-BREF) did not show any significant difference 
between the EG and CG in the overall score after 10 weeks, but there was a 
difference observed in the physical health component. Likewise, in Dalgas et al, 
the physical component score of the Short Form-36 (SF-36) questionnaire was 
improved but no significant difference was reported in the mental component.  
In summary, the effects of PRE on fatigue show improvements during the 
interventional period, whereas findings regarding QoL diverge in the same scale 
as the improvements reported in the physical component.   
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VI) Effects of intervention on CLLO 
There were no studies highlighted the effects of progressive resistance exercise 
on CLLO which indicates the need to carry out more studies the overcome this 
limitation.  
VII) Effects of progressive resistance exercise at the follow-up period 
After a few weeks of intervention, all variables were reassessed in order to 
evaluate how PRE effects were maintained after the training period. In the 
included studies, the follow-up period was divided into two protocols. One 
advised their participants not to continue with any PRE and only to conduct 
normal activity (Dodd et al., 2011; Medina-Perez et al., 2014). The other advised 
their participants to continue unsupervised PRE training during the follow-up 
period (Dalgas et al., 2009; Dalgas et al., 2010; Kjolhede et al., 2014).  
In the first protocol, the studies reported that the participants could not maintain 
the improvements they gained during the interventional period. However, the 
deterioration did not exceed the baseline level. In Medina-Perez et al. (2014), 
the only variable that was maintained was muscle power (see Appendix 8). 
Conversely, the second protocol showed no significant deterioration after the 
intervention period. 
In summary, MS patients who continued unsupervised PRE training after the 
intervention period maintained their muscle performance, fatigue, endurance 
and high scores in the physical QoL component of SF-36, compared to those 
with normal physical activity without ongoing PRE. These findings are important 
outcomes but may also indicate a more robust quality of life and coping ability 
that allows the continued adherence to treatment rather than giving up.       
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4.5  Discussion 
This systematic review aimed to investigate the effects of PRE on MS patients 
in terms of muscle performance and QoL. The literature revealed seven related 
studies and five of them have been classified as high-quality studies based on 
Cochrane Collaboration’s tool for RCTs. There was strong evidence in favour 
of PRE compared to no exercise in terms of muscle performance, functional 
capacity, fatigue, and physical quality of life for MS patients.  
No evidence was found to be superior in terms of exercise duration, intensity, 
and frequency. However, the studies with durations of 12 weeks and 24 weeks 
of intervention have had sustainable outcomes when patients continued self-
training after the intervention period.  
Regarding participants’ disability, the EDSS scores between 1 and 6.5 showed 
an excellent tolerance level, which rejects the myth that exercise therapy may 
increase fatigue level in MS patients. Furthermore, the adherence to the 
exercise was high (between 90 - 100%) in all the studies, which reflects the 
participants’ acceptance of such intervention. Although most of the studies 
reported a drop-out rate between 0% and 20%, with one study having a rate of 
48% (Medina-Perez et al., 2016), some of the studies stated that this had 
started before the intervention (during pre-assessment) (Dodd et al., 2011; 
Medina-Perez et al., 2016) or the reasons were not related to the intervention 
(Dalgas et al., 2009; Dalgas et al., 2010; Kjolhede et al., 2014).    
Participants 
All participants in this review fulfilled the clinical diagnosis of multiple sclerosis. 
However, in regard to patients’ characteristics in the included studies, the 
disease severity was limited to only one type of MS, which was RR, and 
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disability ranged between 1 and 6.5 in EDSS scores. Only one study (Moradi et 
al., 2015), classified as low quality, included both RR and SP types of MS 
patients. However, it was not clear which type of MS advanced the most in terms 
of outcomes. 
PRE has contributed to the improvement of MS patients in many aspects, 
however the sample size in the included studies were small in general (mean 
of 22 [10-38] participants in the experimental group). This could introduce a type 
II error, which can be avoided by increasing the sample size.         
Exercise protocol 
The dose (intensity, duration, and frequency) of the intervention is an important 
factor to determine the effectiveness of this regime. However, the diversity of 
the “dose” in the included studies made it very difficult to decide which one was 
the most effective.  
Despite this diversity, all the studies reported a positive progression in MS 
patients in different aspects. Explanations were given in the studies regarding 
the reasons for choosing their protocol, nothing more than they were following 
the guidelines in the American College of Sports Medicine. The intensity, 
duration and frequency of the treatment sessions all need further future studies 
to guide the health care practitioners in providing the best evidence-based 
practice for their patients.           
Methodological quality  
Randomised controlled trials (RCTs) are classified as the best paradigm of 
interventional studies. Systematic review studies evaluate the effectiveness of 
the therapeutic intervention in these studies by using a checklist or score tool. 
In this review, five out of seven studies fulfilled the key domains in the Cochrane 
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Collaboration’s tool for RCTs. However, the other domains, such as blindness 
of participants and therapists/assessors to the intervention (performance bias) 
or outcome assessments (detection bias) were generally at a high risk of bias. 
This gives important points to consider in future studies:  the blinding of 
assessors and participants (if possible) to improve the quality of the studies.         
Outcome measures  
Although most of the studies measured the same outcomes, different tests were 
used, which made combining data difficult. The large varieties of measurement 
outcomes confirm the need for a general agreement about the most valid, 
reliable, and important measures to assess the effects of therapeutic 
intervention. In addition, this would enable a comparison to be made of the 
effects of different intervention protocols.         
4.6  Conclusion 
Even though there is a plethora of research on the effects of PRE in MS 
patients, the majority are non-RCTs or conference papers. This  systematic  
review,  based on high quality studies, suggests that PRE can be beneficial in 
terms of muscle strength, endurance, fatigue and walking distance in patients 
with MS. Weak evidence was found regarding overall improvement in quality of 
life, except for the physical component which showed significant progress. 
Finally, no evidence was found that one interventional protocol was superior to 
another.  However, the protocols of 12 weeks and 24 weeks’ duration showed 
that participants maintained the outcomes after the interventional period when 
they continued with self-training exercise. It is not enough to just consider the 
optimal intervention outcomes. The patients’ adherence to the intervention and 
any dropouts to the study, which can weaken or strengthen the result regarding 
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intervention effects, needs to be considered. PRE shows a high level of 
adherence and low level of dropping out, which reflects the participants’ favour 
to practice such exercises.  
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5.1  Introduction 
Data about prevalence of CLLO in pwMS has been reported in some countries 
such as Italy and the UK (reviewed in Chapter 3) but the number of studies in 
this area are still small and have different inclusion criteria. Added to this, in 
developing countries, particularly in the Kingdom of Saudi Arabia, it is very 
difficult to approximate how common the problem is due to the scarcity of 
research evidence. By increased recognition of the problem and training of 
health professionals within health care services it will be possible to provide 
appropriate care and target specialist interventions for specific patient groups. 
Data obtained from different geographical and cultural backgrounds, allows for 
exploration of specific elements of the population such as EDSS, BMI and 
disease course and compare it with the previous studies. Therefore, this chapter 
will mainly focus on the first phase of the study which was about identification 
and screening for CLLO in pwMS. The aim of this phase is to report preliminary 
data of the prevalence of CLLO in people with MS (pwMS) who are resident in 
Riyadh city, in the Kingdom of Saudi Arabia. Based on the limited previous 
evidence examined, the study had two hypotheses: 
1) A high prevalence rate of CLLO would be found in pwMS  
2) CLLO in pwMS would be associated with high disability, advanced age, 
and weight.  
As highlighted in Chapter 2 (2.5   Ethical Approvals and Regulatory Aspects), 
ethical approval was obtained before any element of the study was commenced 
and complied with international standards of research (Ebbesen, 2011; MOH, 
2015; Information Commissioner’s Office, 2018).  
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5.2  Objectives of Phase One 
1) To evaluate the prevalence of Chronic Lower Limb Oedema (CLLO) in 
people with MS (pwMS) who are resident in the Kingdom of Saudi Arabia 
and attendees of one of the two hospitals. 
2) To determine the main characteristics of those at high risk of developing 
CLLO 
5.3   Specific Research Questions  
1) What is the prevalence rate of CLLO in pwMS who are resident in the 
Kingdom of Saudi Arabia and attendees one of the two hospitals? 
2) To examine whether EDSS, body mass index (BMI), body weight, age, 
MS type and disease duration have an influence on the developing 
CLLO in pwMS? 
5.4   Methods 
5.4.1 Phase one setting and duration 
As defined in chapter 2, this study was carried out in two hospitals, King Khaled 
University Hospital (KKUH) and King Faisal Specialist Hospital and Research 
Centre (KFSH&RC). In this study patients attending a number of clinics and 
units (see Table 5.1) were screened for CLLO.  Selection of these units was 
based on feedback received from consultants in neuro-immunology in both 
hospitals about where to screen for CLLO in pwMS.  
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Table 5. 1: Phase one setting  
 
Out-patient clinics:  
• Multiple Sclerosis Clinics (MSC) (specialized neuro-immunology clinics)  
• Neuro-rehabilitation clinics, which is under rehabilitation department  
• Lymphoedema clinic, which is under rehabilitation department but run by 
physiotherapist(s) only 
In-patient unite: 
• Medical Day Unit (MDU), which is one-day in-patient unit for some pwMS who 
are not responding to other MS drugs and they go once a month to this unit to 
have Natalizumab (Tysabri) injection by IV infusion. 
 
Duration of This Phase 
The overall duration of phase one was three months started on the 1st of 
January 2018 and ended on the 31st of March 2018. The reason behind ending 
phase one on this date was because the approval for data collection leave was 
for 6 months only from the 1st of January 2018 until the 30th of June 2018 and 
by assuming that last participant will be recruited on the 31st of March for 12 
weeks that means the last session will be on the last week of data collection 
period. The restriction to 6 months’ time frame was explained in chapter 2 (2.12  
Study Regime). Reaching the required sample size would not have succeeded 
without having in advance planning and good time management.    
5.4.2 The identification and screening step 
Time management and cooperation with the clinics’ head nurses made this 
process runs smoothly. Every day, the principal investigator (PI) attended 30-
40 minutes before the clinic started to screen the patient list and access files 
thereby saving time by gathering some information about the patient’s past- 
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history.  
The Patient information sheet (PIS) and consent form (CF) were given to 
patients while they were waiting for their appointment in the waiting room. When 
the patient came to register her/his presence to the appointment, the head 
nurse handed them the PIS and CF and asked them to take their time to read 
it. In terms of any question(s) or enquiries related to the study, they were 
advised to ask the PI when they entered the clinic but after they had completed 
their time with their doctor. In Appendix 9, the first table shows the number of 
clinics that were running in each hospital during the data collection period, the 
average of patient flows each week and the patient characteristics. The second 
table shows how the researcher managed to cover recruitment within the clinics 
during each week.   
Informed consent given on the day of appointment 
For those who provided informed consent on the same day of their appointment, 
they were undertaken a screening assessment (pitting test) immediately once 
they finished with their doctor (in the last few minutes of the appointment) and 
this was taken place in the same clinic. 
Later informed consent   
Potential participants (n= 6) who decided to have an extra time to consider their 
participation, a follow-up text or call was made after 48 hours. Then, for those 
who showed interest to participate (n= 6), a convenient appointment was 
organized in order for the CF to be signed. After this, the screening assessment 
was undertaken and if the participant was found to have CO, they were able to 
proceed with the intervention. The entire process of identification, screening and 
recruitment is described in Figure 5.1 below. 
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Figure 5. 1:  The process of phase one 
 
 
 
 
 
                  
                  
 
  
 
 
 
5.5  Screening Assessment   
The screening assessment was conducted in order to confirm the presence or 
absence of CLLO, two factors were assessed: 
5.5.1 The chronicity of the oedema 
Chronic oedema is classed as persistent when swelling is present for more than 
3 months (Atkin, 2014). In the study, this was judged based on patient’s or 
carer’s feedback. If the oedema presents more than three months, then the 
oedema was considered as a chronic. In some cases, where the participant 
could not give an answer, the second factor was considered the main indicator 
for the screening assessment.   
The number of potential participants who had been given the PIS and CF  
N= 269, in total  
N= 133 in KFSH&RC, N= 136 in KKUH 
At the same time 
N= 263 
 
Needed more time 
N= 6 
 
 
Had a pitting test 
N= 269 Agreed to sign 
CF 
N=6 
Have CLLO 
N= 21 
No CLLO 
N= 248 
 
CF was signed  
After 48 hrs 
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5.5.2 The existence of oedema 
The existence of oedema can be assessed by an observational pitting oedema 
test. This test is clinically considered as a fast and easy method by applying a 
pressure by one or more fingers to different locations in the participant’s skin in 
the clinical setting (Dai et al., 2015). In research setting, the presence or absent 
of oedema is depending on the pressure applied by the examiner and the length 
of application to the area to be examined. However, differences in applying this 
method may generate poor data if the test are not controlled.  
The reliability of the pitting test was examined in 2015 by Dai et al. as a first 
stage study of an international epidemiological study of chronic oedema (Dai et 
al., 2015). The AFTD-pitting test was developed as a standard protocol in order 
to evaluate oedema. The AFTD is an abbreviation derived from the four factors: 
the A which indicates the Anatomical locations of oedema assessment; F is the 
Force required to pit; T is the amount of Time; and D is the Definition of oedema. 
The results showed high agreement between rater (n= 4) (> 0.85) on average 
of 5 to 6 oedema patients, and the kappa coefficient showed fair agreement 
which represent the AFTD as a useful method to assess chronic oedema in 
whole body.  
Therefore, this study adopted the AFTD pitting test protocol to assess the CO 
to assure good quality of data. The procedure was applied as shown in Table 
5.2 below:    
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Table 5. 2:  AFTD procedure 
 
A Anatomical location was at the following area in both side: 
Foot: behind medial malleolus, front to the lateral malleolus; and in the 
dorsum area at the metatarsal bone. 
Leg: was in two random locations around the shin bone, one dorsal and one 
proximal 
Thigh: was also random, one distal and proximal.   
F The examiner was using the thumb to apply the test and the force was strong, 
fixed and stable every time.   
T 10 second for each location measured by mobile timer. 
D Either pitting or non-pitting. 
Example of the pitting text with different participants: 
                   
        Lateral malleolus                   Metatarsal bone                           Shin bone  
 
This test should be pain less and any tenderness during the test should be 
further examined to eliminate any association with Deep Venous Thrombosis 
(DVT). The PI was trained to do this test in the lymphoedema clinic in the 
Queens Medical Centre (QMC) hospital in Nottingham for one day with a 
specialized nurse in the clinic. This screening test during this phase was just a 
quick initial assessment to determine if the potential participant has a CLLO or 
not but further assessment and investigation was carried out in the second 
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phase during the first session. When the potential participant did have a positive 
test, they were asked if they would like to continue and start the intervention. 
Positive pitting test means that when the PI applied the pressure and removed 
it after 10 second, the skin did not rebound back to its original position. Non 
pitting on the other hand, occurs due to changes in tissue composition such as 
fibrosis and adipose tissue and does not cause any lasting indentation. Non 
pitting oedema is a sign of an advanced stage of lymphoedema (Moffatt, Keeley 
and Quéré, 2019b) where the limb has increased in its size but when the pitting 
test is performed there will be a lack of bounce back.  
5.6  Statistical Analysis  
Univariate and bivariate analysis was run using SPSS software version 26. For 
continues variables (age, weight, EDSS, BMI and MS duration), the mean ± 
standard deviation (SD) was calculated while distribution as percentages was 
done for categorical variables (gender and MS type). The distribution of the data 
was normal; therefore, a t-test was used to compare the continuous variables 
and the Chi-square test for categorical variables. In addition, a Logistic 
regression test was undertaken to predicate values of an input and the 
probability of the variables in developing CLLO. Because the outcome of the 
study is categorical (with or without CLLO), the logistic regression test model 
was used.        
5.7  Results  
During the screening phase, 269 pwMS were screened in two hospitals for 
CLLO. Of these 269, 190 (71%) were women and 79 (29%) were men. Table 
5.3 shows the sample characteristics of pwMS, of whom 21 (8%) were suffering 
from CLLO in both legs and 248 (92%) were not affected. The mean age for 
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participants with CLLO was 45 (SD±7.6) with a mean MS duration of 12 years 
and 5 months (150.6 months). The weights, BMI and EDSS were higher in the 
population with CLLO (mean was 75.9 kg, 28.8 kg/m2 and 5.4 respectively) in 
comparison to those without CLLO (mean was 62.9 kg, 23.9 kg/m2 and 2.4 
respectively). From the 21 who presented with CLLO, only 4 (19%) had already 
recognized the swelling and mentioned it to their doctor.  
Most of the sample (with and without CLLO) were suffering from RRMS type 
(n= 255) (94.7%), with PPMS affecting (n= 10) (3.71%) and SPMS (n= 4) 
(1.478%) were less common. Of those with RRMS, 6.3% (16 out of 255) had 
developed CLLO, where 3 out of 4 SPMS and 2 out of 10 in the PPMS had 
CLLO.  
Table 5. 3:  Characteristics of pwMS with and without CLLO 
 
 
Variable 
Chronic edema  
Mean 
difference 
Yes 
N= 21 (±SD) 
No 
N= 248 (±SD) 
Age Mean= 45 (±7.6) Mean= 32 (±9.6) 12.89 
Weight (kg) Mean= 75.9 (±18.0) Mean= 62.9 (±26.4) 13.12 
BMI (kg/m2) Mean= 28.8 (±13.0) Mean= 23.9 (±10.31) 4.84 
MS duration 
(month) 
Mean= 150.6 (±66.0) Mean= 77.67 (±59.4) 73.00 
EDSS Mean= 5.4 (±1.0) Mean= 2.4 (±2.0) 2.98 
Gender 
 Female (%) 
     Male (%) 
 
18 (9.5) 
3 (3.8) 
 
172 (90.5) 
76 (96.2) 
 
- 
MS type 
 RRMS (%) 
 SPMS (%) 
     PPMS (%) 
 
16 (6.3) 
3 (75.0) 
2 (20.0) 
 
239 (93.7) 
1 (25.0) 
8 (80.0) 
 
 
- 
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The bivariate analysis between two groups in Table 5.4 shows that the t-test 
and chi-square was statistically significant for all variables (continuous: age, 
weight, BMI, MS duration, EDSS; categorical: MS type) except for gender. This 
means that when the age or weight or BMI or MS duration or EDSS or MS type 
increase, the chance to develop CLLO increase as well.  
Table 5. 4:  Bivariate analysis  
 
Variable Test  P value  95% CI 
Age t-test= 6.001*** p=0.000 8.6, 17.1 
Weight (kg) t-test= 2.230* p=0.027 1.5, 24.7 
BMI (kg/m2) t-test=2.02* p=0.044 0.1, 9.5 
MS duration 
(month)   
t-test=5.35*** p=0.000 46.1, 99.8 
EDSS t-test= 11.415*** p=0.000 2.4, 3.5 
Gender x2= 2.498 p=0.114 - 
MS type x2= 27.990*** p=0.000 - 
*P<0.05, **P<0.01, ***P<0.001 
 
To examine the relationship between the presence of CLLO and the significant 
variables from the bivariate analysis (age, weight, BMI, MS duration, EDSS, MS 
type), a multivariable analysis by using logistic regression was undertaken as 
shown in Table 5.5.  By running first, a univariate (Crude OR) logistic regression, 
a statistical significance (p= <0.05) was found between dependent CLLO and 
the following independent variables (age, weight, BMI, MS duration, EDSS, MS 
type). A multivariate analysis was undertaken by placing the statistically 
significant variables found in the univariate analysis. 
The analysis showed that (Adjusted OR) logistic regression, 61.8% of the 
variation in the outcome is influenced by the variables in the logistic regression 
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model based on negelkereke r-square (the equivalent of adjusted r2 for binary 
outcomes). A statistical significance (p= <0.05) was found for age, weight and 
EDSS only compared to the parameters found in the univariate analysis 
This indicates that pwMS who are of an advanced age are 1.093(OR) (CI 1.013, 
1.179) times more likely to have CLLO than those with younger age.  In terms 
of weight and EDSS, those who have high weight and more disabled are 
1.047(OR) (CI 1.006, 1,089) and 2.735 (OR) (CI 1.684, 4.441) time higher odds 
respectively of developing CLLO than those with low weigh and less disabled.
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Abbreviations: OR= odds ratio. Note: the dependent variable in this analysis is pwMS developed CLLO coded so that yes CLLO =1 and No CLLO =0     
 
Table 5. 5: Logistic regression analysis of pwMS developing CLLO (first model) 
                    Outcomes: developing CLLO (Yes/No) 
                     Negelkerke R Square = 0.618, Chi-square= 2.248, p=0.972 
Independent variable Univariate OR (Crude)  Multivariate OR (Adjusted)  
OR p value 95% CI OR p value 95% CI 
Age 1.131*** p=0.000 1.077, 1.188 1.093* p=0.022 1.013, 1.179 
Weight (kg) 1.023* p=0.025 1.003, 1.043 1.047* p= 0.024 1.006, 1,089 
BMI (kg/m2) 1.050* p=0.043 1.002, 1.101 1.046 p=0.311 0.959, 1.141 
MS duration (months) 1.015*** p=0.000 1.009, 1.022 1.009 p= 0.140 0.997, 1.021 
EDSS 1.815*** p=0 .000 1.448, 2.275 2.735*** p= 0.000 1.684, 4.441 
MS type (Reference= RRMS) 
Type 1= SPMS 
Type 2= PPMS 
 
 
44.81** 
3.73 
 
 
p=0.001 
p=0.113 
 
 
 
 
 
27.696 
1.180 
 
 
p=0.061 
p= 0.909 
 
0.862, 890.348 
0.070, 20.003  
*P<0.05, **P<0.01, ***P<0.001 
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A final logistic regression model (Table 5.6) was created after testing multiple models while removing and adding variables and testing 
their significance and their effect. The final model appeared significant with 57% negelkereke r-square. This means that pwMS who 
are more disabled, with more weight and in advance age are 1.111, 1.056 and 2.871 (respectively) higher odds to develop CLLO.   
Table 5. 6:  Logistic regression analysis of pwMS developing CLLO (final model)  
                     Outcomes: developing CLLO (Yes/No) 
                     Negelkerke R Square = 0.571, Chi-square= 1.713, p= 0.989  
 
Independent Variable OR P value 95% CI 
Age 1.111** P=0.002 1.040, 1.187 
Weight (kg) 1.056*** P=0.000 1.029, 1.084 
EDSS  2.871*** P=0.000 1.845, 4.468 
*P<0.05, **P<0.01, ***P<0.001 
Abbreviation: OR= odds ratio. Note: the dependent variable in this analysis is pwMS developed CLLO coded so that yes CLLO = 1 and No CLLO=0 
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5.8  Discussion  
The purpose of this phase was to assess the frequency of chronic lower limb 
oedema in people with MS who are resident in the Kingdom of Saudi Arabia 
and determine the main characteristics of those at high risk of developing it. The 
results support what has been identified by other studies (reviewed in chapter 
3) that the CLLO in pwMS is a common problem, however, the prevalence in 
this study was lower (8%) than what have been reported in others. As predicted, 
our analysis showed that those who are more disabled, with more advanced 
age and increased weight were more likely to develop CLLO.  
The low frequency of CLLO in this study could be related to the sample 
characteristics in comparison to the previous studies that highlighted in chapter 
3. The possible reasons for this include that the majority (95%) of screened 
sample in our study were RRMS (255/269). In those, 173 (68%) were with 
EDSS <3.0 and 82 (32%) with EDSS 3.0 and more. None of the 173 have 
oedema, however, 17 (21%) out of 82 found to be positive. This point was the 
point of difference between our results and other studies, as in our study fewer 
physically disabled people were included compared to Solaro et al. (2006), 
Arpaia et al. (2010) and Keeley et al. (2017). Since, for example, data in Arpaia 
et al. (2010) study concerning developing CLLO in pwMS was limited to 
advanced MS who are bedridden or wheelchair bound, this reflects on the 
results which found that 85% of pwMS have CLLO. As agreed in all studies that 
those more disabled are more likely to have lower limb oedema. 
Another possibility is the obesity. Our study indicates that people with higher 
weight are more likely to develop CLLO. The BMI recognized to be statistically 
significant and high in the group with CLLO but not in the other group, which 
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was similarly reported by Keeley et al. (2017) study. In this respect it is important 
to note patients’ nutrition and raise the awareness among healthcare provider 
to discuss this point during patients’ visit. Further research is recommended 
about the possibility of preventing CLLO by adopting a healthy lifestyle that 
includes exercise and good nutrition at the same time.  
The role of self-report has not been examined in previous studies of CO in 
pwMS except in Keeley et al (2017). The study indicates that 38% of the cases 
did not recognize that they suffered with CLLO. Our study results in this respect 
were much higher, as 81% of the screened people who have CLLO were not 
recognized that they have CO and only 19% reported it to their neurologist. 
Detecting and recognizing the oedema is often difficult especially when the 
symptoms are mild. Added to this, low level of awareness among pwMS and 
their health care provider could impact negatively on identifying and receiving 
treatment at early stage of the problem developing. Although those who 
recognized their oedema in our study did inform their neurologist, however, 
under-estimating the problem by their health care provider led to anxiety and 
discomfort which will be discussed in chapter 7.     
Mention should also be made to patients’ age. Multivariate analysis in this study 
demonstrated that older subjects with advanced disability and weight are more 
likely to have CLLO, this conclusion is in line with the results of other previous 
studies. It would seem appropriate from a theoretical point of view that 
measuring indicators that detect CO at early stage can be added during a 
routine visit to neurological clinic, but challenges would be associated with the 
time required to be undertaken and skills health care provider to apply it. Further 
feasible studies are therefore recommended.    
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Some limitation of this study must be considered. This was a preliminary study 
and findings cannot be generalized easily. In addition, results of CLLO 
prevalence in pwMS in this study might under rather than over-estimate the true 
rate as the majority of screened sample were less disabled. Although this was 
limited to one city with two centres included, it’s a foundation for future research 
tackling the same issue. The majority of studies that have been undertaken so 
far have been in Western health care countries, particularly in Europe, and the 
results may reflect the level of healthcare system available that specializes in 
the assessment of lymphoedema and the awareness of the healthcare provider 
in diagnosing and assessing the oedema. 
Obviously, the field would benefit from more rigorous epidemiological studies 
that acknowledge current challenges and changes in identifying chronic 
oedema earlier in pwMS and including different locations worldwide to compare 
outcomes. In addition, neurologist should add some simple questions during 
visit to screen for the risk of chronic oedema and add simple pitting test to the 
neurological assessment.  
5.9  Conclusion  
The main strength of this study is the fact that this is the first preliminary study 
to evaluate and critically assess the frequency of CLLO in pwMS in Saudi 
Arabia. The CLLO in pwMS is undeniably a common problem, which is 
unrecognized, under-estimated and undertreated. By raising awareness about 
CLLO among health care providers and patients, result in early detecting and 
treatment of the problem can avoid the consequences of which may be the 
development of serious illness such as cellulitis. Epidemiological Studies in this 
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area are still limited and further research in other countries including low 
resource income countries is required to compare the outcomes.     
5.10  Summary  
Within this chapter, phase one objectives, specific research questions, methods 
and results have been described. The next chapter will present the quantitative 
phase, where those who agreed to participate from phase one started their 
intervention which will be described in detail.  
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6.1  Introduction  
Focusing on treating the symptom (chronic oedema) and forgetting about the 
origin of this symptom will not help in solving the problem. Furthermore, 
addressing the underlying cause may achieve better outcomes. The CLLO in 
pwMS occurs because of the disease itself. CO is often caused by patient’s 
limited physical activity, especially by the insufficient or incorrect use of the calf 
muscle pumping mechanism (Arpaia et al., 2010). Therefore, phase two of this 
thesis is focused on how to treat the problem from its origin by prescribing a 
progressive resistance exercise that is found to be safe and tolerable for pwMS 
as well as for lymphoedema patients, as research described in chapter 1 and 4 
shows. However, the effects of progressive resistance exercise on patients with 
both neurological and lymphatic problems are unknown. This PhD study is the 
first study that focuses on treating CLLO in pwMS. Progressive resistance 
exercise as highlighted in chapter 1 (1.7  Exercise Therapy and 1.8  Thesis 
Rationale) has a low effect on Uhthoff’s phenomenon, which was the vital point 
behind selecting this exercise for this study.  
This chapter discusses the quantitative method stage of phase two that focused 
on the objectives relating to pwMS treated for CLLO. Ethical approval, informed 
consent, patient information sheet, data production and archiving were 
described in chapter 2.       
6.2  Objectives of Phase Two 
1) To assess the effectiveness of Progressive Resistance Exercise (PRE) 
in the management of Chronic Lower Limb Oedema (CLLO) in people 
with MS who are resident in the Kingdom of Saudi Arabia. 
2) To determine the impact of CLLO on pain and quality of life. 
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6.3  Methods  
6.3.1  Phase two setting and duration  
Phase two was undertaken in the rehabilitation department in both hospitals. 
The overall duration of the data collection was 6 months starting from 1st of 
January 2018 and ending on the 30th of June 2018. As highlighted in the 
previous chapter, the first phase (screening) took place between January 2018 
until March 2018, however, once a participant was recruited from phase one, 
the intervention was implemented after a few days and this where phase two 
started. Each participant took part in the study for 12 weeks with two sessions 
per week. The study ended with the last contact with the last participant. 
6.3.2  Recruitment of participants 
Based on sample size calculation (6.6.1  Sample size and justification) fifteen 
pwMS were recruited from the secondary care hospitals with bilateral CLLO. 
Recruited participants were given a participant sheet with information about the 
study in advance. Participants were given opportunity to ask questions about 
the study and assured that their participation is voluntary and their decision not 
to participate will not affect their access to care. Participants who agreed to 
participate in the study were asked to sign the consent form. It was also 
explained that they could withdraw at any time, but attempts were made to 
minimize participants’ withdrawal to improve statistical reliability. In terms of 
discontinuation, participants were aware that they could withdraw from the study 
at their request or at the request of principle investigator (PI) (for example, due 
to changes in the person’s health). Phase two, as illustrated in figure 6.1, started 
with the first session of the first week and ended in session 24 of week 12.  
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Abbreviation: CF= consent form, W= week, N= number of participants, S= session   
Figure 6. 1: Illustration of phase two process 
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Main outcomes measures were taken in the baseline and discharge session which were the following: 
 
1) Circumference measurement 
2) Quality of Life Measure for Limb Lymphoedema (LYMQOL) tool  
3) Short Form of the McGill Pain Questionnaire (SF-MPQ) 
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6.3.3  Clinical procedure  
Once each participant signed the CF, a convenient schedule of sessions for 12 
weeks was arranged. Each week included two sessions with one day rest 
between the two sessions. For example, if the first session was on Monday then 
the next session was arranged for Wednesday and each week followed the 
same order of day and time. 
In terms of the duration of each session, the first (baseline T0) and last 
(discharge T1) session in phase two were the longest. Beside the intervention 
itself, the pre- assessments in the first session and post-assessments in the last 
session were undertaken in addition which extended the session’s duration 
from 60 to 70 minutes. While the in-between sessions, from 2nd to 23rd, took 
between 25 to 30 minutes. Documentation was taken at the beginning of each 
session by completing the case report form (CRF).  
I) General instruction  
Pre-sessional instructions were sent to participants via SMS message in order 
to allow the participants to be prepared for the session in advance. The 
message included the following: 
• Wear comfortable clothes that allow your therapist to assess your lower 
limb. 
• Wear a comfortable training sneaker shoe. 
• Sleep well and try not to do any exercise on the day of your appointment.  
• On the day of your first appointment, you can bring someone to 
accompany you in case you develop fatigue by the end of this session. 
• You can eat your normal meal or snack before your session. 
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Participants were given information about what to expect during and after the 
intervention in the session such as muscular soreness and fatigue.      
II) Case report forms (CRFs)  
The case report form (CRF) is a printed document designed to record all the 
required information for the study purposes. Each participant was assigned a 
study identity code number for use on CRFs. The documents used participant 
initial of first and last names separated by a hyphen or a middle name initial 
when available, and date of birth (dd/mm/yy). The same study identity code 
number was used on the consent form. The CRF was completed in accordance 
with the principals of Good Clinical Practice (GCP).   
CRFs were treated as confidential documents and held securely in accordance 
with regulations. The PI created a separate confidential record of participants’ 
name, date of birth and a local hospital number to allow for identification of all 
participants enrolled in the study in accordance with regulatory requirements 
and for follow-up as required. All paper forms were filled in using a pen. Errors 
were crossed, no errors were corrected with correction fluid. Any change or 
correction to a CRF was dated, initialled, and explained (if necessary) while 
ensuring the original entry remained visible.  
The CRF was completed as soon as possible after the scheduled visit and was 
signed and dated by the person completing the form. For the purpose of this 
study three versions of the CRF were developed (as described below). 
Depending on the chosen treatment option the PI decided what CRF template 
to use. All CRFs templates included header and footer. The header included 
the CRF template name, participant initials and participant’s study code. The 
footer included study name, date, and page number. The CRFs were piloted 
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and validated using a sample of patients before recruitment for the PhD study 
commenced. The three CRFs templates are: 
1) Baseline (T0) CRFs template  
This template (see Appendix 10) was used in the first session (baseline T0) only 
and included the following information: 
• Cover page (include study title, PI name, name of site, participant initials 
and participant study code) 
• Guidance on how to complete the CRF  
• General information (date of assessment, date of signed consent form)  
• Demographics data (DOB, gender, weight, and height) 
• Medical history  
• Physical examination which included the following: 
❖ Muscle strength: by using manual muscle testing with grad from 
0 to 5 (Table 6.1) (Ciesla et al., 2011). 
Table 6. 1: Manual muscle testing grading system 
 
Technique 
From sitting position, the PI asked the participant first to 
perform do a full range of motion (ROM) against gravity 
for both plantar-flexion and dorsi-flexion. If the participant 
was able to perform this exercise, then the PI was 
gradually adding resistance by pushing the participant’s 
foot to the opposite direction of either plantar-flexion or 
dorsi-flexion. Participants were asked to resist this 
movement. Based on the participant reaction, the PI was 
grading the muscle strength based on the following::   
0 
 
Trace 
No visible or palpable contraction 
1 
Visible or palpable contraction (No ROM) 
2 
 
Poor 
2- : Partial ROM, gravity eliminated 
2: Full ROM, gravity eliminated 
2+: Gravity eliminated/slight resistance   
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3 
 
Fair 
3- : > 1/2 but < Full ROM, against gravity  
3: Full ROM against gravity  
3+: Full ROM against gravity, slight resistance 
4 
Good 4- : Full ROM against gravity, mild resistance 
4: Full ROM against gravity, moderate resistance 
4+: Full ROM against gravity, almost full resistance 
5 
Normal 5: Normal, maximal resistance 
  
❖ Range of motion (ROM) of lower limbs by using goniometer. 
Normal range for plantar-flexion is (0 – 50) and dorsi-flexion is (0 
– 20).  
❖ Skin condition  
❖ Pitting oedema test from sitting position (detailed in Table 5. 2:  
AFTD procedure).  
❖ Leg circumference measurement by using tape measurements.  
❖ Calculating the one repetitive maximum (1-RM) 
• The Quality of Life Measure for Limb Lymphoedema (LYMQOL) tool 
(Keeley et al. 2010), the Arabic version  
• Short form of the McGill Pain Questionnaire (SF-MPQ), the Arabic 
version (Abdrabou et al., 2016) 
• Progressive resistance exercise checklist (include week number, 
session number, exercise sets, repetitions, and number of rests between 
each 2 set, and note)  
• The PI name and sign-off 
2) Follow up CRF template   
This was a checklist template (see Appendix 11) and was used from week 1 
(session 2) until week 12 (session 23). The template included: 
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• Cover page (include study title, PI name, name of site, participant initials 
and participant study code) 
• Date of the session, week number and session number 
• Calculated % of 1-RM 
• Progressive resistance exercise checklist include: repetitions, sets, and 
rest between sets 
• Note column that include questions about participant’s general health 
and feedback about the previous session  
• The PI’s sign-off   
3) Discharge (T1) CRF template  
Information gathered in this template (see Appendix 12) was to some extent 
similar to the information collected in the baseline template. This template 
included: 
• Cover page (include study title, PI name, name of site, participant initials 
and participant study code) 
• Date of discharge assessment  
• Progressive resistance exercise checklist (include week number, 
session number, exercise sets, repetitions, and number of rests 
between each 2 set, and note)  
• General information (weight and height)  
• Physical examination (muscle strength and range of motion (ROM) of 
lower limbs, skin condition, pitting oedema test and leg circumference 
measurements) 
• Study completion checklist (include questions related to participant 
completion and withdrawal) 
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• The Quality of Life Measure for Limb Lymphoedema (LYMQOL) tool 
• Short form of the McGill Pain Questionnaire (SF-MPQ), the Arabic 
version  
• The PI’s name and sign-off. 
III) One repetition maximum (1-RM) 
According to the American College of Sport Medicine (ACSM) and the National 
Strength and Conditioning Association (NSCA) (LeSuer et al. 1997; 
Niewiadomski et al., 2008; Jimenez, 2018), testing the one repetition maximum 
(1-RM) is important prior to exercise to measure muscle strength. Each 
individual has a different and unique level of muscle fitness, which needs to be 
determined to track progress in training. One repetition maximum (1-RM) test 
is considered as a gold standard for assessing muscle strength (Seo et al., 
2012). 1-RM is defined as the maximum weight that can be lifted once through 
full ROM with correct and controlled lifting technique (American College of 
Sports Medicine, 2018). 
The intensity of training can be reported in two ways. First, as a percentage of 
1-RM (%1-RM), i.e., the final weight lifted successfully with one clean repetition 
is considered as 100% of 1-RM. Second, as a resistance appropriate for a given 
number of repetitions, for example 10-RM indicates the ability to perform 
exercise for ten and only ten repetitions (Kjolhede, Vissing and Dalgas, 2012). 
In clinical practice, 86% of 1-RM is the same as 6-RM, however, a standardized 
1-RM test of either way with a short warm up and familiarization found to be a 
reliable measurement to assess muscle strength regardless of muscles location 
and gender (Seo et al., 2012). However, in this study we used the 1-RM instead 
of the number of repetitions (for example 6-RM) because we need to find out 
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what percentage should be used for sets of 6-RM to estimate the 1-RM for each 
participant and to have an idea where is the 6 or 8 or even 7 are at (Richens 
and Cleather, 2014).      
Several factors are important to consider for optimizing 1-RM test, which 
includes selection of starting weight, rest intervals between each attempts and 
percentage increase in weight (Niewiadomski et al., 2008; Halabchi et al., 
2017). By applying the standardized procedure as suggested in the literature, 
the following steps were performed to identify the muscle strength for both 
plantar-flexion and dorsi-flexion for each participant, which was undertaken in 
the first session only to estimate the initial weight that the participant can start 
with. The steps were as the following:   
1) On the first visit, participants warmed up prior to the test by stationary 
bicycle for 5 minutes followed by 1-minute rest.  
2) Participants were familiarized with the device (see section 6.5.2) that 
they will be using and performed 6 - 8 repetition of light load followed 
by 1-minute rest.    
3) Each participant completed the test within 5 attempts and one minute 
of rest was given between each attempt. 
4) Participants started the first set with a load from their choice at 50% 
of predicted 1-RM and performed between 5 to 10 repetitions through 
full ROM. 
5) Participants rested for one minute. 
6) For the second set, load was progressively increased to 
approximately 70 – 75% of the anticipated 1-RM and the repetition 
was decreased to 3 – 5 repetition through full ROM.  
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7) Participants rested for one minute. 
8) Load was increased until failed attempt occurred with 85 – 90% of 
the anticipated 1-RM. 
9) All attempts were performed with the same speed of movement and 
ROM.  
10) The final weight lifted successfully with one clean repetition was 
recorded as 1-RM.  
Example 
 
After warming-up, participant performs a set of 8 plantar-flexion with at load, 
for example 5 kg with a clean full ROM. The load is then gradually increased, 
and repetition decreased until one full repetition can be achieved before 
muscle failure. This last attempt is counted as 100% of 1-RM which is in this 
scenario for example 15kg (15kg equals 1-RM). If intervention program calls 
for 40% of 1-RM, this means that 6kg equals 40% of 1-RM (which can be 
calculated as 0.40x15).       
Note: each muscle group has its own 1-RM. Therefore, same 
processes must be taken for dorsi-flexion.    
 
6.4  Main Outcomes Measures  
The pitting oedema test revealed that the participants have bilateral CLLO that 
involved feet and legs but not thighs. The study results were considered 
successful after 12 week of intervention that showed improvement readings in 
primary and secondary outcomes measures between the first session in 
baseline visit (T0) and the 24th session in week 12 visit (T1). 
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6.4.1  Primary outcome measure  
In literature, there are a number of methods to assess oedema and each has 
its advantages and disadvantages depending on the method’s simplicity, 
sensitivity, and specificity. These methods are based on metric and volume 
measurements, and electronic impedance techniques (Tuğral, Virén and Bakar, 
2017). In the clinical setting limb circumferential measurements by using tape, 
water displacement volumetry and perometry are the most commonly used 
methods (Deltombe et al., 2007). Furthermore, percentage water content by 
using lymphscanner is also a reliable measurement at early stage of the 
oedema (Yu et al., 2020). This is because the sensitive probe can only measure 
accumulation of the fluid in the skin dermis at depth up to 2.5mm. Therefore, if 
the accumulation extends from the dermis to deep fascia then the device cannot 
reflect the severity of the oedema stage (Bakar, Tuğral and Üyetürk, 2018).     
Water displacement method is considered in many studies as a gold standard 
for leg volume measurement (Guex and Perrin, 2000; Deltombe et al., 2007; 
Devoogdt et al., 2019). However, some clinical limitations make this method 
undesirable as a measurement of limb volume. One of the limitations of water 
displacement is that the method requires thorough preparation and is therefore 
time-consuming (Devoogdt et al., 2019). When using this method, it is important 
to follow safety and hygiene procedures including suitable water temperature. 
The other limitation of this method is that it is restricted to patients who do not 
present with wounds or ulcers which can often be the case in patient with 
chronic oedema.    
Contrary to the water displacement method, the limb circumferential 
measurement has been found to be the most convenient and commonly used 
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method in clinical practice (Tan, Coutts and Bulley, 2013). Nevertheless, the 
reliability of the circumferential measurement method depends on the clinician’s 
technique because of the tendency to either overestimate or underestimate the 
true limb volume depends on the clinician’s skills (Deltombe et al., 2007).  
Research shows that perometry is a more suitable method while limiting the 
number of errors (Tan, Coutts and Bulley 2013). This infrared light device is 
reported to be a reliable and quick method for measuring leg volume. It has 
been found that the results provided by perometer are very close to those 
obtained by the water displacement (Tan, Coutts and Bulley 2013, Deltombe et 
al., 2007) than circumference measurement. In contrast, Czerniec et al. found 
a high correlation between the circumference measurement method and 
perometer in the assessment of limb volume (Czerniec et al., 2010). However, 
Czerniec et al. study was conducted on breast cancer related lymphoedema, 
therefore, findings cannot be generalized to a lower limb oedema. One of the 
perometer disadvantages is the high cost of the device, therefore many 
clinicians prefer to use either the circumferential measurement or water 
displacement method to calculate limb volume and circumference differences.  
Considering the advantages, disadvantages, and availability of the above 
methods to evaluate oedema, this study used the tape limb circumferential 
measurement in order to ascertain the effectiveness of the intervention. 
Changes in the lower limbs circumference after the intervention were 
considered the primary outcome. In order to further shape our understating and 
knowledge of differences in changes between different leg segments which can 
help to improve treatment and outcomes, leg volume was also determined. 
Using an appropriate mathematical formula, circumference-based volumes 
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were calculated (subheading 6.4.1 (III) Converting limb circumference to limb 
volume).  
I) Procedure using circumferential limb measurements  
Accessibility and reliability of measuring limb circumferential can be easily  
improved if a standard protocol is strictly followed with a constant tension, limb 
position and measurements sites (Williams and Whitaker, 2015) . Following the 
guidelines for circumference measurement from the Best Practice Document 
for the Management of Lymphoedema, a tape measurement with 4cm intervals 
mark in the limb was the method used (International Lymphoedema 
Framework, 2006) but not the foot. Because the size of the foot is limited in 
length, the circumference measurements were taken at two anatomical 
landmark points instead of 4cm intervals, which were the great metatarsal 
phalangeal joints and the ankle by using the figure-of-8 method (Katz et al., 
2010).  
A non-elastic bendable tape with one-centimetre width was used for leg 
measurements. Measurements were recorded in centimetres. The tape 
measure measurement procedure that had been obtained in this study is 
described in the Table 6.2 below. Measurements were taken during the 
participant’s first and last session with the same experienced certified therapist 
(researcher). In the first session (T0) the measurements were taken before the 
intervention whereas in the last session (T1) the measurements were taken 
after 15 minutes of finishing the exercise (Goto, 2020).           
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Table 6. 2: Procedure using tape circumferance measurment  
 
 
1) Form the sitting position with 90° angle at knee and 
ankle, the participant was asked to firmly place 
his/her feet on the ground. 
2) The participant’s leg can be straight if the 
participant on the supine position and if the patient 
in sitting position, his/her bottom was as close to 
the chair or bed edge as possible.  
 
3) On the medial aspect of the patient’s leg, a starting 
point was determined by using a ruler and 
recording the distance from the floor to 2cm above 
the middle of the medial malleolus. Same 
procedure was done on the contralateral leg. 
4) Then a ruler was placed along the medial aspect 
of the leg and the limb was marked at 4cm intervals 
from the starting point to 2cm below the popliteal 
fossa for swelling below the knee. 
5) If swelling extends above the knee, the patient was 
asked to stand if he/she was in sitting position or 
to stay in supine position and marking continued at 
4cm intervals above the knee to 2cm below the 
gluteal crease. 
 
6) After this, with the limb in a relaxed position, the 
circumference was measured at each mark by 
placing the top edge of the tape measure just 
below the mark. 
7) The tape was enclosed around the targeted point 
with the examiner’s one hand was holding the zero 
end of the tape and the second one was holding 
the other end.  
8) Note of the measurements was written in the 
participant’s CRF (the baseline template). 
Middle of the medial malleolus 
2cm from popliteal fossa 
Starting point 
Last point marked in the leg 
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Middle of the medial malleolus 
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9) Same process was repeated to take 
measurements on the other limb.  
 
II) Intra-rater reliability of the circumferential measurement method 
For evaluating intra-rater reliability method, the above circumferential 
measurement method was carried out. Five volunteers above 18 years old (3 
female and 2 male) were included with no lower limb deformity, no acute 
trauma on the lower limb, no history of renal, liver or heart condition. The PI 
performed the measurements from the reference points described above and 
again repeated the same measurements after one week at the same time of 
the day and position. Until the second reading, participants were asked to not 
enrol in Gym or perform any unusual physical activities other than they normally 
do and they should report any trauma or changes in their limb to the examiner 
in the next measurements.   
For the statistical analysis, intraclass correlation coefficient (ICC) was used to 
calculate intra-rater reliability. The ICC range from 0 to 1 and categorized as 
poor (<0.40), fair to good (0.40 – 0.75) and excellent (>0.75). Results showed 
that measurements were statistically significant with excellent rate (ICC 0.99, 
p<0.001). This result was consistence with Baker et al. study where the results 
after first and second week measurements were statistically significant 
between good and excellent (ICC 0.65 – 0.99, p<0.001) (Bakar et al., 2017). 
III) Converting limb circumference to limb volume  
Determining limb volume and its changes is commonly calculated by using 
direct methods such as water displacement or indirect methods such as tape 
measurement (Mayrovitz, 2009). There are different models to calculate  limb 
volume (Figure 6.2), which generally assume that the shape of the limb is 
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formed from a series of either frustum cones (truncated cones) or cylinders 
(disc), and the limb volume calculated as the sum of the volumes of these 
truncated cones or cylinders (Kaulesar et al., 1993; Kazmi et al., 2010). 
However, foot cannot be calculated in the same way as the leg because it does 
not have the shape of frustum or cylinder (Sander et al., 2002; Williams and 
Whitaker, 2015). Therefore, the results of the volume reduction were only 
presented for the leg.   
Figure 6. 2: Difference between the volume calculation of the leg  
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The first model in the figure is called “Frustum Sign Model” where in the 
measured region there are only two circumferential measurements taken at two 
points (distal and proximal of the leg) and the leg volume is calculated by 
frustum or truncated cone between this area. The advantage of this method is 
in providing a quick and easy measurements; however, the accuracy has been 
reported to be low (Chromy et al., 2015). One of the disadvantages of the 
frustum sign model is the limited number of measurement points that lead to an 
estimate rather than a precise volume measurement. This is particular 
important when assessing patients with oedema because the spread of oedema 
is not homogenous i.e., the affected limb may consist of segments with a high 
volume and segments with a low volume. The use of this method may therefore 
provide an inaccurate volume observation albeit quick. 
Unlike the Frustum Sign Model, the second “Disc Model” takes into 
consideration the volume of each segment of the measured leg. The total 
volume is calculated as the sum of all segments’ volumes. This model is more 
accurate than the first one in terms of calculating the volumes of segments but 
the distance between the segments is equidistant (Sander et al., 2002; Chromy 
et al., 2015). This means that only one circumference from proximal border of 
segment is calculated, where the distal one is not included. The starting point 
in this case is not measured and the volume measurement is calculated starting 
at 4cm above the starting point. This may underestimate the true volume of the 
leg.     
The third “Partial Frustum Model” is a combination of both previous models. It 
has the advantages of involving 1) the distal and proximal border of the segment 
as in the first model and 2) dividing the leg into segments and then the sum of 
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these segments’ volumes gives the overall limb volume. This model has been 
validated by many studies that showed it is an accurate method to calculate 
limb volume  (Katz-Leurer and Bracha, 2012; Chromy et al., 2015). In addition, 
the Partial Frustrum Model was found to have a strong correlation (r= 0,98) with 
water displacement (Kazmi et al., 2010). However, one of its disadvantages is 
that it is a time-consuming measurement method, but this issue can be 
overcome by computing the data with a software such as Microsoft Excel. 
Ensuring correct data entry and constant circumference measurements 
intervals will provide valid outcomes (Williams and Whitaker, 2015). Based on 
the review of the advantages and disadvantages of all three models, the “Partial 
Frustum Model” was selected for this PhD study as the method to calculate limb 
volume based on its inclusiveness and accuracy.  
Method  
Figure 6.3 illustrates two examples of leg circumference measurements and 
volume calculations. The first example shows the procedure that was used 
during this study to take leg measurements. As explained in detail in the 
previous section (I. Procedure using circumferential limb measurements), 
measurements at a 4cm interval were taken using a tape measure starting from 
the ankle up to the proximal end of the leg around 2cm below popliteal fossa. 
The procedure divided the leg into segments. The number of the segments 
varied based on the length of participant’s leg. The circumferential 
measurements were then entered into an Excel spreadsheet to calculate leg 
volume.    
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Figure 6. 3: Example of leg circumference measurements and volume  
                     calculation   
 
The formula used to calculate leg volume in the Excel software was the 
Frustrum formula as can be seen in example 2 (Figure 6.3):  
𝑉 =  
𝜋
3
 ×  ℎ (𝑟2 + 𝑟𝑅 + 𝑅2) 
𝑟 =  
𝐶1
2𝜋
   ,           𝑅 =  
𝐶2
2𝜋
 
or if we proceeded from the circumference: 
𝑉 =
𝜋
3
 × ℎ ((
𝐶1
2𝜋
)
2
 +
𝐶1
2𝜋
 .
𝐶2
2𝜋
+ (
𝐶2
2𝜋
)
2
) 
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𝑉 =  
𝜋
12𝜋2
 ×  ℎ (𝐶12  +  𝐶1𝐶2 +  𝐶22)  
𝑉 =  
ℎ (𝐶12 + 𝐶1𝐶2 + 𝐶22)
12𝜋
  
V is the volume, R is the radius of the proximal border of the segment, r is the 
radius of the distal border of the segment, C1 is the distal circumference, C2 is 
the proximal circumference and h is the height (h= 4cm). 
Each segment has C1 and C2 which represents the distal and proximal border 
of the segment. However, in the next segment what was C2 in the previous 
segment is considered as C1 because it is the distal border of this segment. 
After calculating all the segments, the absolute total leg volume was determined 
by the sum of these segments. In terms of calculating the percentage of leg 
volume change, it was calculated as:  
(𝑝𝑜𝑡−𝑣𝑜𝑙𝑢𝑚𝑒 − 𝑝𝑟𝑒−𝑣𝑜𝑙𝑢𝑚𝑒)
𝑝𝑟𝑒−𝑣𝑜𝑢𝑙𝑚𝑒
 ×  100    
6.4.2  Secondary outcomes measures 
The secondary outcomes measures included instruments that measure pain 
and quality of life of participants. Those instruments were completed at the 
following time points: pre-intervention at week1, session 1 (T0) and post-
intervention at week12, session 24 (T1). The level of pain was assessed using 
the Short Form of the McGill Pain Questionnaire (SF-MPQ) and quality of life 
was assessed using the Quality of Life Measure for Limb Lymphoedema 
(LYMQOL) tool.      
I) Short form of the McGill pain questionnaire (SF-MPQ), the Arabic 
version 
Pain in general has been recognized as a complex, highly personal and 
subjective phenomenon unique to the individual (Greene and Meskell, 2017). 
Inadequate assessment of the pain may lead to poor patient outcomes which 
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cause anxiety, immobility, depression, and most importantly distress and 
suffering. According to the international association for the study of pain (IASP),  
chronic pain is considered to be multifactorial in nature with biological, 
psychological and social factors that contribute to each other (Nicholas et al., 
2019).  
People who suffer from conditions such as MS may experience a complex pain 
that is not tied up to one stimulus only. This complex pain compromises patients’ 
quality of life and limit their activities (Fallatah, Fallatah and Zalat, 2019). 
Various pain tools are available to evaluate individual pain levels such as McGill 
Pain Questionnaire (MPQ), Visual Analogue Scale (VAS) and Brief Pain 
Inventory (BIP). However, the McGill Pain Questionnaire (MPQ) is the most 
widely used, multidimensional instrument for measuring the quality and intensity 
of pain (Terkawi et al., 2017). The original long form of this questionnaire was 
introduced by Melzack and Torgerson in 1971 and was modified to a shorter 
one in 1987 (Short Form of the McGill Pain Questionnaire [(SF-MPQ]) (Melzack, 
1987).   
The SF_MPQ consists of 15 descriptors, 1-11 represent the sensory and 12-15 
represent the affective. Each descriptor is rated on an intensity scale as 
0=none, 1=mild, 2=moderate or 3=severe. In total three pain scores are derived:  
1) The sum of the sensory words chosen 
2) The sum of the affective words chosen  
3) The total of all descriptors 
The questionnaire also includes the Present Pain Intensity (PPI) index and a 
Visual Analogue Scale (VAS). The SF-MPQ is a self-reported questionnaire that 
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is easy to use and usually takes around 5 minutes to complete (Terkawi et al., 
2017). Therefore, it was adopted as a pain assessment tool for this study. 
Since this study intended to be undertaken in a country with Arabic-speaking 
community, the SF-MPQ Arabic version was used for participants with Arabic 
language and the original English version was also provided based on 
participant language preference. However, all the participants used the Arabic 
version. The Arabic version of the SF-MPQ was validated and considered 
reliable by many studies such as in Tashani et al. 2016 (Tashani, Alabas and 
Johnson, 2016), Abdrabou et al. 2016 (Abdrabou et al., 2016) and Terkawi et 
al. in 2017 (Terkawi et al., 2017). For this PhD study the version proposed in 
Terkawi’s study was used because their study was conducted in the Kingdom 
of Saudi Arabia whereas the others were conducted in Libya and Egypt. 
Although Saudi Arabia, Libya and Egypt are all Arabic-speaking countries they 
do have different dialects. Therefore, a permission to use this questionnaire was 
sought and obtained from the author via email and was used with our 
participants pre and post the intervention (Appendix 10 for the SF-MPQ Arabic 
version).        
II) Quality of life measure for limb lymphoedema (LYMQOL) tool  
Chronic oedema and multiple sclerosis are known to significantly  impact on 
persons’ quality of life (QoL) (Greene and Meskell, 2017). Quality of life is a very 
personal matter and is linked to many factors such as culture, belief, social 
background, age and expectations (Keeley, 2008). In the literature, relevant 
health related quality of life tools are described as either generic or cancer-
specific or lymphoedema-specific (Cornelissen et al., 2018). The generic and 
condition-specific tools may not be accurate or informative, as it is either very 
 Quantitative Phase  
131 
 
Chapter 6 
limited to assess problems experienced by breast cancer patients or very 
general with no consideration to patient-centred care which may not reflect what 
matter most to the person (Morgan, Franks and Moffatt, 2005; Keeley, 2008). 
In addition, some of the tools are not formally validated such as Wesley Clinic 
Lymphoedema Scale (WCLS) or post mastectomy lymphoedema (Keeley et al., 
2010). 
A recent review study conducted by Cornelissen aimed to provide an overview 
of the different questionnaires to assess the most complete and accurate QOL 
measure (Cornelissen et al., 2018). Out of 15 different questionnaires found, 
six were lymphoedema-specific questionnaires and the rest were either general 
(n=6) or cancer-specific (n=3). Among those related to lymphoedema-specific, 
two were selected as complete and accurate tools (Lymphoedema Quality of 
Life Inventory [LyQLI] and Lymphoedema Functioning, Disability, and Health 
[Lymph-ICF]) because they cover the following domains: physical function, 
mental function, daily activities, hobbies and job, mobility, social activity and 
sexual function. In contrast the other four tools missed one domain (sexual 
function). However, among those tools, the Quality of Life Measure for Limb 
Lymphoedema (LYMQOL) described as a simple and useful instrument that can 
be used in routine clinical practice (Wedin et al., 2020).    
The (LYMQOL) tool is one of the condition specific tools that is commonly used 
in routine clinical practice. This tool was validated in 2010 by Keeley and 
colleagues and measures lymphoedema using two separate questionnaires, 
one for upper and one for lower limb. Another advantage of the LYMQOL tool 
is that it is not limited to cancer or breast cancer patients. It is a patient-centred 
tool that assesses the impact of lymphoedema on patient’s everyday living and 
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can be used as an outcome measure (Keeley et al., 2010). The reliability of the 
tool was tested by test-retest and split-half test for each domain which was good 
(>0.9) and the internal consistency for each domain was good as well (>0.8). 
Therefore, this tool was selected to measure the QoL of participants recruited 
for this study as they are not cancer-related patients. 
The tool consists of four domains that assess function, appearance, symptoms, 
and mood. Participants can rate their overall QoL at the end of the tool on a 
scale between 0 and 10. The answers to each domain score are: Not at all=1, 
A little= 2, Quite a bit= 3 and A lot=4. The total score is calculated by adding all 
scores together and then diving by the total number of questions answered. If 
one question is not answered a score of 0 is given and if greater than 50% of 
questions are not answered in one domain, this cannot be calculated and 
scored as 0 (Keeley et al., 2010). Four domains and its related questions are: 
Function 1 (a–h), 2, 3; Appearance 4, 5, 6, 7, 8; Symptoms 9, 10, 11, 12, 13, 
14; and Mood 15, 16, 17, 18, 19, 20.  
Although the LYMQOL tool had been translated into several languages such as 
Swedish (Wedin et al., 2020), Turkish (Bakar and Tuğral, 2019) and Dutch (van 
de Pas et al., 2016), it has not yet been translated into the Arabic language. As 
mentioned previously, the community in the Kingdom of Saudi Arabia consists 
mainly of Arabic speakers therefore it was of utmost importance to have an 
Arabic version of LYMQOL -leg for the purpose of this PhD study as this tool is 
a self-reported tool. Therefore, the questionnaire for the lower limb oedema was 
translated into Arabic to be used in this study.   
The first step in the translation process was to obtain permission from the main 
author to translate the LYMQOL tool into Arabic. The translation and cultural 
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adaptation of the tool were carried out in two phases and was conducted as a 
double-blinded experiment. The first phase comprised of initial translation, 
when the original English version was sent to an official translation company in 
Riyadh city and asked them to nominate a person who is a native Arabic 
speaker to translate the tool. The nominated person was blinded to the study 
aims. The second phase consisted of backward translation when the Arabic 
version was sent to the same company but another blinded translator to the 
original English tool was asked to translate the Arabic version into English. The 
backward translated English version was then sent to the main author to detect 
and exclude any discrepancies that could affect the meaning of the original tool. 
Very few amendments were made by the author related to expression terms 
such as (verified changed to validated, and edema/chronic lymphoedema to 
chronic swelling). Piloting of the Arabic version was then conducted on five 
patients with CLLO. No changes were made to the prefinal version and 
therefore the final Arabic version of the lower limb LYMQOL was obtained for 
this study (Appendix 11 for the Arabic version).    
6.5  Intervention Protocol and Regimen  
After screening for potential participants in phase one (described in detail in 
chapter 5), those who agreed to participate and signed the CF were invited to 
phase two that involved the implementation of the intervention. The intervention 
consisted of 12 weeks of progressive resistance exercise (PRE) performed 
twice a week. During the session, a recruited participant was using muscle 
contraction against external load which was calculated according to his/her 1-
RM. Intervention parameters such as exercise load, sets and repetitions were 
progressed based on the intervention programme. The progression model in 
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this study was derived from both the guideline for multiple sclerosis provided by 
the American College of Sport Medicine (ACSM) and for advanced breast 
cancer by the National Institute for Health and Care Excellence (NICE).  
Many studies that were highlighted in chapter 4 followed the same moderate 
resistance training programme for pwMS that the ACSM recommended (Dalgas 
et al., 2010; Kjolhede, Vissing and Dalgas, 2012; Halabchi et al., 2017). The 
guideline suggested that  people with more disability (EDSS> 2.5) can practice 
resistance exercise twice a week with intensity between 60% – 80% 1-RM and 
work up to 2 - 3 sets of 10 – 15 repetitions from 12 to 24 weeks (American 
College of Sports Medicine, 2018, p.361). However, for beginners, 40% - 50% 
1-RM was recommended in the guidelines in terms of initial exercise intensity 
to avoid injuries and fatigue.   
 The guidelines for lymphoedema, on the other hand, was not in contrast with 
the ACSM in terms of time (12 weeks and more) and frequency (2 sessions per 
week) except for the weight-lifting intensity. In the NICE guidelines, the load 
intensity is recommended to be low for breast cancer patients but no clear 
standard of how much the low load is (NICE, 2014). However, some RCT 
studies (Schmitz et al., 2010; Cormie, Galvão, et al., 2013; Cormie, Pumpa, et 
al., 2013) and a very recent systematic review (Wanchai and Armer, 2019) 
about effects of resistance exercise on breast cancer related lymphoedema 
reported that between 50% to 70% 1-RM was safe load lifting with no increase 
of lymphoedema. However, consideration must be taken as these studies were 
for upper limb lymphoedema not lower limb and people can often perform more 
reps at given intensity (load) with lower body than the upper since there is a 
greater percentage of type I muscle fibres that has a fatigue resistance 
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characteristic (Richens and Cleather, 2014). Though, with the scarcity in the 
studies that is related to resistance exercise for lower limb lymphoedema, we 
cannot estimate the safe load/intensity. Added to this, as highlighted in chapter 
1 (subheading 1.3) the muscle fibres characteristics in pwMS show changes 
with a shift in the proportion of fibre types from type I to type IIa in the lower limb 
(Dalgas et al., 2010; Wens et al., 2014) which fatigue easily. 
Therefore, considering that participants in this study suffer from both conditions 
(MS and CLLO) and were beginners, exercise adjustments in terms of intensity 
(load) to a level that is safe and tolerable were made provided. Table 6.3 shows 
the intervention programme that involved the load, sets and repetition 
parameters, which progressed every two weeks. Every two weeks, the exercise 
programme was adjusted to the next level. Once training adaptation was 
achieved in one level (for example level 1 which is week 1 – 2), the next level 
(2, [week 3 – 4]) started with a new load, however, same sets/repetitions of the 
previous level were maintained in order to prepare the muscles for the new 
increase in the intensity, until the adaptation was achieved again in this level. 
Then the level after (3, week 5 - 6), the load was maintained but the increase 
was in the sets and repetitions.      
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Table 6. 3:  Intervention programme 
 
 
Week  
1 – 2 
Week  
3 – 4 
Week 
 5 – 6 
Week  
7 – 8 
Week 
 9 – 10 
Week  
11 – 12 
 
Load  40% 1-RM 50% 1-RM 50% 1-RM 60% 1-RM 60% 1-RM 70% 1-RM 
Sets  3 3 4 3 4 3 
Repetitions  10 10 06 06 04 04 
Rest between sets  From 1 to 2 minutes 
Time in each session Session 1 and 24: from 60 to 70 minutes because it did 
include pre and post assessments alongside with the 
intervention. 
Session 2 to 23: from 25 to 30 minutes  
 
In terms of repetitions as can be seen in the table, the progression decreased 
as a number but it is actually increasing due to the load/repetitions’ inverse 
relationship (Richens and Cleather, 2014). This was highlighted before in 
subheading 6.3.3 (III. One repetition maximum (1-RM)), when the 100% of 1-
RM is defined as the ability to perform clean and controlled full ROM for one 
time period (one repetition). Meaning that, if your repetition decrease, the 
muscle is reaching it full strength which is the 1-RM. 
In short, if a new level started with a new load for example as in week 3 -4, the 
sets/repetitions were maintained from the level before (week 1 -2) and if the 
load maintained in the next level as in week 5 -6, the sets/repetitions then 
increased.   
6.5.1  Components of the intervention session  
All participants had 24 sessions of PRE. Each session included the following 
phases: warming-up, intervention related exercise and cooling-down (Figure 
6.4). In addition to those phases, in the baseline (T0) and discharge (T1) 
sessions the pre and post intervention assessments were also included. 
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Figure 6. 4: Intervention methods 
 
Intervention components Details  
1 Warming-up  Device: stationary bicycle.  
Device programme: zero resistance and 
active mode programme. 
Duration: for 5 minutes.  
Participant’s position: sitting, either on an 
external chair or on participant’s wheelchair. 
The feet were secured with straps in its 
designated place on the device.  
Instructions: the PI was instructing the 
participants to not over-speed and exhaust 
themselves when they cycled.  
Safety: for patient’s safety the exercise was 
performed from sitting position to avoid falling.     
 
2 Intervention related exercise  Device: Elgin leg and ankle exercise device.  
N.P.: next subheading 6.5.2 is describing the 
device in detail. 
Device programme: on plantar-flexion and 
dorsi-flexion movements and isolate the 
inversion and eversion movements.  
Duration: for 20 - 25 minutes.  
Participant’s position: sitting position with 90° 
flexion in both knees and the targeted ankle. 
Participants were sat on a height adjustable bed 
with both knees at the edge of the bed (image 
1).  
Foot position: targeted foot was placed on the 
designated place and secured with anterior and 
posterior straps.  
Weights position: for dorsi-flexion movement, 
the weights were placed on the anterior prong 
and for plantar-flexion the weights were place in 
the posterior prong.   
Instructions: the PI was instructing the 
participants to perform concentric contraction 
(muscle shortening) as fast as possible while a 
slow controlled contraction was performed 
during eccentric contraction (muscle 
lengthening). Example: during dorsi-flexion, 
the participant was asked to raise her/his foot 
as fast as possible and lower it with slow and 
Image 1: proper position  
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Image 2: improper position  
 
 
In both images, participant was in a 
position to perform a dorsi-flexion 
movement. 
controlled movement. Opposite instructions 
were given for plantar-flexion movement.  
Safety: for patient’s safety, the exercise was 
performed with training or any closed shoes 
with socks to avoid injury. Participants were 
recommended to avoid wearing sandals or 
high-heel shoes.  
During performing the movements, participants 
were recommended to hold the edge of the bed 
to support their balance.  
Participants were advised to avoid improper 
position (image 2) while seated to assure the 
involvement of the targeted muscles.   
3 Cooling-down  Device: stationary bicycle  
Device programme: zero resistance and 
active mode programme 
Duration: for 5 minutes  
Participant’s position: sitting, either on an 
external chair or on a participant’s wheelchair. 
Feet were secured with straps in its designated 
place on the device.  
Instructions: the PI was instructing the 
participants to not over-speed and exhaust 
themselves when they cycled. 
Safety: for patient’s safety the exercise was 
performed from sitting position to avoid falls.  
 
 
General considerations: 
In terms of safety considerations, worsening of any symptoms related to MS or 
CO was not expected. However, the PI advised all participants to contact her if 
any unusual symptoms would appear. In addition, information about expected 
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signs such as muscular soreness or fatigue especially in the first week was 
provided and discussed with the participants.   
Another consideration was the intervention characteristics in terms of muscle 
action. Ensuring that the participant was performing the eccentric and 
concentric action was emphasized in order to gain the benefits of the exercise 
as the eccentric action is less metabolically demanding, more neuromuscularly 
efficient and delayed onset muscle soreness (Ratamess et al., 2009; American 
College of Sports Medicine, 2018).  
6.5.2  The intervention device  
Targeting the plantar-flexion and dorsi-flexion muscles was obtained by using 
the “Elgin leg and ankle exercise device” which was used in both hospitals 
(KKUH and KFSH&RC). This device is designed mainly to provide progressive 
resistance exercise for inversion, eversion, plantar-flexion, and dorsi-flexion 
muscles. However, in this study only the plantar and dorsi flexion were involved 
in order to strength the muscles that are responsible for the pumping 
mechanism.  
This portable device as presented in Figure 6.5 contains two crossed bars with 
four prongs for loading disk weights. Each prong can be loaded up to 5-disc 
weights depending on the person 1-RM and the training programme; the disc 
weights are ranging from 0.5 kg (1.25 lb) to 5 kg (11 lb).      
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Figure 6. 5: Device description   
 
 
 
1 & 2= anterior and posterior prongs: for plantar and dorsi flexion  
3 & 4= lateral and medial prongs: for inversion and eversion  
5= anterior and posterior straps: to fix the foot in place 
6= designated place for foot to be positioned  
7= hight adjustment 
8= safety lock: to prevent the movements of one bare when the other in use.   
9= rest position lock: to prevent the movements in all directions.  
10= different size of disk weights   
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Permission to use these images was taken from the mother company through email.  
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6.6  Statistics  
6.6.1  Sample size and justification  
The primary outcome measure in the study was the changes in lower limb 
circumference and volume following the intervention in people with MS who 
developed CLLO. This was presented by mean circumference averaged over 
several measurement points in the limb. There has been no previous study, 
which has assessed the effectiveness of progressive resistance exercise in the 
management of CLLO in people with MS. The majority of previous evidence 
about the current clinical practice in treating chronic oedema (as discussed in 
chapter 2) are relates to upper extremity lymphoedema (breast cancer-related 
lymphoedema) or the treatment has included compression therapy in 
combination with exercise which cannot be used as a comparable to our study.  
The outcome of treatment for lymphoedema is often measured as a change in 
limb circumference or volume but there is no internationally agreed method nor 
definition of what constitutes a clinically significant change. Therefore, given the 
lack of existing data upon which to base a sample size calculation, expert 
opinion method was used to determine a clinically significant outcome for the 
study. In the initial step, participants (two expert physiotherapists with mean of 
15 years’ experience in lymphoedema management) were asked to state a 
minimum reduction in circumference which was felt to be clinically significant 
when patients practice PRE without compression therapy. In a second step, two 
other participants (a nurse and a physician with experience in lymphoedema 
management more than 30 years) were asked to state a minimum percentage 
reduction in volume, which would be considered to be clinically significant. 
Based on their responses, it was proposed that the primary outcome of this 
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study would be a 1.5 cm reduction (-1.5cm) in the mean circumference in one 
level with a standard deviation of ±1.5. Using these parameters, it was 
calculated that 13 participants were required to provide 90% power at the two-
sided 5% significance level. To account for a loss-to-follow-up rate of 20% 
(Kjolhede, Vissing and Dalgas, 2012), a total of 16 participants were required.  
In terms of percentage reduction in volume, participants responded that 5% 
reduction would be considered clinically significant. To make the results 
comparable, the absolute reduction of 1.5 cm was expressed as a percentage 
reduction in circumference using the baseline clinical data in the study. By 
computing this, a 4.8% reduction in circumference and a 5% reduction in 
volume would be considered to be clinically significant after 12 weeks of PRE.    
6.6.2  Methods   
The statistical analysis was taken by the study principal investigator (PI) and 
under statistician consultation. All statistical analysis was performed using IBM 
SPSS Statistics (Version 26. Armonk, NY: IBM Corp).  
For descriptive purposes, continuous data was summarised in terms of mean 
and standard deviation, while the categorical data was summarised in terms of 
frequency counts and percentages. The primary and secondary outcomes were 
presented using a mean, standard deviation and 95% confidence interval. The 
level of significance was set at 0.05. Variables were tested for normality by 
assessing the data distribution on a histogram. 
For the leg volumes, SF-MPQ and LYMQOL, Paired t-test was used to compare 
between pre and post intervention when the data were normally distributed. If 
the data were not normally distributed, the Wilcoxon Signed-Rank test was 
used.   
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6.6.3  Procedures for missing, unused and spurious data  
Only completed data were used for the analysis.  
6.7  Results  
Fifteen participants with bilateral CLLO were selected for the second phase of 
this study. One participant withdrew from the study during the third week of the 
intervention due to transportation issue and her related data were excluded from 
the study analysis. Twenty-eight limbs (14 right and 14 left) of 14 participants 
were analysed. Demographic details of the 14 participants can be seen in Table 
6.4. The adherence to the intervention in the study was 97%, with the median 
number of sessions completed by the participants being 23.21/24 sessions. 
Table 6. 4: Demographic data  
 
Variable N= 14 (±SD) 
Gender 
 Female (%) 
     Male (%) 
 
11 (78.6%) 
3 (21.4%) 
Age (years)  Mean= 44 (±7.1) 
Weight (kg) Mean= 71.2 (±15.1) 
BMI (kg/m2) Mean= 27 (±10.9) 
MS duration (years) 
Mean= 13 (±3.7) 
EDSS Mean= 5.6 (±1.0) 
MS type 
 RRMS  
 SPMS  
     PPMS  
 
9 
4  
1 
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Muscle strength in all participants did improve using the manual muscle testing 
with grad from 0 to 5 as can be seen in Table 6.5. Moreover, a statistically 
significant difference was found in the EDSS (p< .009) after the intervention. 
Table 6. 5: Changes in muscle strength and EDSS 
 
Variable  Pre-intervention 
Mean ( SD) 
post-intervention 
Mean ( SD) 
P-value 
Plantar-flexion (Rt)  4.29 (0.59) 4.86 (0.35) *0.021 
Plantar-flexion (Lt) 3.86 (1.36) 4.14 (1.41) NS 
Dorsi-flexion (Rt) 4 (0.93) 4.79 (0.56) *0.013 
Dorsi-flexion (Lt) 3.50 (1.55) 4.07 (1.49) *0.023 
EDSS 5.67 (0.9) 5.21 (1.24) *0.009 
*Wilcoxon Signed Ranks Test. Abbreviation: Rt= Right side, Lt= Left side, NS= Not significant   
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6.7.1  Changes in limb circumference and volume   
Paired t-test for 14 participants with bilateral CLLO showed no significant difference between pre and post intervention in 
relation to segmental leg volume in both lower limbs as can be seen in Table 6.6. Although, the reduction is not statistically 
significant, a trend towards significance (p value 0.06) has been found in the right-side proximal segments (the 8th). The 8th 
segments here represent the participants (n= 6) with longer legs. 
Table 6. 6:  Leg volume and changes based on different segments arranging from most distal (1st) to most  
                   proximal (8th) 
 
 
leg 
segments 
(n) 
Pre-intervention  
Mean ( SD) 
post-intervention  
Mean ( SD) 
Mean difference Post-Pre 
(95% CI) 
Mean % change 
in limb volume  
P-value 
Rt Lt Rt Lt Rt Lt Rt  Lt  Rt Lt 
1st 
segments 
(n=14) 
203.25 ml  
( 88.45) 
204.67  
( 95.85) 
200.43 ml  
( 78.74) 
203.78  
( 96.18) 
-2.81 ml  
(-11.33, 
5.70) 
-0.89 
(-6.12, 4.33) 
-0.25 -0.35 0.48 0.71 
2nd 
segments 
(n=14) 
228.66 ml  
( 119.5) 
227.52 ml  
( 119.68) 
222.46 ml  
( 103.75) 
223.01 ml  
( 113.35) 
-6.20 ml 
(-20.10, 
7.70) 
-4.51 ml 
(-11.56, 
2.53) 
-1.01 -1.35 0.35 0.19 
3rd 
segments 
(n=14) 
278.54 ml  
( 
135.67) 
273.22 ml  
( 128.33) 
272.91 ml  
( 120.22) 
267.84 ml  
( 120.77) 
-5.63 ml 
(-22.64, 
11.38) 
-5.37 ml 
(-14.35, 3.6) 
-0.43 -1.37 0.48 0.21 
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4th 
segments 
(n=14) 
340.62 ml  
( 
141.18) 
330.17 ml  
( 137.83) 
332.54 ml 
( 125.65) 
336.21 ml  
( 141.72) 
-8.08 ml 
(-28.9, 
12.73) 
6.03 ml 
(-21.12, 
33.18) 
-1.04 3.04 0.41 0.63 
5th 
segments 
(n=14) 
407.18 ml  
( 151.6) 
401 ml  
( 152.99) 
403.45 ml 
( 142.73) 
411.84 ml  
( 154.99) 
-3.73 ml 
(-26.51, 
19.05) 
10.83 ml 
(-17.29, 
38.96) 
-0.10 3.62 0.72 0.42 
6th 
segments 
(n=14) 
461.45 ml  
( 
171.51) 
459.19 ml  
( 157.3) 
461.51 ml 
( 163.27) 
462.75 ml  
( 149.13) 
0.06 ml 
(-21.68, 
21.81) 
3.56 ml 
(-14.07, 
21.19) 
0.50 1.25 0.99 0.67 
7th 
segments 
(n=11) 
458.85 ml   
( 95) 
460.52 ml   
( 85.21) 
450.28 ml 
( 94.14) 
458.78 ml  
( 100.08) 
-8.57 ml 
(-22.24, 
5.09) 
-1.74 ml 
(-22.18, 
18.68) 
-1.83 -0.68 0.19 0.85 
8th 
segments 
(n=6) 
471.51 ml 
( 73.04) 
467.355 
( 67.66) 
449.07 ml 
( 63.64) 
451.47 
( 74.95) 
-22.44 ml 
(-47.31, 
2.42) 
-15.88 ml 
(-36.12, 
4.36) 
-4.48 -3.54 0.06 0.1 
Abbreviations: SD= standard deviation, n= number of participants, Rt= right leg, Lt= left leg. In relation to segmental number, the 7th and 8th 
segments were lower in the number than the other segments due to variation in leg length in each participant.  
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Figure 6. 6: Distribution of mean percentage changes from pre-intervention to post-intervention in each segments. Negative values are decreases. 
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In terms of leg circumference, a mean reduction in the absolute leg circumference of -0.66% for the right leg and no reduction 
found in the left side (Table 6.7). In terms of foot, no reduction was found in both side after the intervention (0.95% in the right 
feet and 0.03% in the left). Comparing this result with what was considered to be, in the experts opinion step, as a minimum 
reduction in circumference (-4.8%), the percent changes in absolute limb circumferences were not considered clinically 
significant after a 12 weeks of PRE.   
Table 6. 7:  Changes in circumference over several measurement points in the leg in each participant 
 
Participant 
number 
Pre-intervention leg 
circumference (Mean) 
cm 
Post-intervention leg 
circumference (Mean) 
cm 
Changes in leg 
circumference (Mean) 
cm 
% change of 
absolute leg 
circumference 
% change of 1.5 cm 
reduction of 
absolute baseline 
Rt Lt Rt Lt Rt Lt Rt Lt Rt Lt 
P1 284.5  
(30.45)  
298.2  
(33.13) 
278.2  
(30.91) 
292.1 
(32.46) 
-6.3  
(-0.70) 
-6.1  
(-0.68) 
-2.21 -2.05 -4.75 -4.53 
P2 269.9  
(29.99) 
263.3  
(29.26) 
266.6  
(29.62) 
253.1  
(28.12) 
-3.3  
(-0.37) 
-10.2  
(-1.13) 
-1.2 -3.87 -5.00 -5.13 
P3 222.6  
(27.83) 
234.2  
(29.28) 
222.5  
(27.81) 
229.3  
(28.66) 
-0.01  
(-0.01) 
-4.9  
(-0.61) 
-0.04 -2.09 -5.39 -5.12 
P4  293.2  
(32.58) 
267.9  
(29.77) 
288.1  
(32.01) 
283.5  
(31.50) 
-5.1  
(-0.57) 
15.6  
(1.73) 
-1.74 5.82 -4.60 -5.04 
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P5 229   
(28.63) 
226.6  
(28.33) 
227.2  
(28.40) 
224.8  
(28.10) 
-1.8  
(-0.23) 
-1.8  
(-0.23) 
-0.79 -0.79 -5.24 -5.30 
P6 305.3  
(33.92) 
303.6  
(33.73) 
301.9  
(33.54) 
303.6  
(33.73) 
-3.4  
(-0.38) 
0.00  
(0.00) 
-1.11 0.00 -4.42 -4.45 
P7 288.5  
(32.06) 
278.4  
(30.93) 
290.5  
(32.28) 
275.5  
(30.61) 
2  
(0.22) 
-2.9  
(-0.32) 
0.69 -1.31 -4.68 -4.85 
P8 181.2  
(25.89) 
180.6  
(25.80) 
181.9  
(25.99) 
180.3  
(25.76) 
0.7  
(0.10) 
-0.3  
(-0.04) 
0.39 -0.17 -5.79 -5.81 
P9 235.9  
(29.49) 
234.2  
(29.28) 
240.7  
(30.09) 
238.6  
(29.83) 
4.8  
(0.60) 
4.4  
(0.55) 
2.03 1.88 -5.09 -5.12 
P10 215.5  
(26.94) 
222.7  
(27.84) 
222.4  
(27.80) 
224   
(28.00) 
6.9  
(0.86) 
1.3  
(0.16) 
3.20 0.58 -5.57 -5.39 
P11 336.4  
(37.38) 
343   
(38.11) 
317.9  
(35.32) 
333.8  
(37.09) 
-18.5  
(-2.06) 
-9.2 
(-1.02) 
-5.50 -2.68 -4.01 -3.94 
P12 332   
(47.43) 
326.8  
(46.69) 
320.3  
(45.76) 
325.6  
(46.51) 
-11.7  
(-1.67) 
-1.2  
(-0.17) 
-3.53 -0.37 -3.16 -3.21 
P13 284.8  
(35.60) 
284.7  
(35.59) 
297.2  
(37.15) 
293.8  
(36.73) 
12.4 
 (1.55) 
9.1  
(1.14) 
4.35 3.20 -4.21 -4.21 
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P14 198.9  
(28.41) 
193.6  
(27.66) 
191.3  
(27.33) 
197.8  
(28.26) 
-7.6  
(-1.09) 
4.2  
(0.60) 
-3.82 2.17 -5.28 -5.42 
Mean  262.69  261.27 260.48 261.13 -2.21 -0.14 -0.66 0.04 -4.80 -4.82 
Abbreviation: P= participant, Rt= right leg, Lt= left leg.  
Measuring absolute leg circumference changes in 14 participants with bilateral CLLO before and after 12 week of progressive resistance exercise. 
Absolute leg circumference is the sum of all measurement points in the leg. Mean circumference averaged over several measurement points in the limb 
was also calculated by adding the measurement points and divided it by the number of measurements points. The last two highlighted columns represent 
what the percent change is in the 1.5 cm circumference reduction using the pre-intervention data.     
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In terms of leg volume changes, bilateral CLLO show a mean reduction in the absolute leg volume of -1.72% (range -0.14 to -
10.92) for the right leg and no reduction found in the left side (Table 6.8). Some of the participants show increase in the 
absolute leg volume after 12 weeks of intervention. Comparing this result with what was considered to be, in the experts 
opinion step, as a minimum reduction in leg volume (5%), findings revealed that the percent changes in absolute leg volume 
were not clinically significant between pre and post intervention.  
 
Table 6. 8:  Measuring leg volume change in fourteen participants with bilateral CLLO  
 
 
participant 
number  
Pre-intervention absolute 
leg volume (ml) 
post-intervention absolute 
leg volume (ml) 
 
changes in absolute leg 
volume (ml) 
% change in 
absolute leg volume 
Rt Lt Rt Lt Rt Lt Rt  Lt  
P1 2624.02 2912.86 2499.92 2793.11 -124.1 -119.75 -4.73 -4.11 
P2 2373.38 2250.94 2296.76 2061.75 -76.62 -189.19 -3.23 -8.40 
P3 1784.23 1973.30 1781.66 1900.89 -2.57 -72.41 -0.14 -3.67 
P4 2878.10 2373.55 2732.50 2641.35 -145.6 267.8 -5.06 11.28 
P5 1882.63 1866.78 1866.18 1840.85 -16.45 -25.93 -0.87 -1.39 
P6 2997.41 2977.57 2955.25 2988.65 -42.16 11.08 -1.41 0.37 
P7 2686.75 2524.37 2774.15 2486.36 87.4 -38.01 3.25 -1.51 
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P8 1275.33 1277.63 1284.89 1269.57 9.56 -8.06 0.75 -0.63 
P9 1964.05 1940.63 2076.43 2041.04 112.38 100.41 5.72 5.17 
P10 1672.67 1785.64 1797.78 1818.30 125.11 32.66 7.48 1.83 
P11 3678.44 3828.54 3276.77 3600.69 -401.67 -227.85 -10.92 -5.95 
P12 4396.35 4258.12 4086.23 4220.19 -310.12 -37.93 -7.05 -0.89 
P13 2939.21 2934.17 3250.54 3147.83 311.33 213.66 10.59 7.28 
P14 1599.71 1507.17 1474.96 1621.22 -124.75 114.05 -7.80 7.57 
Mean  2482.3057 2457.948 2439.57 2459.41 -42.73 1.47 -1.72 0.060 
Abbreviation: P= participant, Rt= right leg, Lt= left leg. Measuring total leg volume changes in 14 participants with bilateral CLLO before and after 12 
week of progressive resistance exercise. Total leg volume is the sum of all segments volumes.  
 
 
 
 
 
 
 
 Quantitative Phase  
153 
 
Chapter 6 
Measurements of limb circumference and volume changes as a percentage of the preintervention value (figure 6.1- A & B), 
which are the primary clinical outcome measure, indicate that there was no significant effect of PRE after 12 weeks in pwMS 
who have bilateral CLLO and the outcomes of either measurements were quite close to each other.    
 
(A) 
 
         
Figure 6. 7: Distribution of percentage changes from pre-intervention to post-intervention: (A) Circumference, (B) volume. Negative values are  
                    decreases.
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6.7.2  Short form of the McGill pain (SF-MPQ) 
Using Paired t-test, there was a significant reduction in pain (as measured by 
the VAS) following the intervention with moderate effect size (d= -0.4) based on 
Cohen’s convention (Cohen, 1988). However, no significant difference was 
found between pre and post intervention in sensory, affective, and total 
description of SF-MPQ questionnaire (Table 6.9).  
A Wilcoxon Signed-Rank Test in PPI indicated that the median post-intervention 
ranks were statistically significantly lower than the median pre-intervention, Z= 
-2.27, p< .027, meaning that the Present Pain Intensity (PPI) index was 
improved after the intervention. 
Table 6. 9:  Paired t-test for SF-MPQ 
 
SF-MPQ 
description  
Pre-
intervention 
Mean ( SD) 
post-
intervention 
Mean ( SD) 
Mean difference 
Post-Pre (95% CI) 
P-value 
Sensory   8.57 (8.21) 7 (7.64) -1.57 (-4.04, 0.90) 0.19 
Affective  2.78 (3.44) 2.78 (3.35) 0.00 (-0.71, 0.71) 1.00 
Total of 
descriptors 
11.35 (11.35) 9.78 (10.59) 1.57 (-1.10, 4.24) 0.22 
VAS 4.29 (3.34) 2.55 (2.69) -1.73 (-2.98, -0.49) 0.01 
 
*PPI 1.21 (1.71) 0.35 (0.63) - 0.02 
*Wilcoxon Signed-Rank test. Abbreviation: PPI= Present Pain Intensity, VAS= Visual 
Analogue Scale.
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6.7.3  Quality of life measure for limb lymphoedema (LYMQOL)  
Paired sample t-test was conducted to evaluate the quality of life pre and post 
the intervention. The results of the test were significant in domain 5 (LYMQOL 
VAS) as can be seen in the Table 6.10 with moderate effect size (d= -0.4) based 
on Cohen’s convention (Cohen, 1988). However, in the other domains the 
results were not significant.   
Table 6. 10:  Paired t-test for LYMQOL 
 
LYMQOL 
domains 
Pre-
intervention 
Mean ( SD) 
post-
intervention 
Mean ( SD) 
Mean difference 
Post-Pre (95% CI) 
P-
value 
Domain 1 
(function) 
2.35 (0.84) 2.32 ( 0.66) -.025 (-.51, 0.46) 0.91 
Domain 2 
(appearance) 
2.11 (0.85) 1.91 (0.86) -.20 (-.67, 0.26) 0.36 
Domain 3 
(symptoms) 
2.65 (0.90) 2.37 ( 1.12) -.28 (-.75, 0.17) 0.20 
Domain 4 
(emotions) 
1.85 (0.97) 1.65 (0.65) -.20 (-.55, 1.55) 0.24 
Domain 5 
(LYMQOL 
VAS) 
5.42 ( 1.94) 7.42 ( 1.55) 2 (.69, 3.30) 0.006 
Abbreviation: VAS= Visual Analogue Scale. 
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6.8  Discussion  
The purpose of this study was to demonstrate the effectiveness of progressive 
resistance exercise in the management of chronic lower limb oedema in people 
with multiple sclerosis and to determine the impact of CLLO on pain and quality 
of life. Intervention outcomes with respect to changes in oedema were assessed 
based on limb circumferences, which were used to estimate limb volume 
changes using a mathematical formula. Circumference-based measurements 
has been validated as a good estimators of both arm and leg volume in previous 
studies (Karges et al., 2003; Mayrovitz et al., 2007). The measurements were 
performed at 4 cm intervals of the leg and at two anatomical landmark points of 
the feet. Concerning the changes after the intervention, the excess limb volume 
in patient with bilateral CO cannot be calculated because we do not have a 
control limb (Katz-Leurer and Bracha, 2012). Therefore, monitoring the changes 
in the absolute circumference and volume of each limb provides information 
about intervention outcomes over time, which can be presented as a 
percentage change from the baseline value (Williams and Whitaker, 2015).   
Compared to pre-intervention, no significant reductions in circumference 
measurements nor volume were observed after the 12 week of PRE. However, 
it can be seen in Table 6.6 that the segments volumes were responding 
differently to the intervention with more volume reduction noticed in the proximal 
part of the leg than the distal, some areas were stable, others increased and 
more reduction occurred in the right side than left. These findings could be 
explained by increasing muscle bulk in some parts of the limb and reduced 
oedema in others. This would require further investigation with appropriate 
measures which can detect changes in muscle bulk and fluid content. 
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This idea is supported by Dalgas et al. study which reported that biweekly 12 
week of PRE in pwMS (EDSS 3 – 5.5) consisting of 3 – 4 sets of 15 – 8 
repetitions of 1-RM did increase participants’ thigh volume by 2.9  2.7% which 
indicated an increase of the muscle mass (Dalgas et al., 2010). Dodd et al. also 
reported that muscle strength in pwMS increased in average of 16.8% in leg 
press and 29% in reverse leg press after twice a week of PRE for 10 weeks 
(Dodd et al., 2011). Likewise, Medina-Perez et al. found that 12 week of PRE 
significantly improved muscle strength and power (p=0.004 and p<0.001 
respectively) but not endurance and the training adaptation was maintained 
after 12 weeks of detraining (Medina-Perez et al., 2014). Based on the previous 
literature, there is no doubt the resistance exercise has a positive effect on 
improving muscle strength and power. However, the majority of studies that 
assessed the effects of PRE on pwMS were not designed to assess the factors 
behind muscle strength and they are often attributed to neural adaptations but 
not to the muscle mass increase.  
To the best of our knowledge, the only study that used very similar protocol to 
our study was Dalgas et al., where changes in muscle mass was reported after 
12 weeks of the PRE in pwMS (Dalgas et al., 2010). This can explain our results, 
since more volume increase in the middle part of the leg (segments 5 and 6) 
was found, where the muscle bulk of gastrocnemius, soleus and tibialis anterior 
are located and the increase was in the left more than right as the participants 
were having more muscle weakness in the left than the right side. Supporting 
this, we found also that muscle strength for the participants improved after the 
intervention in both plantar-flexion and dorsi-flexion movements in the left more 
than right side which could justify the findings.        
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On the other hand, a reduction in volume was noticed in the proximal and distal 
part of the leg. From an anatomical point of view that these parts include the 
tendons of the anterior and posterior leg muscles which does not have the same 
biomechanical response to exercise as the muscle. Muscle tissue may 
hypertrophy following a long period of training, while the tendons are made of 
collagen which transmit the mechanical force of muscle contraction to the bone 
and their size may not be affected by exercise (Bordoni and Varacallo, 2018). 
Conversely, Brumitt et al. reported in their clinical commentary paper that 
tendons could respond to resistance exercise by increasing total number and 
diameter of collagen fibrils (Brumitt and Cuddeford, 2015). However, the paper 
did not clarify under which training parameter the adaptation was happened. 
Added to this, the paper was undertaken on normal subjects and it is difficult to 
assume the same tendon adaption could happen in pwMS due to different 
muscle and tendon physiological characteristics as a result of the disease 
(highlighted in chapter 1). 
Although the reduction was found in areas where the tendons of the muscles 
are located. However more reduction was notable in the proximal than the distal 
part of the leg. Considering the normal distribution of lower limb lymphoedema 
(LLL), Iker et al. study found that the lymphoedema to be more located in the 
distal part of the extremity (Iker et al., 2019). Similar findings were reported in 
Mayrovitz et al. retrospective study on 190 patients with unilateral and bilateral 
limb oedema. The study showed that limb segments were responding differently 
to the intervention with more reduction noticed in the proximal (mean difference 
(SD) 1,248 823) than distal (1,204 775) (Mayrovitz et al., 2007). This can be 
linked to the gravity effects and the exercise effects on calf muscle pump and 
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on venous hemodynamic in the leg which could support the lymphatic flow in 
the leg more than feet (Keilani et al., 2016). Added to this, the small muscle in 
the feet that does not have the same pumping mechanism as the calf muscle 
which could lead to less reduction of the fluid in the distal part of the lower limb 
(Corley et al., 2010).  
Conducting this study on this patients’ population was challenging, as the 
effects of PRE can be interpreted differently when it comes to MS and chronic 
oedema. Since we aimed to increase calf muscle pumping mechanism to create 
external compression of lymph vessels in order to push the fluid upward to 
decrease the oedema, the effects were considered positive when the muscle 
strength increased. This could be associated with increased mass especially 
since we were training people complaining of weakness in their lower 
extremities. At the same time, we were looking for a reduction in the volume 
due to a reduction in oedema which might be masked by the hypertrophied 
muscle. However, reading through previous studies on cancer-related lower 
limb lymphoedema in which their aim was to assess the effects of PRE on 
developing or aggravating lymphoedema reported that the resistance exercise 
did not develop lymphoedema in those at high risk to develop it or increase it in 
those who already have it (Mayrovitz et al., 2007; Katz et al., 2010). This could 
add to our understanding about the result that the increase could be related to 
muscle mass not the fluid. Further unmeasured variables such as water content 
in tissue may account for difference and requires attention in future studies.  
Although the circumference and volume reduction were not statistically 
significant, there were a significant effect found on QoL and pain suggesting 
that PRE has an impact on a patient’s QoL as a result of their chronic condition. 
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Undoubtedly, the contribution of MS on patient’s QoL in this study should not 
be neglected. The intervention did improve the muscle strength and the EDSS 
which indicate that the MS has an impact as well on pain and QoL. However, 
measuring QoL in pwMS was not the scope of this study. Despite the small 
sample size of the study, the findings were in agreement with other existing 
knowledge in previous studies (Greene and Meskell, 2017; Tuğral, Virén and 
Bakar, 2017; Dai et al., 2019; Mercier et al., 2019) in various countries, where 
poor QoL and pain in patients with CO was reported.  
In a sample of patients living in Turkey with unilateral lower limb lymphoedema, 
Tugral et al. reported an improvement in QoL after a 4 week of complex 
decongestive physiotherapy (CDP) (pre-post treatment: 5.2 2.1 to 7.1 2.2, 
p=0.003) (Tuğral, Virén and Bakar, 2017). These are in line with our findings 
indicating that treatment can improve patient’s life to better physical, 
psychological, and social QoL. In Ireland, a sample of 90 patients with CLLO 
reported to have a poor QoL in each of four domains of LYMQOL tool and in 
the overall QoL measured score (5.7 compare to 5.4 in our study pre to 
intervention) (Greene and Meskell, 2017). A recent international, multicentre, 
prospective study by Mercier et al. in six countries with a total of 1094 patients 
reported that the impact of chronic oedema was high in all LYMQOL domains 
(i.e. poor) and was more in case of lower limb oedema than upper one (Mercier 
et al., 2019). However, compare this to our results, our findings showed poorer 
scores in the symptoms domain (2.35 in our study compared to 2.13), function 
domain (2.65 in our study compared to 2.21) and overall VAS (5.4 in our study 
compared to 6.3) which could be linked to the fact that combination of 
impairments (MS and CLLO) with low physical activities may have a contribution 
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with our outcomes. Supporting this assumption, interesting results was reported 
in Dai et al. study on a Japanese sample (Dai et al., 2019). A generic QoL score 
(LYMQOL VAS) of 5 was reported in those who were inpatient and 8 in 
outpatient which indicate that less physical activities may have a strong impact 
on patient’s QoL. This suggests that patients with chronic oedema and low 
physical activities are more likely to have poor QoL than those with more 
activities in their daily life.    
Regarding the pain, our finding indicates that CLLO can have a significant 
physical consequence which can complicate and challenge the performance of 
patient’s daily activities. The change in pain, muscle strength and symptom 
severity (EDSS) can be associated with changes in QoL. These associations 
may indicate that PRE is a treatment that contributes to reductions in pain and 
MS symptom severity which transforms into improvements of QoL, however a 
future study is needed to test this theory.  
6.9  Phase two strengths and limitations  
This is the first known study of intervention of CLLO on pwMS which is a 
strength in that it adds to our understanding about this population and can be 
the bedrock and template for future research. Added to this, the study was not 
selective in terms of disease type where the majority of MS studies are limited 
to relapsing-remitting MS type and it was carried out in two hospitals. However, 
several factors may limit the interpretation of this phase results and the 
understanding of the PRE effects on CLLO in pwMS. Firstly, the small sample 
size which may compromise generalizability of the findings. Secondly, the 
evaluator and participants were not blind to the study protocol which may have 
contributed to the high reliability rating. However, it is unlikely that the evaluator 
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can remember each specific number of the tape measurements, since around 
20 measures were taken for each participant during pre and post assessments. 
Thirdly, limb volume measurement was limited to only one measure (tape 
measure), which may not present the other changes that may influence the limb 
volume reading such as muscle mass and fat tissue. The final limitation of this 
phase was the lack of control group of those with MS but no oedema or a control 
doing no intervention.  
A future randomized control trial with a larger sample size and with different 
outcome measures is required to support these effects further. In addition, using 
the data from this study would help future study to determine the sample size.     
6.10  Conclusion  
Progressive resistance exercise (PRE) for 12-week has no significant difference 
in the leg volume, however, change was seen in segmental volume (adjacent 
to the proximal than distal part of the leg) which may indicate change in CLLO. 
The intervention has a significant impact on participants’’ overall QoL and pain. 
In addition, significant improvement was found in the EDSS and muscle 
strength for both side dorsi-flexion and right plantar flexion. These findings 
suggested that PRE may be a potential treatment for CLLO in pwMS and further 
studies are required to determine the limitations.  
Exploring issues specifically for this population through a qualitative study to 
facilitate the development in the clinical practice and to evaluate our practice 
from various perspectives is needed and this is the aim of the next chapter.
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4.5  Introduction  
Emotional well-being including psychological and social changes experienced 
by CLLO patients following treatment is a crucial concern and can have an 
impact on quality of life (QoL) (Morgan, Franks and Moffatt, 2005). To develop 
an in-depth understanding of an intervention it is important to engage with 
different factors such as the views of patients and health care providers. We 
need to understand the whole picture in order to change or improve practice. 
As reported in the previous chapter, participants reported improved QoL 
following progressive resistance exercise. However, gaining an understanding 
of the perspectives of patients can improve the robustness of the research and 
inform recommendations for the implementation of interventions in future 
studies. Qualitative approaches aim to provide powerful subjective data, deeper 
understanding and sufficient access to perceptions of  participants in order to 
deliver individualized and needs led care (De Valois, Asprey and Young, 2016). 
This chapter presents the last phase (qualitative) of the study, in which 
participants who undertook PRE were interviewed individually to explore their 
experiences of the intervention. Physiotherapists specializing in lymphoedema 
management in both hospitals were also interviewed in order to provide a 
deeper understanding and common language of their knowledge and beliefs 
about their current practice. The objectives of phase three were to:  
1) Identify and explore factors that contribute to successful or unsuccessful 
use of PRE from the perspectives of participants.  
2) Explore the knowledge and understanding developed by 
physiotherapists of CLLO in pwMS and of current lymphoedema 
practice in terms of exercise therapy. 
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7.2   Ethical Approval and Consideration  
As highlighted in chapter 2 (sub-heading 2.5), this phase of the study was 
developed (together with phase one and two) after the initial protocol was 
approved by the Research Ethics Committee (REC) in King Khaled University 
Hospital (KKUH) (Reference Number:  E-17-2733), and King Faisal Specialist 
Hospital and Research Centre (KFSH&RC) (Reference Number: 
ORA/0247/39).     
Participants who expressed an interest in taking part were invited to participate 
in the interview study (phase three). However, participation in this (and the 
previous) phase was entirely voluntary and the CF emphasised that participants 
who indicated they wished to be involved in phase three should not feel 
obligated to take part in the interview and could withdraw at any time without 
giving a reason. Participants were assured that their withdrawal would not affect 
the quality or quantity of their future medical care. 
All interviews were transcribed verbatim and anonymised using the same 
identification code that was used in phase two. Each digital audio recording was 
password-protected after copying the audio record electronically and was saved 
under the same file code (highlighted in sub-heading 2.6  Data Protection, 
chapter 2).          
7.3   Methods  
This study utilised qualitative methods to gain an in-depth understanding of the 
intervention from perceptions of the participants treated for CLLO. The 
qualitative study also aimed to explore the views of physiotherapists, especially 
their awareness of CLLO and their current practice regimes in terms of 
therapeutic exercise.  Individual, face-to-face, semi-structured interviews were 
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chosen to generate live discussion and uncover subjective views of each 
participant. Unlike focus groups and paired interviews, individual interviews 
allow for an  undiluted focus on the individual interviewee  (Ritchie and Lewis, 
2003).   
7.3.1 Sample  
I) Patient participants  
Participants who completed the intervention (phase two) were eligible to 
participate in phase three and take part in the individual interviews. Out of 14 
participants, ten responded that they wished to participate in an individual 
interview. The remaining four participants who decided not to participate in the 
qualitative study did not provide a specific reason for declining. 
II) Therapy participants 
All therapists who had experience in the management of lymphoedema were 
invited to participate in phase three of this study. Therapists were asked to read 
and sign the consent form including information about the study. Participation 
in the study (phase three) was voluntary. All physiotherapists with 
lymphoedema experience based in KKUH (n=3) and KFSU&RC (n=3) who met 
the inclusion criteria agreed to be interviewed.  
7.3.2  Individual Interview 
Qualitative researchers have to make a choice individual interviews and focus 
groups. The choice of method depends on three key factors: type of data 
required, the subject area and the nature of the study group (Ritchie and Lewis, 
2003). Researchers can explore personal history or experience more effectively 
by focusing on the individual through in-depth interviews. Moreover, interviews 
can provide an opportunity to understand and investigate a person’s 
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perspective by uncovering important underlying issues and are often described 
as a “form of conversation” (Burgess, 1982). Guest et al. (2017) found in their 
randomized study comparison of focus groups and individual interviews that the 
latter was more effective at generating a broad range of items (Guest et al., 
2017).  
Other qualitative methods such as focus groups offer less opportunity for 
generating a detailed account of the studied phenomenon by a lower average 
speaking time per participant. Although focus groups are less expensive and 
allow for faster data collection, individual views and behaviour can be influenced 
by the responses of others and by group dynamics (Liamputtong, 2011). 
Moreover, reserved participants are less likely to share their views in front of 
other people especially when a group includes participants who are vocal or 
confident. The voices of participants with ‘diffident’ personality traits may be lost 
in focus groups.     
Individual interviews are the most suitable research method when researching 
very complex or sensitive experiences. Intangible and more abstract topics are 
well-matched to focus groups, where discussion between participants can 
tackle the subject (Liamputtong, 2011). Group discussions can be used at initial 
stages of research to raise issues that need to be explored and taken forward 
through in-depth interviews (Ritchie and Lewis, 2003). In-depth interviews 
represent a more complete picture of the studied phenomenon and distinguish 
personal opinions about unfamiliar or new topics such as treatment. Given the 
limited evidence on the effects of PRE on pwMS who have CLLO, in-depth 
interviews can therefore provide the valuable information required to 
understand the individual views and experience of the intervention. Opinions, 
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views, and experiences related to the intervention in a relaxed familiar 
atmosphere can allow for collection of data that strengthens the PhD study by 
informing understanding of the use of the intervention from a wider perspective. 
The method chosen for the interview was a semi-structured interview method 
which is often used to guide the interview rather than an unstructured method 
(Given, 2008). Moreover, the responses to each question is not in a fixed range 
like the structured method (Blaxter, Hughes and Tight, 2010). Semi-structured 
interview might help also when interviewing individuals with problems in 
memory or concentration who may have tendencies to deviate from the topic 
(Given, 2008). At the same time, it does not frame their answers and limit 
responses such as in methods that use close questions.  
7.3.3 Data collection    
Two versions of semi-structured individual interview with a topic guide informed 
by both the review of the literature as well as the other components of the study 
were developed. Because not all questions were related to both groups of 
participants, each group had a set of questions related to the interview 
objectives.  Interviews were recorded using the “voice memo” app on the 
interviewer’s mobile phone. The researcher was responsible for the collection, 
transcription, and analysis of the interviews. Before the start of the interviews, 
participants were assured that confidentiality and anonymity would be 
maintained at all times, and it was explained that the interview would be 
recorded. Participants were encouraged to take their time to answer the 
questions and to use their own words. When a participant was unable to 
understand the question, the questions was re-worded and re-phrased using 
simple language.  
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On completion of the interview, the researcher transcribed each interview 
immediately verbatim. Data quality checks were undertaken to assure the 
accuracy of the transcription by listening to the recordings whilst reading the 
transcripts. Electronic data that included study database for phase three was 
held securely by password protected encryption and access was restricted by 
user identifiers and passwords. 
I) Individual interviews with CLLO participants 
The CLLO participants’ interview question guide (Table 7.1) was designed 
based on findings emerging from the literature review (De Valois, Asprey and 
Young, 2016). The introductory question was asked to evaluate the awareness 
and understanding of the participants regarding their problem and the 
intervention. Transition questions were related to participants’ feelings when 
they were diagnosed with CLLO. Key questions were related to the objective of 
this phase, where participants’ opinions and perceptions about the intervention 
were collected. Finally, ending questions were related to their opinions about 
future research. 
The structured interviews lasted from 20 to 25 minutes and were held in the 
same intervention room (outpatient clinic room) at the rehabilitation department 
in both hospitals. Interviews were carried out in session number 23 of study 
week 12.  Participants were reminded about the interview prior to the session 
commencing and advised to allow for extra time for the visit. Session 23 was 
chosen because the post-intervention measurements took place in the last 
session (session number 24). It was not possible to extend the duration of the 
last session to accommodate an interview because of concerns about tiredness 
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and the availability of participants. Due to these constraints, interviews were 
scheduled to occur in the penultimate session before discharge.    
Table 7. 1:   Interview questions  
 
Introductory  What was the research that you participated in? 
Transition  Did you know or hear about the terms chronic oedema or lymphoedema 
before?  
How did you feel about having CLLO? And did you notice the oedema 
in your lower limb? 
Key Before participation, how can you describe your general health? 
After participation, how can you describe your general health? 
What is your opinion about the intervention in terms of frequency, 
intensity and number of sessions?  
What were the most difficult tasks encountered during your 
participation? 
What are the most important aspects you liked in the intervention? 
Ending What do you think if the intervention was more than 12 weeks? 
Would you recommend this intervention to patients with similar 
problems? Why or why not?  
 
All interviews were all conducted in Arabic. To assure the accuracy of 
transcription and eliminate translation-related problem, three elements were 
considered: back translation, consultation and collaboration with other people 
during the translation process (Birbili, 2000). The original Arabic transcription 
was translated into English by one person and then back translated to Arabic 
by a different person. The researcher did the original Arabic transcription and 
then translated it to English and an independent transcriber (who spoke with 
the same Arabic dialect as the participants) translated the English version back 
to Arabic. The English version was approved when both Arabic versions were 
matching.  
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II) Individual interviews with physiotherapists  
The interview questions were designed to meet the objectives. The questions 
were categorized into questions related to knowledge and others related to their 
current practice. The first version of the interview guide was piloted with three 
physiotherapists from other hospitals and based on the interviewee feedback 
one additional question was added. The question was related to therapist 
understanding about 1-RM definition which is related to exercise progression. 
The therapist interviews were held between May and June 2018. Individual 
interviews were held in a meeting room in the rehabilitation department in each 
hospital. The meeting rooms were private and reserved in advance to avoid 
interruptions during the interview. Coffee and water were available in order to 
help create a comfortable and relaxed atmosphere. The interviewer introduced 
herself initially, explained the purpose of the study and provided an opportunity 
to ask questions before the interview commenced. She also gave reassurance 
that attendance was voluntary and that participants were free to withdraw at any 
time without giving a reason.  A set of pre-determined open questions was used 
to explore potential themes. The option was given for participants to be 
interviewed in English or Arabic, however, the therapists preferred to be 
interviewed in English language.   
7.3.4 Data analysis  
Qualitative data analysis is a continuous, iterative and reflexive process (De 
Valois, Asprey and Young, 2016) in which “researchers seek to learn about and 
interpret life experiences” (Sword, 1999, p.270). It requires a researcher’s skills 
and experience, a blend of inspiration and hard-working commitment (Ritchie 
and Lewis, 2003).  One of the  challenges of qualitative research is to ensure  
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that the analysis is transparent and systematic, and delivers the maximum 
insight into the meanings expressed by the participants (Creswell and Creswell, 
2018).  
There are many ways to interpret qualitative data. However, the aim is similar 
to all i.e. finding meaning within the data, making sense of the evidence and 
creating files of summarized data (Ritchie and Lewis, 2003). Making sense of 
data depends, in part, on the method used to organize and categorise data, but 
it relies mainly on the person’s creativity of theoretical thinking and clarity 
(Greene, Caracelli and Graham, 1989). Many analysis processes are shaped 
and associated with specific research disciplines together with the philosophical 
underpinnings (Gale et al., 2013). Regardless of the chosen analysis type, 
making sense of data is the core of the whole process.  
Within a broad family of qualitative analysis methods, inductive reasoning and 
developing themes is a common characteristic. One of these approaches is the 
constant comparative method that adopts inductive data coding to produce 
categories of themes that may help to generate a social theory (Holloway, 
2005). Unlike other approaches, data are reviewed across a matrix to facilitate 
constant systematic comparative style that can refine each theme by systematic 
comparison across cases is the feature of the framework analysis method (Gale 
et al., 2013).  
Framework Analysis is a data analysis method that is used to understand raw 
data in a matrix based analytic system. It was developed during the 1980s at 
the National Centre for Social Research and is becoming widely popular and 
used by qualitative researchers (Ritchie and Lewis, 2003). The method allows 
analysts to move between different levels of “analytical hierarchy” without 
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“losing sight of the raw data” (ibid, p.220). Every theme is displayed in its own 
matrix, where each raw sentence or data represents participant’s responses, 
each column symbolizes a different subtopic (subtheme) and each cell 
summarises data. The matrix shows connections clearly between each 
individual’s views and other aspects of their account  (Gale et al., 2013).  
I) Framework data analysis procedure  
Phase three data were analysed using the Framework Method (Figure 7.1) that 
is inspired by Ritchie and Lewis (2003). In the first stage, audio recordings were 
transcribed verbatim by the researcher and then listened to again whilst reading 
the transcripts in order to check their accuracy. Each transcript was printed and 
read multiple times until it was felt that the diversity of the data had been 
understood and a thorough familiarity was gained with the words and ideas. 
This level represents stage two (Ritchie and Lewis, 2003).  Creswell and Plano 
Clark (2018) suggests that using software programme such as NVivo for coding 
process can improve the quality of the research, however, due to practical and 
time constraints of this thesis, the researcher adopted  manual analysis instead 
of the electronic (Ritchie and Lewis, 2003). 
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Figure 7. 1:   Procedure for framework analysis of interview data 
 
Stage 1: Transcription 
 
Stage 2: Familiarization with the data 
 
Stage 3: Coding 
 
Stage 4: Developing a working analytical framework 
 
Stage 5: Applying the analytical framework 
 
Stage 6: Charting data into the framework matrix  
 
Stage 7: Interpreting the data 
   
While reading the interviews transcripts, the next stage (3) was to assign initial 
codes by underlining words and sentences that have the same meaning or kept 
reappearing using the left-hand margin of the paper to describe the content. It 
was extremely useful as well to note the idea and codes on Post-it Notes in 
order to arrange and identify similarity of ideas emerging during reading of the 
transcript. Coding is a vital stage in interpretation where data are arranged into 
small groups that represent  possible categories (Creswell and Plano Clark, 
2017). The coding process was first undertaken by the researcher herself and  
was reviewed later by a different researcher (a member of the supervisory team) 
to ensure that one particular perspective did not dominate. (Gale et al., 2013).    
After completion of the coding process, the next stage (4) consisted of 
developing a working analytical framework.  The researchers met to discuss the 
codes that were assigned to each transcript.  Each code was discussed in terms 
of what it stated about: 
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• the participant’s views and experiences 
• how this might be useful in addressing the research aims and  
• why these codes were considered important  
In general, there was an agreement between the researchers about assignment 
of codes to the highlighted text.  In the minority of instances where different 
codes were assigned, the differences related to terms used. In one instance, 
for example, the first researcher coded one piece of dialogue as “feeling the 
difference” whereas the other researcher thought that the term “motive” 
described the meaning more accurately. Despite differences in language, both 
researchers agreed that the participant was talking about elements that 
motivated her to complete the intervention. Re-visiting the transcripts together 
resulted in agreement that the code “motives” captured the idea and was 
applied. The coding index of themes was then entered into an Excel 
spreadsheet and colour coded which was then used to label data in the 
transcript in the next stage.  After reading and refining the codes, a five-code 
index related to CLLO participants (Table 7.2) and a three-code index related 
to physiotherapy participants (Table 7.3) with supporting sub-themes were 
identified.    
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Table 7. 2:  Stage 4 colour coded index and sub-themes of CLLO   
                    Participants 
 
Coding index Subthemes  
1. Life history 1.1 Facing difficulties    
1.2 Limited activities before intervention    
2. Motives 2.1 Feeling the difference (physical changes)  
 2.2 Psychological changes    
2.3 Experienced new way of treatment   
2.4 Not less, not more    
2.5 Therapeutic relationship   
3. Uncertainty 3.1 Lack of knowledge and awareness    
3.2 There is a sense of something   
3.3 Underestimated my power   
4. Barriers 4.1 Too much   
4.2 Hard to manage    
5. Lift up the voice 5.1 Could be little but it matters    
5.2 No more fears    
5.3 Open to changes   
 
Table 7. 3:  Stage 4 colored coded index and sub-themes of    
                    physiotherapists participants  
 
Coding index Subthemes  
1. Career pathway  1.1 limited sources  
2. Lymphoedema treatment  2.1 No adjustments  
2.2 Time-consuming 
2.3 Slim knowledge 
3. Awareness on CLLO in 
pwMS  
3.1 Underestimated other non-oncology patients 
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Following stage 4, the analytical framework (stage 5) was applied by labelling 
each transcript using highlighter pens with the same code colours in order to 
identify similarities between transcripts. Each word and sentence was attached 
to its related themes and sub-theme (Ritchie and Lewis, 2003). This stage was 
a labour-intensive and time-consuming exercise because each paragraph had 
to be read line by line and re-read to decide which label to apply.   
After applying labels to the data, the next stage (6) required generating a matrix 
in which data were charted using Microsoft Excel. The matrix included 
references to quotations tagged with a page and line references (Table 7.4). 
Spreadsheets were used to generate the matrix and each one represented a 
category.  In one spreadsheet, each participant occupied one row and each 
code occupied one column. The data from the transcripts were summarised and 
inserted into the corresponding cell in the matrix. The challenge in this stage 
was in the ability to provide a balance between summarizing the data and 
holding the same feeling and meaning of the original one (Gale et al., 2013).  
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Table 7. 4: Example of an extraction from the “motives” matrix of     
                  CLLO participants 
 
Motives 2.1 2.2 
Source  [Quot.#] feeling the difference 
(physical changes) (page & line#) 
[Quot.#]   psychological changes 
(page &line#) 
KK4 [1] I felt my legs started to be stronger 
(1, 21) 
[2] When I touch my muscle, I can feel 
it … it is bigger (1, 24) 
[3] also I started to feel more in that 
area (1, 24) 
[5] I felt the muscle power (2, 39) 
[1] Actually I was enjoying attending the 
sessions (2, 36) 
[2] myself, I would like to continue and 
not stop (2, 46) 
KK5 [1] After participating I start to be 
almost normal (3, 73) 
[2] Because before I knew that after 
10 min, I will be tired and fatigue but 
now much much better (3, 75) 
[3] every session I can see the 
improvement (4, 86) 
[1] I started to walk without any fear 
because I do not feel tired or fatigue 
like before (3, 73) 
[2] and I started to be passionate about 
walking (3, 74) 
[3] I wish if the session was longer (4, 
87) 
KK7 [1] Everything improve the muscle 
power and the balance (5, 113) 
[2] I feel the difference and I improved 
80% (5, 125) 
[1] I wish if the intervention is longer 
than this (5, 116) 
Abbreviation: Quot.=quotations, KK4, KK5, KK7= participants’ ID in the study.  
Due to space constraints, this table depicts a sample of one thematic chart which included more 
columns. The first column in this table is allocated to the participant’s ID and the next two 
columns each represent different sub-themes. Each row relates to one participant.    
 
By reviewing the matrix and making connections between and within the data, 
final themes were generated, and this was the final stage (7) of the analysis. 
During the interpretation stage, it was very important to study the narratives of 
individual cases but also to go beyond this point to develop themes that offered 
possible justifications for what was happening within and between the data 
(Ritchie and Lewis, 2003). Going back and forth between the data and 
interrogating it in many ways helps to develop explanations but this was a time-
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consuming yet vital stage of the study. However, one of the benefits of this 
exercise is that it allowed the analyst to become more familiar with the data 
which informed her ability and skills in understanding the qualitative data 
analysis. Three main themes in CLLO participants and two main themes in 
physiotherapists participants emerged with supporting sub-themes (Table 7.5).    
Table 7. 5:  Main themes and sub-themes in both CLLO and  
                    physiotherapists participants  
 
Themes Sub-themes  
CLLO participants  
1. Life experience before 
having PRE intervention  
1.1. Limited life activities  
1.2. Uncertainty and recognition of the need to care 
2. Participants’ 
experiences after having 
PRE intervention  
2.1 Reading my physical changes 
2.2 Psychological changes associated with PRE 
intervention  
2.3 Finding new and feasible treatment  
2.4 Therapeutic relationship 
2.5 Unhelpful aspects of the intervention  
3. Little changes, but it matters 
Physiotherapists participants 
1. Awareness about CLLO 
in pwMS  
1.1 Knowledge deficits   
2. Current lymphoedema 
practice 
 2.1 Fear of crossing comfort zone  
Abbreviation: PRE= progressive resistance exercise. 
It was very important to choose the themes in a way that gave voice to 
participants’ perceptions. Therefore, after considering the final themes, 
transcripts were re-read to ensure that the themes were an accurate 
representation of the data. Once confirmed that the data fulfilled the study 
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objectives, a review process was initiated aiming to enhance the 
trustworthiness of this phase. One of the supervisors acted as a second 
reviewer and revised the final themes and sub-themes. 
7.3.5 Trustworthiness in phase three 
Unlike quantitative research that is concerned with reliability and validity, the 
robustness of qualitative research is based on authenticity, credibility, 
transferability, dependability, and conformability to establish trustworthiness.  
I) Authenticity  
Taking into account that some participants’ stories may be influenced by 
memory impairment,  the researcher focussed on the originality of participants’ 
experiences and stories, and acknowledged that participants’ narratives 
represented the truth (Ritchie and Lewis, 2003). The researcher understands 
her position in reconstruction and presenting of stories and aimed to keep the 
details to present the stories as truthful accounts.           
II) Credibility 
As with reliability in quantitative research, Lincoln and Guba (1985) suggest that 
the term credibility is equally significant for qualitative research (Lincoln and 
Guba, 1985). Credibility is the agreement and harmony of the findings with 
reality. The concept is more related to the correctness and calling what is 
identified by the “right name” (Ritchie and Lewis, 2003). For example, are the 
finding appropriately identified, truthful and described in depth? The data was 
transcribed and analysed with the supervisor’s guidance to ensure that the 
interpretations were not coming from one person only (Creswell and Creswell, 
2018). The triangulation of the findings from the mixed method study helped to 
confirm and improve the clarity of the research.     
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III) Transferability 
Rich detailed accounts were provided which may enable other researchers to 
transfer the findings to other settings. The data were organized meticulously 
including all the records of analysis and process. All transcripts, Microsoft Word 
and Excel documents were labelled, and all supervision sessions were 
documented and uploaded on the PGR record system.         
IV) Dependability  
Dependability is an important element in trustworthiness process because it 
makes the findings consistent and repeatable. The researcher must ensure that 
there are no gaps in data collection, analysis and findings which would allow 
other researchers to arrive at similar results and conclusions. However, since 
people’s lives are always changing, differences in the findings could be found 
with the same study methods. In-depth explanations of the study design, data 
collection methods and organisation were provided earlier in this chapter.      
V) Conformability  
Each qualitative study is unique in itself, but researchers can take steps such 
as documenting the procedure for checking and re-checking data, revealing 
negative instances to ensure conformability (Ritchie and Lewis, 2003). The 
researcher documented methodological decision making and presented study 
strengths and limitations.               
7.4  Results 
The themes and sub-themes were derived by the Framework Analysis (Ritchie 
and Lewis, 2003). Two groups of participants, CLLO participants (n=10) and 
physiotherapist participants (n= 6), were interviewed individually to fulfil phase 
three objectives. All participants are referenced using an ID code to maintain 
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anonymity. The participants’ verbatim extracts are presented and identified 
using the ID code number which initiated with either KK for King Khalid hospital 
participants or KF for King Faisal hospital and followed by a number for CLLO 
participants (example, KK4) and the initial of the first and surname name in the 
physiotherapists participants (KF, ND).   
7.4.1  Participants’ demographic characteristics  
Both groups were demographically varied, (Table 7.6), the CLLO participants 
were aged 36 - 55 years and the physiotherapists participants were aged 
between 29 – 47. The majority of participants in both groups were females and 
all were of Saudi origin except for one Egyptian participant in the CLLO group. 
The course of MS seen amongst the CLLO cohort ranged from 9 to 20 years, 
70% of them were having RRMS and their disability scored between 4 and 6.5 
on the EDSS scale. As seen in Table 7.6, 50% of the CLLO participants and 
67% of the physiotherapy participants reported being educated to a bachelor 
(undergraduate) degree. Only 40% of the CLLO participants were working and 
40% were divorced or separated. The experience level of the physiotherapy 
group varied from one to 19 years.    
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Table 7. 6:  Characteristics of participants 
 
Characteristics  Number  
CLLO participants (n= 10) 
Gender 
Female: 8  
Male: 2  
Marital status 
Married: 4  
Divorced/separated: 4  
Widowed: 0 
Single: 2  
Education  
School: 1  
Diploma: 4 
Degree: 5 
Master: 0 
PhD: 0 
Employment  
Working: 4 
Retired: 1 
Housewife: 2 
Unemployed: 3 
MS type  
RRMS: 7 
PPMS: 1 
SPMS: 2 
EDSS 
EDSS 4: 3                   EDSS 6: 3 
EDSS 5: 1                   EDSS 6.5: 2 
EDSS 5.5: 1 
Physiotherapists participants (n= 6) 
Gender  
Female: 5 
Male: 1 
Education 
Diploma: 0 
Bachelor degree: 4 
Master: 2 
PhD: 0 
Certified and working in 
lymphoedema management   
*KK, SK: 5 Y                       **KF, ND: 19 Y 
*KK, KR: 1 Y                       **KF, SH: 2 Y 
*KK, ZM: 11 Y                     **KF, FM: 9 Y 
Abbreviation: MS= multiple sclerosis, EDSS= Expanded Disability Status Scale, RRMS= 
Relapsing Remitting multiple sclerosis, PPMS= Primary Progressive multiple sclerosis, SPMS= 
Secondary Progressive multiple sclerosis, Y= years. * King Khaled university hospital 
participants. ** King Faisal Specialist Hospital and Research Centre participants.  
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7.4.2  CLLO participant findings  
The identified themes and sub-themes as highlighted in Table 7.5 result from 
participant descriptions of their experiences of the progressive resistance 
exercises (PRE) used to treat their CLLO. The first theme is life experience 
before receiving the PRE intervention which included limited life activities, and 
uncertainty and recognition of the need to care. The second theme is the 
participants’ experiences following the PRE intervention, including reading 
physical changes, psychological changes associated with PRE, finding a new 
and feasible treatment, the therapeutic relationship, and unhelpful aspects of 
the intervention. The final theme is about small changes, although they matter.  
I) Life experience before receiving the PRE intervention  
Disability level varied between participants; however, similar physical issues 
and QoL were reported.  Encountering daily difficulties as a person with MS that 
fluctuates from one day to the next limited every life. Moreover, the inexperience 
and lack of awareness of CLLO added to their pain and poor QoL without 
understanding the rationale behind this problem which caused further 
psychological issues. Some participants expressed uncertainty and confusion 
when they reported the changes in their lower limb and the need to care, which 
may suggest that there is a lack of knowledge about the impact of CLLO among 
health care providers.  
a) Limited life activities 
Trying to avoid normal daily activities such as walking, sit to stand and 
socializing because of MS symptoms led to a lock down of the person in his/her 
body and limiting life activities.  
 Qualitative Phase   
185 
 
Chapter 7 
Participant KK5 said: “My walks are limited and any journey with long 
distances I tried to avoid it.”  
While participant KK4 reported that: “My general situation is 
deteriorating with the time because I do have PPMS. I am not using 
any medication to control it. In my daily life I’m facing a lot of difficulties 
the MS controlling my life.” 
For some, depending on others or assistive devices such as a walking frame or 
cane was psychologically frustrating. 
Participant KK11 stated that: “I had heaviness in my legs with difficult 
walking and imbalance and because of this I am always nervous …. I 
cannot do 3 to 4 steps without any help.”  
Participant KK12 reported that: “I have to lean or depend on anything 
like cane to do sit to stand.”  
Some interviewees underestimated their ability and muscle power to do new 
activities. 
Participant KK13 said that: “I never imagine myself able or capable to 
carry weights.”  
While participant KK4 said that: “I do have some weight at home 
belongs to my son when he practices but I never try it.”   
Participant KK5 reported that this was: “first time …. I never did in my 
life weights lifting.”  
The lack of knowledge was further apparent when participants recognized 
changes in their lower limb, but their experience was fraught with uncertainty. 
b) Uncertainty and recognition of the need to care 
All participants reported lack of knowledge and awareness of CLLO.  
Participant KK4 stated that “I heard about it first time from you …. It is 
a new information for me that people with MS could develop CLLO.”  
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Participant KK5 reported that “it was my first time …. although I am 
always updated in what is new in the MS field but never ever come 
across such a terms.”  
Participant KK7 said that: “My first time .... [patient laughed]… even I 
can’t say lymphoedema.” 
Participant KK8 was also in a line with the other and said that this was: 
“first time to hear from you and I am very thankful for that.”   
Uncertainty and confusion over CLLO were also noted. Some participants felt 
and had a sense that something is not normal, but they linked the feeling to MS.  
Participant KK4 said that: “I felt it was heavy, but I thought because of 
the MS.” 
Participant KK5 noticed that her feet: “shifted from a normal form into 
spongy feeling .... I mean, I cannot complete any walk because of this 
problem.” 
Participant KK10 stated that she felt “nothing more than heaviness.” 
Four participants noticed oedema in their lower limb and reported it to their 
health care practitioner (HCP), but they had been neglected.  
Participant KK9 said that: “I felt heavily and oedema in my legs …. 
actually my doctor did not …. he is always in hurry and he never spend 
time looking at me …. what mater for him is my MRI images and lab 
results.” 
Participant KK11 stated that: “.... I though it is nothing serious .… I 
noticed that and I talked to my doctor about it but he never told me that 
it could be chronic oedema and he did not even give me any medication 
for it …. the doctor was always rushing out my appointment.”   
Participant KK12 reported that she: “have it from very long time and I 
remember that my physiotherapist is the one who noticed that and 
referred me back to my doctor and he did refer me to the vascular 
clinics …. but I did not go. The appointment was very far, and I was 
fine at that time …. No one told me it is a serious condition.” 
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Social changes: 
 
▪ Participating 
more with other 
▪ Less isolation   
Physical changes: 
 
▪ Strength  
▪ Less fatigue 
▪ More walking 
▪ Endurance 
▪ Standing with more 
balance 
 
Psychological changes: 
 
▪ Confidence  
▪ Enjoyment  
▪ Happiness 
▪ Good mood 
▪ Feeling of achievements  
Participant KK13 reported that: “my doctor did not do anything although 
I had mention it several times to him.” 
Throughout the interviews, confusion and uncertainty were reported. Most 
participants stated that they did not feel they were given adequate medical 
attention. This lack of medical awareness among HCPs about CLLO in pwMS 
could create anxiety among the participants thinking that their MS symptoms 
are worsening or that the medication is not improving their condition. 
II) Participants’ experiences after having PRE intervention  
For all participants, this was an unknown form of intervention and participants 
held initial doubts about their capability to perform the exercise.  All participants 
reported that they felt the positive outcomes at the end of the intervention. 
Furthermore, they reported that the intervention was a positive experience 
which resulted in physical, psychological, and social changes, as summarised 
in figure 7.2, which contributed to a positive perception of the intervention.      
Figure 7. 2: Participants’ positive effects of progressive resistance  
                    exercise (PRE) 
 
 
 
 
 
 
 
 
 
 
Positive outcomes of PRE 
intervention 
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a) Reading my physical changes  
Understanding the problem and the feeling of more control of their body raised 
the bar of the participants’ expectations about their physical capability. The 
subjective and objective outcomes that the participants experienced throughout 
the intervention period were markers of success that measure the intervention. 
Changes in muscle strength, power and mass was expressed by most of the 
participants.  
Participant KK4 said that: “I felt my legs started to be stronger …. When 
I touch my muscle I can feel it, it is bigger …. I felt the power in my 
muscle.” 
Participant KK7 reported that: “Everything improve the muscle power 
and the balance.” 
Similarly, participant KK8 said that: “I felt my muscle become stronger.” 
and participant KK10 reported that: “The general health improved, and 
I can feel my both legs is lighter now.”   
Several participants talked about having their life back to normal and how their 
physical health would deteriorate if they did not participate in this programme.  
Participants KK5 stated that: “After participating I start to be almost 
normal …. every session I can see the improvement …. every day is 
better than the one before.” 
Participant KK4 reported that: “my situation now is deteriorating, not 
because of the intervention but because of the disease course itself. 
This physio sessions for 3 months, which I didn’t have such this 
exercise before, if I did not do it my situation would be worse …. and 
this is my belief.”   
Participant KK12 said that: “I’m good once I started with you.” 
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Common physical benefits of this intervention included the ability to walk a 
longer distance than they used to, sit to stand more easily and feeling more 
independent during their daily living.  
Participant KK4 said that: “sit to stand position from my chair started to 
be easier.” 
Participant KK5 shared her experience as “before I knew that after 10 
minute I will be tired and fatigue but now much much better.” 
Participant KK10 stated that she: “can climb the stairs depending on 
my both legs rather than one …. I have noticed the benefits.” 
Participant KK11 reported that: “I can do 3 to 4 steps without any help 
or support.” 
Participant KK12 said that: “I improved a lot .… I started to do sitting 
and standing more easily than before without leaning or depending on 
anything like cane …. I'm good once I stared with you.” 
Participant KK13 mentioned that: “I became more active and walk 
without help.”  
Participant KF14 stated that: “my ability to walk in terms of time 
improved, before I can do 10 min and now I can do more …. I liked the 
results.”  
Interestingly, some participants noticed and felt the improvement and the 
reduction in their swelling. 
Participant KK9 replayed that she “have been improved in terms of 
swelling.” 
Also participant KK10 reported that: “The general health improved, and 
I can feel my both legs are lighter now …. I have noticed the benefits” 
Participant KK11 said that: “felt better and my leg heaviness became 
very very light …. swelling of my legs decreased and everyone notice 
that in both legs and feet …. I saw the changes.” 
 Qualitative Phase   
190 
 
Chapter 7 
Participant KK13 reported that: “I became more active and walk without 
help, swelling decreased …. add to this I am more flexible and the 
tightness that I fell in my legs and knees decreased.” 
One participant (KK4) noticed sensory changes in her lower limb, she said that 
“I started to feel more in that area.” Other participant experienced changes in 
their balance which reflected positively on their gait.  
Participant KK7 said that: “Everything improved, the muscle power and 
the balance.” 
Participant KK11 reported that her: “gait became easier and everyone 
around me noticed this.” 
Participant KK13 said that: “movement became faster and balance 
improved 80%.” 
While participant KF14 notice “little improvement in terms of balance.”  
Some participants evaluated their physical improvement as percentages. 
Participant KK13 said that she improved between “85% to 95%” and participant 
KK7 felt “80%” improvement. No one spoke about physical discomfort or injury 
during the intervention period.      
b) Psychological changes associated with PRE intervention  
The psychological and emotional impact of progressive resistance exercise was 
described by several participants. Some of them described the psychological 
benefits as they felt “psychological comfort” (participant KK13), “reaching an 
achievement” (participant KF14) and “enjoying attending the sessions” 
(participant KK4).  
An improvement in mood and happiness was highlighted as positive results by 
several participants.  
Participants KK12 said that: “'I’m good once I started with you.”  
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Participant KF14 reported that she: “liked the results .… I felt I am 
reaching an achievement.” 
Participant KK4 expressed her experience by saying: “myself, I would 
like to continue and not stop …. I was enjoying attending the sessions.” 
Participants KK5 said that: “every day is better than the one before.” 
One participant (KK5) reported feeling of improved confidence and normality, 
and overcoming her fears: “After participating I start to be almost normal …. I 
started to walk without any fear because I do not feel tired or fatigue like before 
…. I started to be passionate about walking.”  
Feeling the enjoyment from participating in the intervention was also reported. 
Participant KK4 said that “I was enjoying attending the sessions.” Also, 
participant KK9 state that “rather than sitting in the home with no movement I 
prefer to come and do this exercise.” Furthermore, the feeling of enjoyment, 
improved confidence and feeling of normality resulted in more social interaction 
for some participants. Participant KK5 valued the effects of the intervention on 
her social life as “before any journey with long distance” she “tried to avoid it” 
but after the intervention she “started to be passionate about walking and I want 
to attend the *Eid1 while I’m wearing my high heel.”  
For all participants, this was a new/unknown form of experience, and some of 
them felt initially uncertain about the effects of this intervention. Participant 
KK11 said that “I was looking forward to see the results”, and participant KF14 
reported that her “situation was worse than now” but after the intervention she 
“did improve and liked the results.”       
 
1 Eid: is a Muslim festival and they celebrate it two times per year.   
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c) Finding a new and feasible treatment 
Participants appreciated that the PRE was an intervention that was new to 
them. The PRE was seen as a “convenient” (participants KK4 KK5, KK8 and 
KK11), “easy” (participant KK10) and “very nice” (participant KK12) intervention. 
Several participants expressed their wish to continue after the intervention 
period ended and also wished that the sessions and timeline were longer.  
Participant KK4 said that: “I think it is convenient, may be if it is less 
than that I may not notice any improvement.” 
Participant KK7 stated that: “I wish if the intervention is longer than 
this.” 
Participant KK5 also said that: “I wish if the session is longer.”  
Moreover, the intervention was seen as a possible form of exercise to learn and 
perform. Participant KK4 reported that “carrying weights as an idea did not 
terrified me” and participant KF14 said that “I never imagine myself able or 
capable to caring weights …. I felt I am reaching an achievement.”     
d) Therapeutic relationship 
Narratives describe participants’ frustrations with their doctor’s unfamiliarity 
when they reported oedema in their legs as highlighted in the sub-theme 
‘uncertainty and recognition of the need to care’. Most participants reported 
difficulties in the communication and relationship with their doctors. Difficulties 
were associated with limited medical awareness and lack of knowledge about 
CLLO in pwMS. Moreover, the way healthcare messages were delivered to 
patients by medical doctors was perceived as harsh which was also reported 
as one of the reasons for poor communication.  
Participant KK12 reported that: “I’m good once I started with you …. 
but the physiotherapist before, she told me that I will be on a wheelchair 
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if I do not do the exercises … she hurt my feeling a lot ….  that’s why I 
hated to come to physio clinic again.”  
In contrast, good communication during the intervention with the researcher 
was one reason adherence to the intervention was maintained. The interviews 
show that beside the new device and the new method of treatment, the 
therapist-patient relationship was perceived as one of the biggest benefits of 
the intervention when the participants were asked about “what was the most 
you like about the intervention?”.  
Participant KK11 said that: “I liked you … you have an amazing 
personality and I pray for you every time I went out of the session.” 
Participant KK4 stated: “your personality.”  
Participant KK12 reported that: “I’m good once I started with you …. To 
see you as the most thing I liked.”   
Participant KK13 said that: “First, I liked you …. you are incredible …. 
second, the bicycle and weights lifting those moved my joints and 
muscle a lot and add flexibility and decreased the tightness that I fell in 
my legs and knees …. do you believe that the sound in my knees 
disappeared … the sound that I had before …. and I improved 95%.”    
Participant KK14 said: “You doctor, and I felt I am reaching an 
achievement and I did improve.” 
e) Unhelpful aspects of the intervention  
The interviews also show the disadvantages of taking part on the intervention 
when the participants were asked about “What were the most difficulties 
encountered during your participation?”.  One area of responses was related to 
time management specially for the employed participants or carer. One 
participant (KK11) said: “nothing but the only difficulty I faced is to manage my 
time because my work as a teacher”. Another participant (kk9) reported that: “it 
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might be difficult …. every time I need to arrange the time based on my 
husband’s working hours …. You know he is the one who brings me to the 
session.”   
Transportation was also reported as an unhelpful aspect during the 
intervention.  
Participant KK13 stated that: “traveling to take this session” was the only 
difficulty she faced. Also, participant KK12 reported the “transportation” and 
participant KK9 stated that “the difficulty would be in my transportation specially 
for the one who is going to bring me here.”   
All except two participants (KK10, KK14), expressed an interest in participating 
if the intervention continued for longer than 12 weeks. For those who 
commented they would not value taking part if the intervention was for longer 
than 12 weeks reported that “It might be boring for me” (participant KK14) or “it 
will be a lot” (participant KK10).           
III) Little change but they matter   
The positive outcomes were felt by participants, even if the changes were 
objectively minimal for them the results were satisfying.   
Participant KK11 reported that: “we are as MS patients look for any 
changes in our situation even if it just 30% that for us is a record.”  
Participant KK4 said that: “even if I did not achieve 100% 
improvement, at least I can have 50% or 70% improvement and not 
reach to this oedema.”       
The participants through this experience challenged their physical impairments 
such as lower limb weakness, lack of balance and fatigue, which reflected 
positively on their fear of trying a new path of treatment. Some participants 
stated that the satisfaction and improvement they felt would encourage them to 
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participate in such a programme even if the timeline was longer than 12 weeks. 
Some participants believed that a longer treatment duration would bring more 
positive outcomes.  
Participants KK5 said that: “I will participate, and it will be better than 
12 weeks and even the session time I would like to be longer than this 
….. I wish if the session was longer.” 
Participant KK11 stated that: “if there is a satisfaction results like now 
I would do it.” 
Participant KK8 reported that he: “will come even if it is more than 12 
weeks.”  
Participant KK7 was in a line with the other and “wish if the intervention 
is longer than this.” 
The need for such a treatment was evident. They were passionate to carry out 
and share their experience with other pwMS.   
Participant KK11 stated that: “actually I did recommend this treatment 
already to my MS friends because I saw the changes.” 
Participant KK8 said that: “I recommend this treatment for 
strengthening and feeling light.” 
While participant KK5 felt that “it is impossible that people with MS is 
not doing this treatment.”       
7.4.3  Physiotherapy participant findings  
The identified themes and sub-themes highlighted in Table 7.5 result from 
participants’ descriptions of their knowledge and understanding of CLLO 
in pwMS and the current lymphoedema practice in terms of exercise therapy. 
The first theme is awareness about CLLO in pwMS which includes knowledge 
deficits. The second theme is current lymphoedema practice, including the fear 
of crossing their comfort zone.   
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I) Awareness about CLLO in pwMS 
All of the physiotherapists reported knowledge deficits about CLLO in pwMS. 
Even those with greater professional experience of lymphoedema management 
expressed uncertainty in understanding the development of CLLO in pwMS. 
The knowledge deficits reported seemed to relate to an insufficient theoretical 
foundation and practical knowledge before and after entering the specialty. 
Interestingly, all participants were trained by the same certified lymphoedema 
trainer who completed her training 20 years previously in oncology related 
lymphoedema and primary lymphoedema. She is the first Saudi Arabian 
physiotherapist to introduce lymphoedema management in physiotherapy 
practice. Her scope of practice is mainly with breast cancer-related 
lymphoedema.     
a) Knowledge deficits  
All participants articulated that they were unaware of the possibility of 
developing CLLO in pwMS as a result of immobility or lack of physical activities.  
Participant K.R-KF said: “No, I never treated MS patient with CLLO.” 
Participant Z.M-KK with 11 years’ experience in lymphoedema 
management said: “no didn’t treated MS …. actually, my first time to 
know they might develop CLLO.” 
Participant N.D-KF stated that: “for my whole career I didn’t receive any 
referral for treating MS patient with lymphoedema …. mainly 95% of 
my patients are breast cancer patients.” 
Participant S.K-KK said: “no I never treat MS patient before.” 
Participant F.M-KF: “for 9 years I didn’t receive a referral for MS 
patient.”  
Participant S.H-KF: “in our hospital, mainly we are treating breast 
cancer patients and I never have MS patient in my clinic.”  
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Some participants reported that the information and training provided in the 
certified lymphoedema therapist course related primarily to breast cancer 
patients and primary lymphoedema. 
Participant K.R-KF said: “I was certified one year ago, and the training 
was in two parts, theoretical and practical and we learned how to treat 
breast cancer lymphoedema with compression therapy, MLD and 
CDT.” 
Participant S.H-KF: “I attended an intensive course with (N.) and we 
did the exam to be certified …. The training we had about anatomy of 
lymphatic system and the course of lymphoedema and how we can 
treat the patients with MLD, compression and CDT.”  
However, four participants reported that they developed their skills by 
attending workshops and courses in the USA, the UK and Germany.      
Participant Z.M-KK stated that she had her first training: “In Riyadh with 
(N.) as she provided an intensive course about lymphoedema …. Can’t 
remember exactly the content …. this was long time ago…. but it was 
about oncology …. mainly breast cancer and how we use the CDT, 
MLD and compression therapy …. I also attended courses in the USA 
”  
Participant F.M-KF reported that: “9 years ago …. When I joined the 
hospital, there was a need for a male therapist in lymphoedema clinics 
and I got my practice and certificate in the management of 
lymphedema patients … but also I was attending so many courses 
online or I travel to build up my skills …. I went to America and Germany 
to get courses in lymphoedema treatment …. mainly my training 
related primary lymphoedema and oncology patients.”   
Participant S.K-KK said: “I had a course with (N.) and learned how to 
diagnose the lymphoedema, the anatomy of lymphatic system and the 
treatment program such as CDT, MLD and bandaging or compression 
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…. But listen I also had a certificate from Germany and also I did my 
master in the UK and my dissertation was in lymphoedema field.”  
Participant N.D-KF said that: “I earned my certificate from America 20 
years ago and I became an official trainer in lymphoedema 
management …. I can’t remember exactly but I came across all the 
area related to lymphoedema.”  
Gaps in knowledge were further evident when participants expressed their 
views about current lymphoedema practice.  
II) Current lymphoedema practice  
All participants were certified before working with lymphoedema patients. Their 
knowledge was acquired from courses and workshops after their bachelor’s 
degree. Two participants completed their education and earned their master’s 
degree, one was in the field of breast cancer-related lymphoedema from the UK 
(participant S.K-KK) and the other participant was related to health care 
management in Bahrain (participant N.D-KF).    
a) Fear of crossing comfort zone 
The participants reported that they were treating their patients based on 
protocol that includes CDT, MLD, compression therapy and exercise. 
Answering the question to what kind of treatment options they are offering to 
their patients:  
Participant K.R-KF said that: “MLD, education, home exercise, skin 
care, compression therapy.” 
Participant S.H-KF: “MLD, education, home exercise, skin care, 
compression.”  
Participant F.M-KF: “MLD, compression therapy, active ROM for some 
of the patients. Exercise only I give it for those who are physical not 
active.” 
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Participant S.K-KK: “MLD, compression therapy, treadmill, bicycle, 
home exercise and hydrotherapy for lower limb only. Always the 
compression therapy is my treatment. Not always I used exercise.” 
Participant Z.M-KK: “It is depending on the patient’s situation either I 
do CDT or MLD with compression therapy, exercise and education.” 
Participant N.D-KF: “MLD, education, home exercise, skin care, 
compression therapy.” 
Limitations in knowledge were not only in the participants’ awareness about 
CLLO in pwMS, but also in their practice and thinking out of the box when they 
face an unfamiliar case.  
Participant S.H-KF said that she faced “only one” patient that she could 
not use for her compression therapy as the “Patients was referring to 
the clinic with unknown cause of abdominal swelling and pain after 
uterus cancer. I could not use the compression therapy for her 
abdomen because fluid was getting out when there is a compression 
and the fluid was under investigation.” 
PI: what did you use as alternatives? 
Participant S.H-KF: “nothing, I referred her back to her doctor. I was 
afraid that if I will do something it might aggravate her situation.”  
Participant F.M-KF stated that he could not use the compression 
therapy with patients that was having a “cardiac problem or 
hypertension or allergic to garment such as sarcoma” and when he 
asked about what alternatives did he use he said “depend on the 
patients may be gentle exercise such as ROM exercise.”   
Participant Z.M-KK reported that she faced “some patients who does 
have wounds and only used bandages but no garments. Some patient 
also I cannot use garment with them because they feel uncomfortable 
and allergic to it.”   
PI: what did you use as alternatives? 
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Participant Z.M-KK: “depend on the patient age, and her welling to do 
the treatment …. MLD, exercises, education.”  
In terms of exercise therapy, fear of crossing their comfort zone and doing 
what other therapists are doing was reported by some participants. 
Participant S.H-KF said that: “Some of my choice is based on evidence 
but for the other we do follow same program in the hospital.” 
Participant F.M-KF stated that he only uses: “active ROM and only 
TheraBand as resistance exercise …. I don’t use weight with my 
patients …. It might trigger their lymphoedema or could cause pain …. 
my knowledge is based on courses I attended.” 
Participant Z.M-KK said: “My advised in terms of exercise is just what 
the other do not based on evidence.”    
The resistance exercise given to patients was only limited to one type of 
exercise. TheraBand was the only resistance exercise noted which is 
available in different colours and each has a different intensity which does 
not need to be calculated.  
Participant K.R-KF said: “Only TheraBand” 
Participant S.H-KF reported that: “we do follow same program for all 
our patients which included pumping exercise for hand, active ROM, 
active assistant with cane for those who has tightness, stretching and 
strengthening and I used antigravity exercise and isometric. No weight, 
only TheraBand.” 
Participant F.M-KF stated: “Only TheraBand as a resistance exercise.” 
Participant Z.M-KK also said: “I never used any exercise with weight 
…. only TheraBand …. I started with the yellow.” 
Participant N.D-KF said: “functional strengthening exercises with 
TheraBand.” 
One participant (S.K-KK) only reported her use of PRE: “Just recently this 
year I used PRE for upper extremity, but with restrictions such as after one-
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month post-operative and this was after I did my master degree in this area 
…. before I did not use any PRE with my patients.” 
All participants expressed unfamiliarity with term 1-RM. Participant N.D-KF 
said that “… because we do not use weights …. we don’t have time to do 
exercise with patients and we give exercise only as home instruction and 
without weights.”  
7.5  Discussion  
Phase three of this study aimed to identify and explore factors that contribute to 
successful or unsuccessful PRE from the perspectives of the participants, to 
explore the physiotherapist knowledge and understanding of CLLO in pwMS 
and the current lymphoedema practice in terms of exercise therapy.  
7.5.1  Perspective of CLLO participants about PRE 
The perceptions of ten CLLO participants with MS who participated in PRE for 
12 weeks were positive overall with minor undesirable effects which are not 
related to exacerbation of signs and symptoms of the MS or chronic oedema. 
Transportation issues and time management required to attend sessions were 
two unhelpful aspects of the intervention. One way to overcome this is to use 
tele-rehabilitation which obviates the need to travel (Fjeldstad-Pardo, Thiessen 
and Pardo, 2018). It could save time and travel costs compared to out-patient 
rehabilitation (Khan et al., 2015).  
All participants showed an interest in participating when questioned about the 
acceptability of completing an intervention which continues beyond 12 weeks.  
However, two people reported that longer PRE might be boring or too much for 
them. Feelings of boredom can be experienced when exercise schedules are 
not varied (Dodd et al., 2006). Therefore, it is important to introduce different 
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exercises from time to time to maintain the motivation. No participants reported 
deterioration in their MS condition, which is in line with other reported studies 
(as highlighted in Chapter 4), neither did they feel that their oedema increased 
which indicates the positive effects of the intervention.  
Findings reported that there is uncertainty and lack of awareness about CLLO 
among pwMS which corresponds with Keeley et al. (2017). A self-reported 
survey of pwMS indicates that 38% of the CLLO cases were not recognized by 
the participants themselves (Keeley et al., 2017). Williams et al. (2004) also 
undertook interviews with different types of lymphoedema patients and reported 
uncertainty of some participants who developed swelling, and associated 
anxiety and illness for many years before being diagnosed. The delay in 
providing diagnosis occurred  due to health care providers’ poor understanding 
and knowledge about lymphoedema and the many different presentations 
(Williams, Moffatt and Franks, 2004). These findings correspond with the 
findings of this PhD study, especially the dilemma and feelings of uncertainty 
and confusion that resulted in the development of anxiety among participants. 
The natural progression of the condition and the impact of delayed diagnosis 
and treatment has physical and psychological consequences that can influence 
participants’ QoL. This suggests that different educational materials in written, 
digital or video format, need to be considered to increase awareness and 
facilitate early detection and diagnosis of CLLO. In addition, health care 
providers need to improve their knowledge of the different aetiologies of chronic 
oedema and lymphoedema and not limit scope of practice to oncology-related 
patients in order to better support and deliver early treatment to those in need.       
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The quantitative analysis in the previous chapter was not statically significant in 
terms of participants’ lower limb volume reduction, however, the qualitative 
findings painted a different picture. Although not experienced by all, some 
participants reported that they felt the changes in their limb with expressions 
such as “my both legs are lighter now, (KK10)”, “my leg heaviness became very 
very light …. swelling of my legs decreased (KK11)” and “swelling decreased, 
(KK13)” which indicate that there was a positive reaction to the intervention. The 
most likely reason for the disagreement between the findings is the increase in 
the muscle mass which could mask the reading of volume reduction. This 
assumption could be supported by most of the participants’ responses as they 
detected an increase in  muscle strength and some of noticed the increase in 
the mass as KK4 said “I felt my legs started to be stronger …. when I touch my 
muscle I can feel it, it is bigger”. Moreover, comments from some participants 
about improvement in their balance, sit to stand, the ability to walk more steps 
and to walk safely without an aid indicate that there were improvements in 
muscle strength. These findings are consistent with findings from other studies 
(chapter 4), showing that the PRE for 12 weeks in pwMS is associated with 
improved physical outcomes which reflected positively on the participants’ 
adherence. Dodd and colleagues (2006) undertook interviews with 9 pwMS at 
the end of 10-week of PRE and highlighted that many of the participants valued 
the physical and psychological improvements which were associated with better 
exercise adherence (Dodd et al., 2006). This is matched with Clarke and Coote 
(2015) as participants raised the positive effects of the intervention on fatigue 
which is the key factor in programme completion (Clarke and Coote, 2015). Like 
those participants interviewed in both studies, these participants bring about 
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similar opinions suggesting that reaching participants’ expectations is the 
motive to adhere to the treatment sessions and reaching the desired results.   
Moreover, some participants suggest that people who have a good relationship 
with the therapist and see signs of progression might be more likely to complete 
the intervention. This assertion is confirmed by findings of Learmonth et al. 
(2013) whose participants appreciated the support of physiotherapists 
(Learmonth et al., 2013). Similarly, Clarke and Coote (2015) suggested that 
verbal encouragement and delivering clear instructions to participants can have 
a major impact on patient’s commitment to complete the treatment (Clarke and 
Coote, 2015). This suggests that the communication between therapists and 
patients including educational and verbal encouragement can be one of the 
factors that can optimise outcomes.  
Although so many participants mentioned the value of reaching the researcher 
and the good relationship with her, however, the fact that the intervention and 
interviews has done by the same person must be taken into consideration. It 
can mean that the participants would be less able to present a less favourable 
impression of the intervention itself because of the positive effect of the 
relationship. However, to minimize the social desirability bias the aim of phase 
three was anonymous  and the participants was told that their opinions have to 
be truthful (Jo, 2000).        
Although the PRE is an intervention that aims to improve physical functioning, 
psychological benefits were also reported. The majority of the participants 
reported significant psychological benefits which mirrored the quantitative 
findings in phase two in terms of overall improvement in QoL. Words such as 
comfort, returning to normality and enjoyment were used by several participants 
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to describe their psychological benefits. This is confirmed by the findings of 
Dodd et al. (2006) and Learmonth et al. (2013) whose participants reported 
physiological and social benefits from participating in exercise programmes. 
Similarly, Clarke and Coote (2015) reported that participating in 12 weeks of 
exercise improves involvement in leisure hobbies such as gardening which can 
have secondary benefits for feelings of well-being.  However, there is limited 
evidence in the literature about the psychological benefits of PRE from the 
perspective of people with CLLO.  Further studies are needed to explore this 
area in greater depth. 
Another factor that contributed to the participants’ positive experience is the 
feeling of control and empowerment of their body (De Valois, Asprey and 
Young, 2016). People with MS experience different physical and psychological 
impairments during their life that leads them to be socially isolated (Aljumah et 
al., 2013). The sense of improvement was the motive, as reported by some 
participants “even if the changes were little, it matters for pwMS”. Such feelings 
as reported in De Valois et al. (2016) study enabled the participants to engage 
more in social activities such as family and friends’ relationships.       
Interestingly, none of the participants had prior experience of this type of 
exercise, therefore it was a novel experience for them. However, participants 
expectations about the intervention’s outcomes were not taken into account, 
and it would be of interest if all the participants were asked about their 
expectations of PRE at the baseline and not only at the end of the intervention. 
This would bring additional information and could help clinicians to understand 
which aspect is driving the changes in the treatment outcomes. One participant 
at the beginning of the programme underestimated the physical improvement 
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that could be gained when she was chatting with the researcher as the 
participants experienced different MS rehabilitation programme and most of it 
were under her expectations.   
Throughout the intervention programme, the perceived changes acted as the 
motive to complete the intervention. In addition, the interviews showed that 
there was an interest in continuing with PRE if it lasted for more than 12 week 
which reflect that the pwMS are open to changes toward the way of receiving 
therapy. These findings are consistent with findings of Dodd et al. (2006), 9 
participants spoke about their desire to complete the 10-week PRE programme 
as they liked and believed in its beneficial effects. The results of our qualitative 
data suggest that PRE is a promising intervention that positively improve pwMS 
QoL through improving the physical and psychological functioning without 
provoking an MS attack. The feeling that some participants had regarding their 
oedema which contradicts our quantitative findings suggests that future 
research should additionally measure the changes of the water in the tissue and 
not the only the limb volume size.    
7.5.2  Physiotherapist knowledge and understanding of CLLO in pwMS   
          and the current lymphoedema practice 
Gaps in knowledge about CLLO in pwMS were reported by all participants. The 
lack of knowledge among the first medical contacts in Schulze et al. (2018) 
study, leads to misdiagnosis and under-treatment which impacts on health care 
outcomes. In addition, it could lead to life threatening consequences for the 
patients such as cellulitis (Moffatt et al., 2019a). All participants reported that 
they are mainly treating breast cancer and cancer related lymphoedema 
patients and their skills, knowledge, and training focus on this population. This 
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limited practice can translate into a poor detection of non-cancer related 
patients and delayed treatment, which was confirmed by the ignorance that the 
CLLO participants felt when they reported their swelling to their physician. This 
ignorance among health care practitioners (HCPs) could be a result of poor 
basic education in the university.  
In the Kingdom of Saudi Arabia, the existing knowledge gap in lymphoedema 
practice can be attributed in part to the fact that the field of lymphology is not 
currently included in undergraduate physiotherapy curricula.  The speciality is 
being developed through individual efforts and through postgraduate education. 
This finding is consistent with a recent study of worldwide assessment of health 
personnel dealing with lymphoedema in 208 countries. The study reported that 
there is insufficient training in this field for Asian, North American and European 
countries, and lymphology should to be taught in medical school pre-registration 
in order to bridge the gap in knowledge (Schulze et al., 2018). Davies (2011) 
also identified that 42% of physiotherapists indicated that teaching simple 
lymphatic drainage is needed  and only 13% of HCPs felt that their 
lymphoedema education needs were mostly met (Davies, 2011). Unfortunately, 
many counties are not aware of the importance of this speciality and have not 
clear national strategy to address this problem which left the field unquantified 
until now (Stout, Brantus and Moffatt, 2012). This suggests that basic global 
structure which includes a strong knowledge foundation from an undergraduate 
level that is evidence-based for chronic oedema and lymphoedema 
management is needed to promote optimal health outcome for this patient 
population. 
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The framed knowledge among the participants pose barriers to their practice. 
As a result, some participants experienced difficulties in making a decision 
when they face unfamiliar conditions. Similar to Schulze et al. (2018), the 
unbalanced education and training among physiotherapists who focused mainly 
on oncology patients have led to their limited clinical experiences. In addition, 
limited experiences can drive practitioners to be more inattentive which can lead 
to misdiagnosis and delayed treatment to those unfamiliar conditions and 
generate confusion and uncertainty among the patients. This suggests that 
being a lymphoedema specialist entails a life-long development of skills and 
refinement of clinical experiences that would stretch the practice to involve a 
wider spectrum of patients suffering from chronic oedema.                  
The findings also show that disparities between practice and research related 
to resistance exercises exist. Fear avoidance behaviours was observed in the 
interviews, as participants avoided using weights with their patients fearing that 
it might trigger the lymphoedema. Furthermore, some participants reported that 
their practice was not evidence-based and they were simply following the 
hospital protocol. This finding is consistent with Thomas (2018) study, 
suggesting as a first contact line with patients, HCPs need to provide evidence-
based information and tailor the treatment to individual patients’ needs. Like 
other studies, the findings reinforce the need for further education among HCPs 
and encourage the use of evidence-base practice (Williams, Moffatt and 
Franks, 2004; Davies, 2011; Stout, Brantus and Moffatt, 2012; Thomas., 2018). 
Future studies with a larger sample size are needed to ascertain what 
physiotherapists are currently practicing and advising patients.                                    
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7.6  Phase three strengths and limitations  
This phase has a number of strengths. It explored for the first time the unique 
experiences and perceptions of pwMS who suffer from CLLO toward the PRE 
treatment. The physiotherapists’ knowledge of CLLO in pwMS and the current 
practice in terms of treating chronic oedema were also explored. Furthermore, 
it addresses the overall effects of the treatment rather than focusing on specific 
physiological symptoms such as reduction in oedema. Another strength of this 
phase is the inclusion of unrecognized, undertreated, and under-researched 
group of people who requires more attention to improve their QoL. 
The small sample size in this phase may limit the range of experiences and 
cannot be generalized to another group. However, it is important to 
acknowledge that this is a first study that tackled this area and future research 
with a larger sample size is needed to add to the findings. Further limitation is 
the lack of data about CLLO participants’ concerns about prevention of 
symptoms deterioration and safety were not expressed in the interviews.  
Since the researcher was the one who implemented the intervention and also 
conducted the interviews, it could be difficult for the CLLO participants to be 
honest about their opinions. Nevertheless, the continuity might have contributed 
positively by enabled them to feel relaxed and comfortable about sharing their 
experiences with the same researcher. There is a risk that the physiotherapists’ 
identifty could be revealed inadvertently, since only 6 were interviewed and 
these are based in 2 organisations. 
7.7  Conclusions  
The qualitative data showed that the PRE was experienced to be a feasible and 
meaningful therapy. The physical and psychological changes that the 
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participants felt suggest that a PRE program may be a feasible fitness option 
for people with MS to encourage them to be more physically and psychologically 
stimulated and reduce the risk of developing CLLO. Participants valued the 
untraditional way of treatment that facilitated a transformation from 
disempowerment to feeling in control of their body. This finding highlights the 
need for qualitative analysis which captures positive effects of PRE that could 
not be measured by standard quantitative outcomes.      
The lack of awareness among health care providers about CLLO in pwMS 
suggests that this specific gap in knowledge needs to be recognized in order to 
provide a meaningful treatment plan. Additionally, exploring the current 
lymphoedema practice in Saudi Arabia may suggest further insight into how to 
add strengths to our practice to involve more chronic conditions such as non-
oncology related lymphoedema.  The amount of qualitative data that were 
generated and the themes that were created warrant further research. In 
addition, the need to develop educational and information resources for public 
is recommended to improve the treatment and support pwMS with CLLO.  
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8.1  Introduction  
This mixed methods study was conducted at two centres in Riyadh city, in the 
Kingdom of Saudi Arabia. This innovative study introduced an intervention for 
a patient population with two distinct conditions (namely chronic lower leg 
oedema [CLLO] and multiple sclerosis [MS]) with a wide range of symptoms 
and different levels of impairments that creates difficulties when trying to tailor 
safe and convenient interventions.   
This PhD study consisted of three distinct phases. Phase one determined the 
prevalence of (CLLO) in pwMS who reside in the Kingdom of Saudi Arabia and 
attend the King Khaled University Hospital (KKUH) or King Faisal Specialist 
Hospital and Research Centre (KFSH&RC). Moreover, this phase determined 
the main characteristics of those at high risk of developing CLLO and compared 
the findings with existing evidence. Phase two assessed the effectiveness of 
Progressive Resistance Exercise (PRE) in the management of CLLO and the 
impact of CLLO on quality of life (QoL) and pain.  Phase three explored 
participants’ experiences and opinions of PRE, and explored physiotherapists’ 
understanding and knowledge of CLLO in pwMS (including current 
lymphoedema management options). Findings gained from this mixed method 
study provide a greater 1) exploration of the effects of PRE in treating CLLO in 
pwMS and 2) understanding of current health care practices.  
In phase one, results demonstrated that CLLO is a common problem in pwMS 
which is under-recognised and under-treated. Similar to Solaro et al. (2006), 
Arpaia et al. (2010) and Keeley et al. (2017), the findings show that those who 
are less physically active, of higher age and BMI are more likely to develop 
 Overall Discussion and Conclusion  
213 
 
Chapter 8 
CLLO. However, the prevalence in this study was lower (21%) than that 
reported previously.  
The results of phase two show that there is no significant difference in leg 
volume from baseline following the intervention, however, the intervention had 
a significant impact on QoL and pain. Although the findings indicated no 
reduction in leg volume overall, there was a reduction in the volume of leg 
segments adjacent to the proximal rather than distal part of the leg. Muscle 
strength and EDSS improved significantly.  This suggests that PRE is a 
promising therapy that contributes to improving patient QoL, although further 
research is needed to confirm these results.  
Phase three findings corroborate the findings of phase two in terms of physical 
and psychological changes that the CLLO participants experienced which 
resulted in an improved QoL. The data show that health care practitioners 
(HCPs) have a limited knowledge and awareness of CLLO in pwMS and their 
practice is focused primarily on oncology related patients. The CLLO 
participants expressed confusion and uncertainty about CLLO and reported that 
the condition is not recognised by their doctors. The most common motives to 
complete the intervention were good therapist-patient communication, new 
methods of treatment and visible signs of improvement. 
Within this chapter, the aim of the study and the objectives are revisited to 
synthesize and discuss findings of this thesis. The main aim of this study was 
to gain an improved understanding of the prevalence and impact on CLLO in 
pwMS, and the contribution of progressive resistance exercise on its 
remediation. The following study objectives shape the structure of this 
discussion.  
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1) Measure the prevalence of CLLO in pwMS who are resident in the 
Kingdom of Saudi Arabia and attendees one of the two hospitals. 
2) Determine the main characteristics of those at high risk of developing 
CLLO. 
3) Assess the effectiveness of PRE in the management of CLLO 
in pwMS who are residents in the Kingdom of Saudi Arabia.  
4) Determine the impact of CLLO on pain and Quality of Life (QoL).  
5) Identify and explore the factors that contribute to successful or 
unsuccessful completion of PRE from the perspectives of the 
participants.  
6) Explore the physiotherapists’ knowledge and understanding of CLLO 
in pwMS and the current lymphoedema practice in terms of exercise 
therapy. 
The chapter will also discuss the overall strengths and limitations, implications 
of the study, recommendations, and overall conclusions.  
8.1.1 Measure the prevalence of CLLO in pwMS who are resident in the 
Kingdom of Saudi Arabia and attendees one of the two hospitals. 
The purpose of phase one was to assess the frequency of CLLO in pwMS that 
has not been studied previously in the Kingdom of Saudi Arabia. The data 
demonstrated that CLLO is a common problem amongst pwMS. Eight percent 
of people screened with MS were found to have unrecognized CLLO. This 
resonates with studies conducted elsewhere (Solaro et al., 2006; Arpaia et al., 
2010; Keeley et al., 2017) in England and Italy. However, the study shows a 
lower prevalence rate compared to published international studies e.g. a 
prevalence of 45% in MS centre of the university of Genoa and the regional 
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centre of Italian Multiple Sclerosis Society of Italy (Solaro et al., 2006), 85% in 
one neurological rehabilitation centre in Southern Italy, and 62% in one hospital 
in the South of England. This variation between our results and the other studies 
can be related to the sample characteristics. Participants involved in Solaro et 
al. (2006), Arpaia et al. (2010) and Keeley et al. (2017) studies were reported 
to present with more advanced MS symptoms than those screened in this study. 
The mean EDSS score was 2.4 (±2.0) in 92% of screened pwMS and none of 
them showed signs of CLLO whereas the mean EDSS scores in other studies 
were 5.227 (±2.11) in Solaro et al. (2006), >6 in Arpaia et al. (2010) and 
between 3 and 6 in Keeley et al. (2017). This indicates that patients who present 
with lower levels of disability and are more physically active are at low risk of 
developing CLLO.  
Although CLLO is a common condition in pwMS, the problem is undiagnosed 
and under-recognised among HCPs which could have an impact on patient QoL 
and lead to life-threating consequences such as cellulitis (Moffatt et al., 2019a). 
Delayed diagnosis leads to delayed treatment which makes the management 
of the CLLO condition a challenge. The findings of this study demonstrate that 
the majority of participants did not recognize that they have lower limb oedema 
which corresponds with a study conducted by Keeley et al. (2017). Lack of 
knowledge among pwMS about the possibility of developing CLLO and among 
HCPs in recognizing the condition was confirmed in phase three findings 
(qualitative phase) which highlights the need to increase awareness and 
education about this problem. To date, the focus of previous studies has been 
to estimate the prevalence of CLLO in specific groups of the population, hence, 
it is important to examine prevalence among a more heterogeneous population. 
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The scope of this study covers two hospitals in one region; however, the 
research provides important data that provide a bedrock foundation for future 
studies in the region.    
8.1.2 Determine the main characteristics of those at high risk of  
           developing CLLO. 
Although the prevalence of CLLO in pwMS in the Kingdom of Saudi Arabia was 
lower compared to other studies, the characteristics of those at high risk of 
developing CLLO were comparable with previous research. Phase one showed 
that CLLO in pwMS is associated with advanced age, higher obesity and 
disability levels which corresponds with Solaro et al. (2006), Arpaia et al. (2010) 
and Keeley et al. (2017) studies. The findings show that pwMS who are of an 
older age (45 years, SD ±7.6) have 1.093 times higher odds of developing 
CLLO than those of a younger age. Moreover, patients with a higher BMI 
(28.8kg/ m2, SD ±13) and higher level of disability (EDSS 5.4, SD ±1) have 
1.047 and 2.735 time higher odds respectively of developing CLLO.  However, 
a statistically significant relationship was not found between CLLO and disease 
duration (p= 0.140) or between CLLO and stage of MS (p= 0.061 for SPMS and 
p= 0.909 for PPMS). This is in contrast to Solaro et al. (2006) study who 
reported that disease duration of 20.5 (±11.3) years and secondary progressive 
MS (more than 50%) were associated with the development of CLLO.   
CLLO in pwMS represents an additional burden to individual lives that further 
affects patient mobility and reduces their physical activities which culminate in 
a poor QoL and social isolation. Findings from phase one contribute to the 
understanding of CLLO prevalence in pwMS and identify the main 
characteristics of those at high risk of developing CLLO. This knowledge has 
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the potential to improve health care practices in the Kingdom of Saudi Arabia. 
Adding a few simple questions such as if the patient has noticed any swelling 
in lower limb and since when, to a neurological screening test can detect CLLO 
at an early stage.  
CLLO is under-diagnosed, under-researched and under-treated within the MS 
population at the moment, CLLO treatment options offered in the Kingdom of 
Saudi Arabia are designed for the treatment of cancer-related CLLO which are 
not necessarily suitable for non-cancer related CLLO. There is a need to 
enhance the position of lymphology as a specialty and expand healthcare 
practitioners’ understanding of CLLO which would lead to the development of 
innovative treatment options for specific CLLO patient groups. To improve the 
health care practices for this group of people (pwMS who developed CLLO) it 
is important to understand and acknowledge the causes of CLLO. Therefore, to 
treat CLLO or to improve CLLO, for the first time this study adopted an 
intervention that is not based on compression therapy or MLD technique. The 
phase two intervention was a progressive resistance exercise (PRE) which 
considered the individuality of each participant and tailored the progressive 
resistance exercise to each patient.           
8.1.3 Assess the effectiveness of Progressive Resistance Exercise  
          (PRE) in the management of CLLO in pwMS who are resident in    
           the Kingdom of Saudi Arabia  
The purposes of phase two were to demonstrate the effectiveness of 
progressive resistance exercise in the management of chronic lower limb 
oedema in people with multiple sclerosis and to determine the impact of CLLO 
on pain and quality of life. Circumference-based measurements were used to 
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estimate limb volume changes from mathematical formula. Compared to pre-
intervention, the results show no significant reductions in overall circumference 
measurements and no significant reductions in the volume after 12 weeks of 
PRE. However, individual segment volumes responded differently to the 
intervention. Volume reduction increased in the proximal part of the leg 
compared to the distal, some areas were stable and other areas increased 
(more around the bulk of the calf muscle). These findings correspond to some 
extent with the findings of phase three in which some participants (4 out of 10) 
reported that they felt changes in their legs. Feelings such as “lightness in the 
limb” and “swelling reduction” were expressed by some participants which 
indicate that the intervention may have triggered a positive physiological 
reaction.  
The most likely reason for the difference in findings is the increase in the muscle 
mass which could mask any volume reduction due to a reduction in oedema in 
some areas especially in the middle of the leg where our results found the most 
significant increase. This assumption could be supported by results from phase 
three since most of the participants reported an increase in muscle strength and 
some noticed an increase in the mass of the calf. These findings resonated with 
findings from studies conducted by Dalgas et al. (2010), Dodd et al. (2011) and 
Medina-Perez et al. (2014) who reported an increase in muscle mass, strength, 
power, and volume after a PRE programme. It is therefore possible that volume 
reduction could not be detected because circumference measurements can 
only reflect superficial changes, but the water content of tissues need to be 
measured by other measurement tools or devices. Supporting this, phase two 
also found that muscle strength improved following completion of the 
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intervention in both plantar-flexion and dorsi-flexion movements which is 
consistent with an increase in the muscle mass.  
Although the reduction in volume was found in areas where tendons of the 
muscles are located (proximal and distal end of the leg), the reduction was not 
uniformly distributed. More reduction was notable in the proximal rather than in 
the distal part of the leg. This finding is consistent with Iker et al. (2019) and 
Mayrovitz et al. (2007) studies where lower limb lymphoedema was found to be 
more likely located in the distal part of the participants’ extremities. On one 
hand, the effects of gravity could play a role in accumulating fluid especially 
because the participants in our study were in a sitting position where gravity is 
not eliminated and these factors could explain why less volume reduction was 
noticed in the distal portion. On the other hand, the mechanism of PRE with calf 
muscle and venous hemodynamic around this area could explain this finding 
(Keilani et al., 2016). PRE in this study mainly targeted the leg muscle and not 
the foot muscles to support lymphatic flow in the leg through calf muscle 
pumping mechanism. Because the foot muscles did not bear weight during the 
intervention,  the veins were not compressed and the venous foot pump 
mechanism may not have been fully activated which could explain less volume 
reduction around the distal part (Corley et al., 2010).   
As highlighted in chapter 6, conducting this study within the pwMS population 
with CLLO was challenging since the outcomes of the intervention could affect 
both the disability due to MS and the chronic oedema. Although there was no 
statistically significant reduction in leg volume, the improvement in muscle 
weakness due to MS had improved. The striking issue is the improvement in 
the pwMS EDSS without a real attempt of this study to benefit participants 
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functionally. However, the sense of physical changes in terms of oedema that 
the participants described in phase three cannot be neglected. Previous studies 
on cancer-related lower limb lymphoedema that aimed to assess the effects of 
PRE on developing or aggravating lymphoedema reported that the resistance 
exercise neither contributed to the development of lymphoedema in those at 
high risk of developing the condition  nor worsened lymphoedema  in those who 
already presented with the condition (Mayrovitz et al., 2007; Katz et al., 2010). 
This could improve our understanding of the result i.e., the increase in volume 
could be related to the hypertrophied muscle (muscle mass) and not the fluid. 
Further, unmeasured variables such as water content in tissues may account 
for the difference and future studies should consider these variables.   
8.1.4  determine the impact of CLLO on pain and Quality of Life (QoL) 
Although the circumference and volume reduction were not statistically 
significant in this study, findings show a positive impact on QoL and pain. 
Undoubtedly, the contribution of MS to a person’s QoL in this study should not 
be neglected. The improvement in muscle strength and EDSS score indicates 
that the MS might have an impact on pain and QoL, however, measuring QoL 
in pwMS was not the focus of this study.  
Given that participants in this study have combined impairments (MS and 
CLLO), this would lead to the possibility that the combination of both conditions 
will negatively impact their QoL. The findings from phase two were corroborated 
by the findings in phase three. There was evidence that participants experience 
a low  QoL and pain which affect their activity of daily living which is in 
agreement with other existing knowledge published in previous studies (Greene 
and Meskell, 2017; Tuğral, Virén and Bakar, 2017; Dai et al., 2019; Mercier et 
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al., 2019) in various countries. Some participants in phase three reported that 
they were actively trying to avoid certain daily activities such as walking, sitting 
to standing and socializing before they started the intervention to avoid the 
deterioration in MS symptoms which limited their life activities. In addition, 
participants stated that they were depending on others or assistance tools such 
as a walker or a cane to manage their activities of daily living which was 
psychologically frustrating. Before the intervention, comparing the LYMQOL 
scores with other studies (Mercier et al., 2019 and Dai et al., 2019), our findings 
showed worse QoL scores in symptoms domain, function domain and overall 
VAS. This may support the suggestion that CLLO in pwMS can have significant 
physical consequences which can complicate and challenge the performance 
of patient’s daily activities.    
A combined analysis of both the quantitative and qualitative data post-
intervention showed that participants improved their physical, psychological, 
and social well-being. All participants showed changes in their pain score, 
muscle strength and symptom severity (EDSS) which reflected positively on 
their QoL. These findings may indicate that PRE is a treatment that reduces 
pain and MS symptom severity which then subsequently improves QoL, 
however, future research is needed to test this theory.  
8.1.5  Identify and explore the factors that contribute to successful or  
            unsuccessful of PRE from the perspectives of the participants   
Phase three of this study aimed to identify and explore factors that contribute to 
successful or unsuccessful PRE from the perspectives of the participants. The 
perceptions of ten CLLO participants with MS were positive overall, a few 
participants reported minor undesirable aspects of the intervention. As 
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highlighted in chapter 7, the unhelpful aspects concerned transport and time 
issues related to session attendance. These aspects however did not affect 
adherence to the intervention. Phase two showed that 97% of participants 
completed the median number of sessions i.e., 23.21/24 sessions. This finding 
corresponds with previous research that reported 92%, 99%, 99% and 95% 
respectively (Dodd et al., 2006; Dalgas et al., 2009, 2010; Medina-Perez et al., 
2014). 
Participants’ high commitment to the completion of the intervention could be 
linked to many factors. Findings in phase three demonstrated that 1) the positive 
therapeutic relationship between the participants and the researcher, and 2) 
participants’ sense of physical and psychological improvements were the 
drivers for the participants to continue with the intervention. In addition, 3) 
achieving patient’s expectations can also contribute to the adherence to 
treatment sessions and obtaining the desired results. Evidence in the literature 
is consistent with these findings which suggest that HCPs should consider these 
key factors during clinical practice to achieve better patients’ outcomes.  
As part of their studies Dodd and colleagues (2006), and Clarke and Coote 
(2015) undertook interviews with pwMS at the end of PRE. Both studies report 
that the intervention had a positive impact on participants’ physical and 
psychological well-being which contributed to the programme completion. 
Learmonth et al. (2013) study concluded that patients who have a good 
relationship with their therapist and see signs of progression may be more likely 
to complete the intervention. Moreover, verbal encouragement and delivery of 
clear instructions to participants can have a major impact on patient’s 
commitment to completion of the treatment plan as highlighted by Clarke and 
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Coote (2015). In order to optimise patient’s outcomes and enable changes in 
clinical practice, a balanced communication that includes educational and 
verbal encouragement, recognition of individual needs and expectations, and 
involvement of patients in tracking their changes must be taken into account 
when providing treatment.   
Another factor that contributed to participants’ positive experience is the feeling 
of control and empowerment of their body (De Valois, Asprey and Young, 2016). 
People with MS experience different physical and psychological impairments 
during their life that leads  to  social isolation (Aljumah et al., 2013). The sense 
of improvement was the motive, as reported by some participants “even if the 
changes were little, it matters for pwMS”. Such feelings as reported in De Valois 
et al. (2016) study enabled the participants to engage more in social activities 
such as fostering relationships with family and friends.  
Interestingly, all participants except two showed interest in participating in an 
intervention that would continue beyond 12 weeks.  Those two participants who 
were not interested reported that longer PRE might be boring or too much for 
them which resonated with findings from Dodd et al. (2006) study. Feelings of 
boredom can be experienced when exercise schedules are not varied (Dodd et 
al., 2006). It is therefore important to propose different exercises from time to 
time to maintain patients’ interest and motivation. The high adherence levels 
and determination to complete the intervention in this study may be explained 
by the progressive nature of the exercises that progressed in load, sets and 
repetitions. 
Participants in phase three reported that there is uncertainty and lack of 
awareness about CLLO which corresponds with Keeley et al. (2017). Phase two 
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results indicate that 81% of participants with CLLO did not recognize the 
swelling which is almost double the results in Keeley et al. (2017) self-reported 
pwMS study where 38% of participants were not aware of their swelling. The 
participants’ lack of awareness is linked to the poor understanding and 
knowledge about chronic oedema in pwMS among HCPs as indicated in the 
qualitative phase, which is in line with Williams et al. (2004). Lack of awareness 
of CLLO can result in delayed diagnosis, progression of chronic oedema and 
the development of anxiety (William, Moffatt and Franks, 2004). The natural 
progression of CLLO and the impact of delayed diagnosis and treatment has 
physical and psychological consequences that can influence participants’ QoL.  
As highlighted before, some participants reported poor QoL, anxiety and 
psychological frustration which led to life adjustments to cope with the pain and 
impairments. This suggests that health care providers need to improve their 
knowledge of the different aetiologies of chronic oedema and lymphoedema 
and to not limit the scope of practice to oncology-related patients in order to 
better support and deliver early treatment to those in need. In addition, different 
educational materials are needed to increase the awareness of CLLO among 
pwMS. These recommendations can save patients from the development of 
feelings of confusion, uncertainty, and anxiety due to the CLLO changes.           
The quantitative analysis in the previous chapter did not show statically 
significant findings in terms of participants’ lower limb volume reduction, 
however, the qualitative findings showed a different picture. Although not 
experienced by all, some participants reported that they felt changes in their 
limb. Phrases such as “both legs are lighter now”, “leg heaviness became very 
very light” and “swelling decreased” were reported. Importantly, none of the ten 
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participants articulated that they felt an increase in their oedema which 
corresponds with Mayrovitz et al. (2007) and Katz et al. (2010) research. 
Although bulkiness around calf muscle was reported by a few participants, the 
increase was linked it to the improvement in their muscle strength. Comments 
from some participants about improvement in their balance, the ability to sit to 
stand, and their ability to walk more steps and to walk safely without an aid 
indicate that there were improvements in muscle strength. These findings 
correspond with the quantitative findings in phase two that reports improvement 
in muscle strength and EDSS after the completion of the intervention. 
Furthermore, the data identified that no participants reported deterioration in 
their MS condition, which is consistent with other studies (Dalgas et al., 2009; 
Dalgas et al., 2010; Medina-Perez et al., 2014; Kjolhede et al., 2014) that 
described the PRE as a safe and tolerable treatment for pwMS patients.  
Even though the PRE aimed to improve physical functioning, psychological 
benefits were also reported. The majority of participants reported significant 
psychological benefits and described these benefits in words such as ‘comfort’, 
‘returning to normality’ and ‘enjoyment’. These findings correspond with the 
findings of Dodd et al. (2006), Learmonth et al. (2013) and Clarke and Coote 
(2015) whose participants reported not only physiological but also secondary 
psychological and social benefits from participating in exercise programmes. 
Currently, there is a limited evidence in the literature about the psychological 
benefits of PRE from the perspective of people with CLLO.  Further studies are 
needed to explore this area in greater depth.     
None of the participants had a prior experience of this type of exercise, therefore 
it was a novel experience for them. Participants’ expectations about the 
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outcomes of the intervention were not taken into account, however, it would be 
of interest if all the participants were asked about their expectations of PRE in 
the beginning and not only at the end of the intervention. This would provide 
additional insights and could help clinicians to understand which aspects are 
driving the changes in the treatment outcomes.   
Throughout the intervention programme, the perceived changes acted as the 
driver to complete the intervention. In addition, the interviews showed that there 
was an interest in continuing with PRE if it lasted for more than 12 weeks. This 
finding shows that pwMS patients are open to changes in the way how their 
treatment is delivered. Results from the qualitative study suggest that PRE is a 
promising intervention that positively improve pwMS’ QoL through improving 
the physical and psychological functioning without provoking an MS attack. The 
feeling that some participants expressed regarding their oedema contradicts 
our quantitative findings. Future research should additionally measure changes 
in the tissue water content and not the only changes in the limb volume.    
8.1.6 Explore the physiotherapists knowledge and understanding 
of CLLO in pwMS and the current lymphoedema practice in terms 
of exercise therapy.  
When the diagnosis and treatment were delayed, CLLO participants reported 
feeling of confusion and uncertainty. Findings in Phase Three showed that there 
were gaps in knowledge about CLLO in pwMS among all physiotherapists which 
resulted in physiological and psychological consequences that negatively 
impacted patients’ QoL. These findings resonate with Schulze et al. (2018) 
findings who found that the lack of knowledge among the first medical contacts 
led to misdiagnosis and under-treatment which impacted on patient’s health 
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care outcomes. A recent study (Moffatt et al., 2019a) described the costs of 
delayed diagnosis and complications such as irreversible tissue changes or 
chronic wounds for CO patients. 
All participants reported that they are mainly treating breast cancer and cancer 
related lymphoedema patients and their skills, knowledge, and training focus on 
this patient population. The limited focus of clinicians’ practice can translate into 
a poor detection of non-cancer related CO and delayed treatment, which was 
confirmed by CLLO participants who felt their clinicians had a poor 
understanding of CO when they reported their swelling to them. This 
inexperience among health care practitioners (HCPs) could be a result of poor 
basic education in the university as highlighted previously. The existing 
knowledge limitations in lymphoedema practice can be attributed in part to the 
fact that the field of lymphology is not currently included in undergraduate 
physiotherapy curricula in the Kingdom of Saudi Arabia (KSA). The speciality is 
being developed through individual efforts and through postgraduate education. 
Current gaps in the educational system in the KSA are in line with other 
countries such as in Oceania, North America and Africa as indicated by Schulze 
et al. (2018) and Scotland in Davies (2011), who both found that undergraduate 
healthcare students received insufficient training in this field of lymphology. 
Unfortunately, many counties are not aware of the importance of this speciality 
and do not have a clear plan to address this pedagogical problem which left the 
field of lymphology unquantified until now (Stout, Brantus and Moffatt, 2012). 
Regardless of the potential reasons of knowledge limitations among HCPs, 
further education is needed to address the issue and promote optimal health 
outcomes for this patient population. 
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Furthermore, the limited knowledge among the participants poses barriers to 
the development of their practice. Unbalanced education and training among 
physiotherapists led to the restriction of their clinical experiences. The data 
show that some participants experienced difficulties in making decisions when 
they face unfamiliar conditions. This may generate confusion, distrust and 
uncertainty among patients and their HCPs. Being a lymphoedema specialist 
entails a life-long development of skills and refinement of clinical experiences 
that would expand their practice to involve a wider spectrum of patients suffering 
from chronic oedema. 
This phase showed contrasting findings relating to the perception of resistance 
exercise and their practice by physiotherapists. In the qualitative interviews, 
physiotherapists did not state they avoid resistance exercises with their 
patients. However, when later asked about prescribing weights exercise to their 
patients, physiotherapists reported feelings of fear about whether weights 
exercise could trigger their patients’ lymphoedema. Their fear of triggering 
lymphoedema led to the avoidance of using weight exercises. Even though 
there is a plethora of reliable evidence advocating the positive effects of 
resistance exercise on lymphoedema, disparities between practice and 
research related to resistance exercises exist which resonates with Thomas 
(2018) study. Moreover, some participants reported that their practice was not 
evidence-based, and they were simply following the hospital protocol which is 
consistent with Thomas (2018) findings that suggest that HCPs need to provide 
evidence-based and patient-centred care to meet individual patients’ needs. 
Like other studies, Phase three findings reinforce the need for further education 
among HCPs and encourage the use of evidence-base practice (Williams, 
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Moffatt and Franks, 2004; Davies, 2011; Stout, Brantus and Moffatt, 2012; 
Thomas, 2018). Future studies need to ascertain what physiotherapists are 
currently practicing and advise patients and carers. 
8.2  Overall Strengths and Limitations 
Despite the challenges of this study, the study provides a template for future 
research and could be used as a guide to start a discussion about early 
diagnosis and treatment for CLLO in pwMS. One of the strengths of this study 
is the chosen mixed-methods study design. Gathering data through quantitative 
and qualitative methods enabled triangulation and developed our 
understanding of the studied phenomena.   
Each phase of the study however had its limitations. In phase one, the 
prevalence study was conducted in two hospitals in one city. The findings from 
the prevalence study are specific to the geographical location and type of setting 
(hospital) and thus cannot be applied to the population of the Kingdom of Saudi 
Arabia (KSA). Conducting national prevalence studies is resource-expensive 
and time-consuming and would require a large research team.  A population 
prevalence study was not the focus of this research. However, the fact that there 
is no national study of CLLO in pwMS in the KSA confirms the need for further 
prevalence studies that would map the issue and propose steps forward to the 
development of best clinical practice.  
The sample sizes of the quantitative and qualitative studies in this PhD study 
were small, therefore, the findings should be interpreted with caution and cannot 
be generalized to other groups. Additionally, the researcher was the one who 
delivered and analysed both the quantitative and qualitative studies which 
means that the participants might be reluctant to present a less favourable 
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impression of the intervention during the interview. The researcher was unable 
to include neuro-immunology doctors to explore their knowledge of CLLO in 
pwMS. Due to time restrictions, the views and knowledge base of neuro-
immunology doctors could not be presented in this study. Therefore, future 
studies need to consider involving their knowledge and awareness about CLLO 
in pwMS.  
The researcher also acknowledges that it would have been of interest to have 
carried out interviews with the CLLO participants at the beginning of the 
intervention and compare any changes in opinions and expectations with the 
views expressed at the end of the intervention. Although 4 participants out of 
10 did not participate in individual interviews that did not reduce the credibility 
of the qualitative study because saturation of the themes was reached. To 
strengthen future studies it may be pertinent to include a control group, involve 
a multi-disciplinary lymphoedema team e.g. nurses, doctors and social workers, 
and utilise additional limb volume measurements that can detect changes in the 
water content in the studied limbs.                       
8.3  Implications for Clinical Practice and Research 
The results of this study have important implications for future research, 
education, and clinical practice for health care professionals. This section 
delivers the implications of phase one, two and three for better clinical practice 
and research.   
8.3.1  Future research directions 
This study is the first evidence of the effects of resistance exercise on CLLO in 
pwMS. Findings from this study suggest that more research is needed in pwMS 
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with CLLO. Suggestions on topics of future research include but are not limited 
to: 
• Increase the number of chronic oedema and lymphoedema prevalence 
studies in the Kingdom of Saudi Arabia in order to improve our health 
care services and access hard-to-reach patients that require special and 
urgent care. 
• More randomized controlled trials comparing different PRE parameters 
such as dose, frequency, intensity, and timing and determine which 
parameter has a positive impact on CLLO.  
• The collection of longitudinal data in CLLO populations with MS to 
establish the need for long-term care.  
• Use of more specific outcome measures that can detect the reduction in 
CLLO especially the water content of tissue. 
• Future studies may assess when the responses to PRE emerge during 
the progression programme.  
• Focus on interventional studies that involve pwMS patients with early 
stages of the disease who are able to participate in high level exercises.  
• Further research examining whether there are methods to prevent the 
development of CLLO and early detection of risk factors that may lead to 
the development of CLLO.   
• Further qualitative research exploring patients’ and carers’ perspectives 
that consider social and QoL domains.  
• Finally, future research in CLLO in pwMS should focus on improving the 
methodological aspects such as large sample sizes and long-term 
follow-up.    
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8.3.2  Implications for practitioners  
Chronic lower limb oedema (CLLO) in pwMS is a complex and challenging 
condition.  Evidenced-based knowledge and awareness among HCPs needs to 
be increased and developed to enable people with different types of chronic 
oedema and lymphoedema to be treated and face less uncertainty and 
confusion. In addition, the definition of chronic oedema needs to be specified 
and adopted in the KSA and take into account non-oncology related 
lymphoedema. Further education for HCPs is needed as the sample of the 
physiotherapists in this study showed knowledge deficits and practice governed 
by fear of triggering oedema rather than delivery of evidence-based practice. 
HCPs should understand that the practice must not be based on “one size fits 
all” and treatment should be tailored to individual needs. In addition, they need 
to enhance their skills to screen those with early symptoms of chronic oedema 
in order to provide early treatment. 
This study adds to previous evidence which suggested that pwMS with a low 
physical activity level, long disease duration and an EDSS score above 3 are at 
high risk of developing CLLO. Therefore, professionals must consider regular 
monitoring and conducting a full assessment with early detection and 
intervention. Early detection with early intervention e.g., PRE is likely to reduce 
the risk of worsening CLLO, however, longer and larger study is required to 
confirm this finding.  The measures must not only limit the volume of swelling 
but should also be extended to address psychological and social well-being. 
Moreover, patient involvement has to be considered as well to enable both 
professionals and patients to reach optimal and feasible treatment outcomes.  
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This study identified the need for ongoing information and support for pwMS 
and carers. All health care professionals must educate their patients about early 
signs and symptoms of CLLO and how to access specialised lymphoedema 
services.                    
8.3.3  Implications for education  
Bridging the gap between education and practice is important, so that HCPs are 
ready to treat their patients with confidence using evidence-based practice. In 
the KSA undergraduate healthcare courses should be assessed and gaps in 
CO education should be addressed to provide students with the necessary 
knowledge and skills.   
In terms of patient education, different forms of educational materials must be 
provided such as video films and webinars to deliver information in an attractive 
and easy-to-understand way. Sharing patients’ experiences through written 
publications or face-to-face encounters such as webinars or conferences can 
strength the educational tool.          
8.4  Overall Conclusion  
In this thesis, the systematic review summarised the prevalence of CLLO in 
pwMS demonstrating that CLLO is a common, unrecognized, and under-treated 
problem which requires more attention from the health care system. Our 
analysis shows that the frequency of CLLO in the Kingdom of Saudi Arabia is 
lower than in other countries, however, early detection and treatment of CLLO 
can prevent patients from developing secondary conditions such as acute 
infection and permanent damage. Progressive resistance exercise (PRE) in the 
systematic review study was found to be safe, tolerable, and effective for the 
development of muscle strength in pwMS.  
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Although the results from the quantitative study show that PRE had no effect on 
the overall CLLO in pwMS, patient QoL and pain improved significantly after the 
intervention.  The qualitative data showed important improvements in patients’ 
physical and psychological well-being; however, this finding was not confirmed 
by statistical analysis. Meaning that a larger quantitative future study is needed 
to confirm the finding of the qualitative data. The lack of awareness among 
health care providers about CLLO in pwMS suggests that this specific gap in 
knowledge needs to be recognized in order to provide a meaningful treatment 
plan.  
This study used a single measurement method to capture changes in limb 
volume, however, given the small sample size this study was unlikely to detect 
subtle changes in CLLO in pwMS. Further research is needed with larger 
samples and more sensitive measurements that can detect the water content 
in tissue beside muscle mass. This mixed methods approach offers a powerful 
tool and useful framework that contributed to the illumination of clinical practice 
and improvement of policy.    
8.5  Recommendations for Changing Practice 
All MS patients who are undergoing medical follow-up in MS clinics should 
receive information about CLLO, especially if the person is at a risk of 
developing the condition. CLLO is a progressive condition, however, it can be 
maintained and controlled when diagnosed and treated in a timely manner. 
Routine neurological visits should include simple screening questions to detect 
and diagnose chronic oedema at an early stage to avoid potential 
complications. Findings from phase three reported that participants 
(physiotherapists) possess a limited knowledge of CO and its consequences. 
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Providing information verbally alone is not sufficient because some pwMS may 
have difficulties with memory, it is therefore important to provide information 
about CLLO in alternative formats (such as written text, audio or video files).  
Leaflets should be available in many locations not only inside the clinic but also 
in the waiting area. The language used must be simple delivering clear 
messages. The leaflet may include a patient story and should also promote the 
benefits of exercise and good nutrition. The information materials must be 
reviewed from time to time and updated if based on evidence-based practice.    
Currently, the evidence and knowledge of the beneficial effects of exercise in 
pwMS with CLLO is insufficient. Added to this, timing of when starting the 
exercise is also slipped and less attention is given to this aspect. Therefore, 
interprofessional working is required between doctors and physiotherapists to 
serve each individual based on their needs. MS patients must understand the 
rationale behind the timing and the type of exercise.  
This study has identified the scarcity of knowledge about CLLO in pwMS among 
physiotherapists. HCPs should be able to access different national and 
international educational resources such as accredited educational courses, 
conferences, and workshops to develop their skills and improve their 
knowledge. Furthermore, educational systems for undergraduate and 
postgraduate students should be re-assessed and improved to reduce gaps in 
the curriculum. 
To initiate improvement in knowledge, I would recommend launching an 
awareness campaign for HCPs in hospitals in different KSA regions to reach 
front line practitioners. Moreover, the campaign should also be communicated 
via social media to reach more healthcare professional and patient groups.   
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8.6  Dissemination of the Study Findings  
Phase two findings of this study were presented at the Skin Integrity 
International Summer School at the University of Nottingham in September 
2017, at the University of Tokyo, Japan in August 2018, and at Nottingham 
Trent University in September 2019. In 2019, the findings were also presented 
at the 7th International Conference & Exhibition on Physiotherapy & Physical 
Rehabilitation in Italy in March, and the 9th International Lymphoedema 
Framework (ILF) conference in the USA in June.  
In January 2020, the researcher was invited to become the lymphoedema 
research chair in the King Saud University to support and oversee research that 
can contribute to the improvement of current lymphoedema practice and 
education. However, because of the COVID-19 pandemic the research work 
was postponed to October 2020. Once the thesis is complete, the study results 
will be prepared for submission to International Scientific Indexing (ISI) journals.                               
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Appendix 5: Characteristics of excluded studies in chapter 3 
 
 
Author (year) Reason for exclusion 
Sarno et al. 2014  
 
 
 
 
 
Not related, the topic or the aims of the studies did 
not fit the review inclusion criteria. 
Amarenco et al. 2003 
Viswanathan et al. 2016 
Ninomiya et al. 2015 
Arpaia et al. 2011 
Akiyama et al. 2005 
Battafarano et al. 1995 
Yokota and Tanabe 1992 
Lassmann et al. 1976 
de Andrade Freitas Oliveira et al. 2013 
Llorenç et al. 2012 
Carrick et al. 2005 
Kisimbi et al. 2013 
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Appendix 6: The Joanna Briggs Institute (JBI) prevalence critical appraisal tool. 
 
Overall appraisal: Included or Excluded or Seek further info. Answer: Yes or No or Unclear or Not Applicable (NA). 
NB: The green highlighted rows are the mandatory questions and the answer to those questions must be “yes” to include the study    
Author name (year) 
JBI prevalence critical appraisal tool question  Solaro et 
al. (2006) 
Arpaia et 
al. (2010) 
Keeley et 
al. (2017) 
Q1: Was the sample representative of the target population? N N N  
Q2: Were study participants recruited appropriately? Unclear unclear Y 
Q3: Was the sample size adequate? Y Y Y 
Q4: Were the study subjects and the setting described in detail? Y N Y 
Q5: Was the data analysis conducted with sufficient coverage of the identified sample? N  N Y 
Q6: Were objective, standardized criteria used for the measurement of the condition? Y  Unclear Y 
Q7: Was the condition measured reliably? Y Unclear  Y 
Q8: Was there appropriate statistical analysis? Y  Y Y 
Q9: Are all important confounding factors/ subgroups/ differences identified and accounted for? N  N Y 
Q10: Were subpopulations identified using objective criteria? NA   N NA 
Overall appraisal 
5/10 
Included 
2/10 
Excluded 
8/10 
Included 
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Appendix 7: Characteristics of Excluded Studies in chapter 4 
 
 
Author (year) Reasons for Exclusion 
Taylor et al. (2006) 
 
 
Abstract only. Researcher was not able to get full text, 
not even from the library inter-loan system. 
 
Plummer (2016) 
Hayes et al. (2011) 
De Souza et al. (2009) 
Aidar et al. (2017) 
Keller et al. (2016) 
 
Novotna et al. (2015) 
 
 
 
 
 
 
 
 
 
Conference abstract. 
Isner-Horobeti et al. (2014) 
Bernhardt et al. (2013) 
Jolk et al. (2013) 
Medina-Perez et al. (2012) 
Jolk et al. (2012) 
Bernhardt et al. (2012) 
Dodd et al. (2011) 
Bernhardt and Marziniak (2011) 
Aghaie et al. (2010) 
Dalgas et al. (2009) 
Kjolhede et al. (2013) 
 
Weikert et al. (2011) 
 
 
Not related, the aims of the studies did not fit the review 
inclusion criteria. 
Skjerbaek et al. (2013) 
White et al. (2004) 
Kjolhede et al. (2012) 
Wens et al. (2015) 
DeBolt et al. (2004) 
Hale (2004)  
Filipi et al. (2011) 
 
Summers (2000) Dissertation 
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Appendix 8: Cochrane Collaboration’s tool to assess the risk of bias in the included studies  
 
1 Dalgas et al. (2009) 
 
Methods  • Randomised, controlled trial conducted in Denmark. 
• Study period: 24 weeks (12 intervention + 12 follow-up) 
• Blinding of randomisation: no  
• Blinding of intervention: no 
• Complete follow-up: yes 
• Blinding of outcome measurement(s): yes 
Participants  38 participants, RT: 19 & CG: 19, mean age: RT 49.1 y & CG 47.7 y, years after diagnosis: RT=8.1 & 
CG=6.6, EDSS: 3.0-5.5, mean in RT=3.9 & CG=3.7, MS type: only RR.  
Withdrawals: 7/38 (4RT & 3CG), final participant number was: RT=16 & CG=15.  Reasons were 
worsened lower back pain and personal problems not related to the intervention. 
Adherence: 99% 
Interventions  RT: 16 participants (F=10 & M=6) 
Warm-up on stationary bicycle for 5 minutes. Every session ended with a cool-down exercise.  
The intervention was performed with 2 sessions/week for 12 weeks.  
Weight machines were used for leg presses, knee extensions, hip flexions, hamstring curls and hip 
extensions. Between each set, a 2-3 minute recovery time was given. 
*During the follow-up time, the participants were advised to continue un-supervised training.  
The progression model was as follows: 
Weeks  Sets Repetition RM 
Week 1-2 3 10 15 
Week 3-4 3 12 12 
Week 5-6 4 12 12 
Week 7-8 4 10 10 
Week 9-10 4 8 8 
Week 11-12 3 8 8 
 
  
 
280 
 
Appendices 
 
CG: 15 participants (F=10 & M=5) 
Normal physical activity until week-12. During the follow-up period, the same progressive programme that 
was used with RT was given and measured in week-24. 
Outcomes  Outcome measures were taken at baseline, week-12 and week-24. The week-24 measurement (de-
training period) was taken to see if the dependent variables were maintained. 
 
 
 Baseline Week-12 Week-24 
RT CG RT CG RT CG 
Knee flexor Maximum Voluntary 
Contraction (KF MVC) 
 
174.8 
 
168.6 
 
194.8 
 
171.6 
 
190.8 
 
190.1 
Knee extensor Maximum Voluntary 
Contraction (KE MVC) 
 
73.2 
 
67.2 
 
81.8 
 
66.4 
 
78.2 
 
71.1 
1 RM leg press 
102.4 --- 140.1 86.4 --- 114.4 
Functional Capacity Score (FS) 
100 100 121.5 96.7 121 108.9 
Chair Stand test (CST)  
12.9 12.2 9.3 12.9 9.2 9.9 
Stair-Climbing test (SCT) 
12.5 14.7 10.8 16.1 10.8 14.9 
10-minute walk test 
7.7 7.3 6.6 7.9 6.7 7.6 
6-minute walk test 
440.9 437.8 495.4 436.2 494.6 455.9 
 
Effects of PRE for 12 weeks: 
The KE MVC and KF MVC were improved by 15.7% and 37.1%, respectively, in the RT group. In the CG, 
there were no changes. Also, the FS was improved in the RT by 21.5% vs 3.3% in the CG. 
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Effects of 12-week follow-up period: 
Only the KE MVC and FS were maintained at the follow-up in the RT group. In the CG, the effects of PRE 
after the trial were similar to what the RT gained during the trial. 
Notes   
Risk of bias 
Bias  Reviewer’s judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk No information was provided other than “…randomly assigned)”. 
Allocation concealment (selection bias) Unclear risk No information was provided. 
Blinding of participants and personnel 
(performance bias) 
High risk The participants and personnel were not blinded to the intervention. 
Blinding of outcome assessment (detection 
bias) 
Low risk (… blinded pre-testing……) (post-testing and testing at follow-up were 
blinded)   
Incomplete outcome data (attrition bias) Low risk Outcome data were reported for all randomised participants. 
Selective reporting (reporting bias) Low risk Study protocol was available (NCT00381576). 
Other bias  Low risk Only RR was included.  
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2 Dalgas et al. (2010) 
 
Methods  Randomised, controlled trial conducted in Denmark. 
Study period: 24 weeks (12 intervention + 12 follow-up) 
Blinding of randomisation: no  
Blinding of intervention: no 
Complete follow-up: yes 
Blinding of outcome measurement(s): yes 
Participants  38 participants, RT: 19 & CG: 19, mean age: RT 49.1 y & CG 47.7 y, years after diagnosis: RT=8.1 & 
CG=6.6, EDSS: 3.0-5.5, mean in RT=3.9 & CG=3.7, MS type: only RR.  
Withdrawals: 7/38 (4RT & 3CG), final participant number was: RT=16 & CG=15. The reasons were: 
worsened lower back pain and personal problems not related to the intervention. 
Adherence: 99% 
Interventions  RT: 16 participants (F=10 & M=6) 
Warm-up on stationary bicycle for 5 minutes. Every session ended with a cool-down exercise.  
The intervention was performed 2 sessions/week for 12 weeks.  
 
Weight machines were used for leg presses, knee extensions, hip flexions, hamstring curls and hip 
extensions. Between each set, a 2-3 minute recovery time was given. 
*During the follow-up time, the participant was advised to continue un-supervised training.  
 
The progression model was as follows: 
 
Weeks  Sets Repetition RM 
Week 1-2 3 10 15 
Week 3-4 3 12 12 
Week 5-6 4 12 12 
Week 7-8 4 10 10 
Week 9-10 4 8 8 
Week 11-12 3 8 8 
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CG: 15 participants (F=10 & M=5) 
Normal physical activity until week-12. During the follow-up period, the same progressive programme 
used with RT was given and measured in week-24. 
Outcomes  Outcome measures were taken at baseline, week-12 and week-24. The week-24 measurement (de-
training period) was taken to see if the dependent variables were maintained. 
 
 
 Baseline Week-12 Week-24 
RT CG RT CG RT CG 
Fatigue Severity Scale (FSS) 5.8 5.5 5.2 5.6 4.9 5.1 
Multi-dimensional Fatigue Inventory (MFI-
20) 
12.9 11.6 12.1 13.7 12.7 11.8 
Major Depression Inventory (MDI) 10.3 8.8 7.9 9.9 8.7 8.9 
SF-36 for quality of life (physical 
component) 
41.4 42.6 44.9 41.6 45.3 41.5 
SF-36 for quality of life (mental 
component) 
54.3 55 56.8 53.1 55.4 57.8 
 
Effects of PRE for 12 weeks: 
Fatigue, mood and QOL showed significant difference in RT than CG.  
 
Effects of PRE at follow-up: 
No deterioration was found in the RT group compared with the baseline scores. In the CG, improvements 
were recorded in fatigue and SF-36 for quality of life (mental component), however, the mood and SF-36 
for quality of life (physical component) had no improvements.  
Notes  
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Risk of bias 
Bias  Reviewer’s judgement Support for judgement 
Random sequence generation (selection bias) Unclear bias No information was provided other than “…randomly assigned)”. 
Allocation concealment (selection bias) Unclear bias No information was provided. 
Blinding of participants and personnel 
(performance bias) 
High bias  The participants and personnel were not blinded to the intervention. 
Blinding of outcome assessment (detection 
bias) 
Low bias (…blinded pre-testing……) (post-testing and testing at follow-up were 
blinded)   
Incomplete outcome data (attrition bias) Low bias Outcome data were reported for all randomised participants. 
Selective reporting (reporting bias) Low bias Study protocol was available (NCT00381576). 
Other bias  Low bias Only RR included. 
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3 Dodd et al. (2011) 
 
Methods  Randomised, controlled trial conducted in Australia. 
Study period: 22 weeks (10 intervention + 12 follow-up) 
Blinding of randomisation: yes  
Blinding of intervention: no 
Complete follow-up: yes 
Blinding of outcome measurement(s): no 
 
Participants  52 F + 19 M = 76, RT: 39 & CG: 37, mean age: RT 47.7 y & CG 50.4 y, years after diagnosis: NA, Ambulation Index: 
between 2-4, MS type: only RR.  
Withdrawals: 5/76 (3 RT & 2 CG).  
Adherence: 92% (RT: 18.4/20 and CG: 6.2/10) 
 
Interventions  RT: 36 participants. 
Warm-up and cool-down exercises were not reported in the study.  
The intervention was performed at 2 sessions/week for 10 weeks.  
Weight machines were used for leg presses, knee extensors, calf raises, leg curls and reverse leg presses. Between each 
set, a 2-minute recovery time was given. Each session lasted for 45 minutes.  
2 sets and 10-12 repetitions of 10-12 RM. The weight was increased when 2 sets of 12 rep. could be completed. Between 
sessions, a 48-hour rest was given. 
*During the follow-up period, participants only had normal activity, with no PRE.  
 
CG: 35 participants. 
Normal physical activity and social program. The social program was given for 1 hour/week for 10 weeks. 
*During the follow-up period, the same program was followed.  
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Outcomes  Outcomes measures were taken at baseline, week-10 and week-22. The week-22 measurement (de-training period) was 
taken to see if there was any reduction in the dependent variables. 
 
 
 Baseline  Week-10 Week-22 
RT CG RT CG RT CG 
Primary outcome:  
2-minute walking test (2-MWT) 120.2 112.1 122..9 112.9 118.6 113.7 
Secondary outcomes:  
Muscle strength 70.0 62.2 85.8 66.0 80.2 68.3 
Muscle endurance 43.4 40.7 80.9 49.7 70.2 53.1 
Muscle performance 30.8 27.4 37.3 28.5 35.8 32.1 
Modified fatigue impact scale (MFIS) 41.9 40.0 31.7 37.0 39.0 36.2 
Health related quality of life (WHOQoL-Bref) 3.8 3.9 4.2 4.0 3.7 4.0 
Multiple sclerosis spasticity scale-88 (MSSS-88): stiffness 27.0 25.1 22.4 24.7 26.5 24.2 
Multiple sclerosis spasticity scale-88 (MSSS-88): spasms 22.3 22.8 20.3 23.3 23.4 21.7 
 
week-10: 
Muscle performance: leg press strength in RT increased by 16.8% but did not exceed the 26% required for minimum 
important difference. However, the reverse leg press strength in RT increased by 29.8% which exceeded the 29% required 
for minimum important difference. 
Fatigue and quality of life: total fatigue reduction in RT decreased by 5.9 units but did not exceed the 7.9 units required for 
minimum important difference. Similarly, in the QOL domain, the RT improved by 1.5 units, but this was less than the 
minimum important difference of 2.3 units.    
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week-22: 
Muscle performance: after 22 weeks, there were no significant increases in muscle performance and endurance. 
However, the decline was not to the baseline measurement point.  
Fatigue and quality of life: the fatigue domains in RT did not decrease more than the week-10 point. After week-10, this 
gradually increased to the baseline level. In QOL, after week-22, the RT group returned to the baseline level again.   
Notes  
 
Risk of bias 
Bias  
Reviewer’s 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Computer-generated random sequence. 
Allocation concealment 
(selection bias) 
Low risk Sequentially numbered opaque envelopes, containing the allocation written on a card inside. 
Blinding of participants and 
personnel (performance bias) 
High risk  Healthcare providers and participants were not blinded to the intervention. 
Blinding of outcome 
assessment (detection bias) 
High risk  Healthcare providers and participants were not blinded to the assessments. 
Incomplete outcome data 
(attrition bias) 
Low risk  Outcome data were provided for all randomised participants. 
Selective reporting (reporting 
bias) 
Low risk  Study protocol was available (ACTRN 12607000101482). 
Other bias  Low risk Only RR was included.  
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4 Kjolhede et al. (2015) 
 
Methods  Two-centre, randomised, controlled trial conducted in Denmark. 
Study period: 48 weeks (24 intervention + 24 follow-up) 
Blinding of randomisation: no  
Blinding of intervention: no 
Complete follow-up: yes 
Blinding of outcome measurement(s): no 
Participants  35 participants, RT: 18 & CG: 17, mean age: RT 43.2±8.1 y, median years after diagnosis: 5 (range 
between 0.5-28), median EDSS: 3 (range between 2-4), MS type: only RR.  
Withdrawals: 6/35 (1 RT & 5 CG), final participant number was 29 (RT=17 & CG=12). The reasons were: 
in RT: the drop-out was before the intervention began due to pain (x=1). In CG: time constraints (x=2), 
withdrawn at follow-up period due to time constraints and logistical difficulties (x=3).  
Adherence: 93±5% 
Interventions  RT: 17/18 participants (one drop-out before the intervention period) 
Warm-up and cool-down exercises were not mentioned in the study.  
The intervention was performed at 2 sessions/week for 24 weeks with 48 hours separating the sessions.  
Weight machines were used for horizontal leg presses, hip flexions, prone hamstring curls, leg extensions, 
cable pull downs and cable triceps extensions. Between each set, a 2-3 minute recovery time was given. 
*During the follow-up time, the participants were allowed to continue community self-guided training.  
 
The progression model was as follows:  
 
Weeks  Sets Repetition Intensity  
Week 1-2 3 10 15 RM 
Week 3-4 3 12 15 RM 
Week 5-6 3 10 12RM 
Week 7-8 4 10 10 RM 
Week 9-10 4 8 8 RM 
Week 11-12 4 6 6 RM 
Week 13-14 3 10 12 RM 
Week 15-16 4 10 10 RM 
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Week 17-18 4 10 10 RM 
Week 19-20 4 8 8 RM 
Week 21-22 4 6 6 RM 
Week 23-24 5 6 6 RM 
 
CG: 12/17 participants (two dropouts before the intervention period, 3 during the follow-up period). 
Normal physical activity until week-24. During the follow-up period, the same progressive programme was 
given. 
Outcomes  Outcomes measures were taken at baseline, week-24 and week-48. The week-48 measurement (follow-up 
period) was taken to see if the dependent variables were maintained. 
 
 
 Baseline Week-24 Week-48 
RT CG RT CG RT CG 
Time 25-ft Walk Test (T25FWT) 1.65 1.77 1.82 1.77 1.8 1.86 
5-time Sit To Stand (5STS) 10.0 9.0 7.9 9.3 7.4 7.7 
2-minute Walk Test (5MWT) 1.60 1.63 1.78 1.67 1.75 1.69 
12-item MS Walking Scale (MSWS-12) 32.5 27.2 24.0 26.0 31.4 20.7 
Ascending stairs climb test 11.0 12.6 9.6 13.1 9.9 12.0 
Effects of PRE for 24 weeks: 
All variables were improved during the intervention period in the RT group. In the CG, no changes were 
found in any of the variables.  
Effects of PRE at follow-up: 
After 48 weeks, the effects in the RT group were maintained, except for MSWS-12, which returned to 
baseline level. 
Notes  
 
 
Risk of bias 
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Bias  Author’s judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk  No words other than (“…subjects were randomised..”) 
Allocation concealment (selection bias) Low risk Allocation was concealed by sealed envelopes.  
Blinding of participants and personnel 
(performance bias) 
High risk Participants and personnel were not blinded to the intervention. 
Blinding of outcome assessments (detection 
bias) 
High risk Participants and personnel were not blinded to the assessments.  
Incomplete outcome data (attrition bias) Low risk All drop-out participants were included in the final analysis.   
Selective reporting (reporting bias) Low risk  Study protocol was available (NCT01518660). 
Other bias  Low risk Only RR was included. 
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5 Medina-Perez et al. (2014) 
 
Methods  Multi-centre, randomised, controlled trial conducted in Spain. 
Study period: 24 weeks (12 intervention & 12 de-training) 
Blinding of randomisation: no  
Blinding of intervention: no 
Complete follow-up: yes 
Blinding of outcome measurement(s): no 
Participants  23 F + 19 M = 42, RT: 30 & CG: 12, mean age 34.05 y, years after diagnosis in RT: 11.3±6.1 & in CG: 12.2±4.5, mean 
EDSS between 1-6 (RT: 4.5±2.1 & in CG:4.1±0.5), MS type: only RR.  
Withdrawals: no one.  
Adherence: all 42 participants completed the full intervention period with an average adherence of 22.9±1.5 out of 24 
sessions.   
Interventions  RT: 16 F + 14 M = 30 participants. 
Warm-up on stationary bicycle and 1 set of 5 repetitions with a light load. Every session ended with a cool-down 
exercise.  
The intervention was performed at 2 sessions/week for 12 weeks.  
Weight stack machines were used for knee extensors. Between each set, a 3-minute recovery time was given. 
Between sessions, a 48-hour rest was given. 
*During the follow-up period, any PRE or structured physical activity was avoided.   
The progression model was as follows:  
 
Weeks Set 1 Set 2 Set 3 
Week 1-2 35% of MVIC, 10-12 rep. 50% of MVIC, 8-10 rep 35% of MVIC, 10-12 rep 
Week 3-4 40% of MVIC, 10-12 rep. 55% of MVIC, 8-10 rep. 40% of MVIC, 10-12 rep. 
Week 5-6 45% of MVIC, 10-12 rep. 60% of MVIC, 8-10 rep. 45% of MVIC, 10-12 rep. 
Week 7-8 50% of MVIC, 10-12 rep. 65% of MVIC, 8-10 rep. 50% of MVIC, 10-12 rep. 
Week 9-10 55% of MVIC, 10-12 rep. 70% of MVIC, 8-10 rep. 55% of MVIC, 10-12 rep. 
Week 11-12 55% of MVIC, 10-12 rep. 70% of MVIC, 8-10 rep. 55% of MVIC, 10-12 rep. 
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CG: 7 F + 5 M= 12 participants. 
Normal physical activity took place. 
*During the follow-up period, any structured physical activity was avoided. 
Outcomes  Outcome measures were taken at baseline, week-12 and week-24. The week-24 measurement (de-training period) 
was taken to see if there was any reduction in the dependent variables.  
The dependent variables were:  
 
 Baseline Week-12 Week-24 
RT CG RT CG RT CG 
Maximal Voluntary Isometric 
Contraction (MVIC) 
754 615 811 606 755 604 
Maximal torque: 300 238 323 235 300 234 
Average muscle power 173 149 200 148 193 155 
Muscle endurance 21 18 22 19 20 19 
 
 
Notes   
Risk of bias 
Bias  Reviewer’s 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk  No information other than “randomly assigned”. 
Allocation concealment (selection 
bias) 
Unclear risk No information. 
Blinding of participants and 
personnel (performance bias) 
High risk Blinding of intervention: no. 
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Blinding of outcome assessment 
(detection bias) 
High risk Blinding to assessment: no. 
Incomplete outcome data (attrition 
bias) 
Low risk  Outcomes were reported for all enrolled participants.  
Selective reporting (reporting bias) Unclear risk  The protocol was not available.  
Other bias  High risk One type of MS was included. 
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6 Medina-Perez et al. (2016) 
 
Methods  Multi-centre, randomised, controlled trial conducted in Spain. 
Study period: 12 weeks of intervention  
Blinding of randomisation: no  
Blinding of intervention: no 
Blinding of outcome measurement(s): yes 
Participants  77 participants were recruited, but after withdrawals, only 40 were included and analysed (RT: 20 & CG: 
20), both genders: F = 20 & M = 20, mean age in RT = 45.6y & CG = 41.3 y, years after diagnosis in both 
groups 10.4 y, mean EDSS (RT: 3.9 & in CG: 4.2), MS type: only RR.  
Withdrawals: 37/77 participants. In RT: 18 participated in less than 75% of the sessions, 10 not assist to 
testing sessions and 2 dropped-out. In CG: 8 participated in structured physical activity and 11 not assist 
to testing sessions.  
Adherence: 95% = All 40 participants completed the full intervention period with an average adherence of 
22.8 out of 24 sessions.   
Interventions  RT: 10 F + 10 M = 20 participants. 
Warm-up on stationary bicycle. Every session end with a cool-down exercise.  
The intervention was performed at 2 sessions/week for 12 weeks.  
Weight stack machines were used for knee extensors. Between each set, a 3 minute recovery time was 
given. Between sessions, a 48-hour rest was given. The progression model was as follows:  
 
Weeks  Set  Repetitions  MVIC 
Week 1-2 3 10 40% of MVIC 
Week 3-4 3 10 50% of MVIC 
Week 5-6 4 6 50% of MVIC 
Week 7-8 3 6 60% of MVIC 
Week 9-10 4 4 60% of MVIC 
Week 11-12 3 4 70% of MVIC 
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CG: 10 F + 10 M = 20 participants. 
Normal physical activity took place. 
Outcomes  Outcome measures were taken at baseline and at week-12. 
The dependent variables were:  
 
 Baseline Week-12 
RT CG RT CG 
Maximal Voluntary Isometric 
Contraction (MVIC) 
866.4 858.5 943.1 871 
Maximal torque 360.2 353.8 392.9 358.3 
Average peak power level of MVIC 
(40%) 
266.2 278.5 317.5 269.1 
Average peak power level of MVIC 
(50%) 
288 291.9 324.8 279.8 
Average peak power level of MVIC 
(60%) 
276.3 287.5 321.8 278.9 
Average peak power level of MVIC 
(70%) 
237.1 267.8 274.3 240.2 
Average peak power level of MVIC 
(80%) 
211.5 223.8 242 189.2 
All the variables were improved in the RT group, but no changes were found in the CG.  
 
Notes  
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Risk of bias 
Bias  Author’s judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk No information was provided other than “(… participants were randomly 
assigned…)”.  
Allocation concealment (selection bias) Unclear risk  No information was provided. 
Blinding of participants and personnel 
(performance bias) 
High risk Each participant was informed about the study protocol before consenting to 
the intervention.  
Blinding of outcome assessment (detection bias) Low risk  The researcher who took the assessment was blind to the study outcomes.  
Incomplete outcome data (attrition bias) High risk  The drop-out participants were not included in the final analysis.  
Selective reporting (reporting bias) Unclear risk  The study protocol was not available and it was difficult to know if there 
were deviations from the protocol. 
Other bias  Low risk   Only RR was included.  
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7 Moradi et al. (2015) 
 
Methods  Randomised, controlled trial conducted in MS Iranian society in Iran.  
Study period: 12 weeks  
Blinding of randomisation: could not determine 
Blinding of intervention: no 
Complete follow-up: no 
Blinding of outcome measurement(s): yes 
Participants  20 males only, mean age 34.05 y, years after diagnosis in RT: 8.12±4.79 & in CG: 6.5±5.78, mean EDSS in both groups: 3, 
MS type: RT (5RR,3SP) CG (6RR, 4SP).  
Withdrawals: 2 in RT in the 1st week for personal reasons. Their matched controls were also excluded in the final evaluation. 
The other 8 RT participants completed the full intervention period with no MS related exacerbations reported.   
Interventions  RT: 
Warm-up for 5-10 minutes on a stationary bicycle or treadmill, followed by stretching. Every session ended with a cool-down 
exercise for 5-10 minutes.  
The intervention duration was 30 minutes/session, for 3 sessions/week for 8 weeks.  
Conventional weight machines were used for seated rowing, chest presses, leg extensions & presses. Between sessions, a 
24-hour rest was given. 
 
The progression model was as follows:  
 
Weeks  Sets Repetition 1 RM 
Week 1 1 6-10 50% 
Week 2 1 10-15 60% 
Week 3-4 1 10-15 70% 
Week 5-8 1 10-15 80% 
 
CG: 
Normal physical activity took place. 
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Outcomes  Outcome measures were taken at the baseline and at the end of the intervention (pre-intervention to post-intervention). 
• 10-metre time walk test: RT: decreased, CG: N/C 
• Three-minute step test: RT: increased, CG: decreased 
• Time up & go test: RT: decreased, CG: N/C  
• Flamingo stand test: RT: increased, CG: N/C 
• Seated rowing, chest presses, leg extensions & presses: RT: increased, CG: decreased 
• EDSS: RT: decreased, CG: increased 
Notes  
 
Risk of bias 
Bias  Reviewer’s 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk  Randomisation according to random digits by a table of random numbers. 
Allocation concealment 
(selection bias) 
Unclear  Could not determine. 
Blinding of participants and 
personnel (performance bias) 
Unclear  Could not determine. 
Blinding of outcome 
assessment (detection bias) 
High risk Blinding of outcome assessments: no. 
Incomplete outcome data 
(attrition bias) 
High risk The withdrawal data were disclosed but were not included in the final analysis.    
Selective reporting (reporting 
bias) 
Unclear risk The study protocol was not available and it was difficult to know if there were deviations from the protocol. 
Other bias  High risk  Only male participants were recruited and only mild to moderate MS was present.  
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Appendix 9: illustration of the average number of patients flow per week  
                      during screening phase (phase one)  
 
 
Table 1: The number of clinics in each hospital and the average number of patients  
               flow per week.  
 
KKUH 
 
 
 
 
KFSH&RC 
 
 
 
 
Abbreviations: KKUH= King Khaled University Hospital, KFSH&RC= King Faisal Specialist Hospital and 
Research Centre, C1=Clinic 1, C2=Clinic 2, N=New patient, F/O= Follow-up patient    
   
 
 
 
 
Number of clinics 
Average of patients flow per week 
Per clinic Characteristic In total 
Multiple sclerosis 
clinics 
2 
7 in C1 
15 in C2 
C1= the majority 
were N 
C2= the majority 
were F/O 
30 
Neuro-rehabilitation 
clinics 
6 1 All were F/O 6 
Lymphoedema clinic 2 8 All were F/O 16 
Medical day unite This is an in-patient unite which included 62 patients until 
31/Mar/2018   
Number of clinics 
Average of patients flow per week 
Per clinic Characteristic In total 
Multiple sclerosis clinics 3 8 
On average 5 were 
N 
32 
Neuro-rehabilitation 
clinics 
8 1 All were F/O 8 
Lymphoedema clinic 4 4 The majority were 
F/O 
16 
Medical day unite This is an in-patient unite which included 44 patients until 
31/Mar/2018  
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Table 2: Researcher timetable during each week 
 
Day 8-9 9-10 10-11 11-12 12-1 1-2 2-3 3-4 
Sun MDU    
L
u
n
c
h
 b
re
a
k
  
MDU   
Mon MDU   MDU   
Tue MDU   With Dr.Nora, KKUH 
(neurologist, MS clinic) 
Wed With Dr.Mona, KFSH&RC 
(neurologist, MS clinic) 
With Dr. Algawi, KFSH&RC 
(neurologist, MS clinic) 
Thu With Dr.Mona, KFSH&RC 
(neurologist, MS clinic) 
With Dr. Abdulgader, KKUH 
(neurologist, MS clinic) 
Abbreviations: KKUH= King Khaled University Hospital, KFSH&RC= King Faisal Specialist Hospital and 
Research Centre, MDU= Medical Day Unite 
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Appendix 10: Case report form (baseline template)  
 
 
 
 
 
 
CASE REPORT FORM 
Baseline Template  
 
 
Chronic Lower Limb Oedema in a Population of Saudi Arabian 
Residents with Multiple Sclerosis:  Evaluation of Progressive 
Resistance Exercise 
 
 
 
 
 
 
 
 
 
 
Principal Investigator:  
Name of Site:   
 
 
 
Participant initials       
Study code     
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CRF Instruction 
General  
❖ Complete the CRF using a pen and ensure that all entries are complete and legible. 
❖ Avoid the use of abbreviations and acronyms. 
❖ The CRF should be completed as soon as possible after the scheduled visit. 
❖ Do not use participant identifiers anywhere on the CRF, such as name, hospital 
number etc., in order to maintain the confidentiality of the participant. Ensure that 
the header information (i.e. participant’s initials and ID number) is completed 
consistently throughout the CRF.   
❖ Each CRF page should be signed and dated by the person completing the form. 
❖ The ‘completed by’ Name in the footer of each page must be legible and CRFs 
should only be completed by individuals delegated to complete CRFs on the Site 
Delegation log (and signed by the PI). 
❖ Ensure that all fields are completed on each page:  
• If a test was Not Done record ND in the relevant box(es) 
• Where information is Not Known write NK in relevant box(es) 
• Where information is not applicable write NA in the relevant box(es) 
 
Corrections to entries 
❖ If an error is made, draw a single line through the item, then write the correct 
entry on an appropriate blank space near the original data point on the CRF and 
initial and date the change. 
❖ Do NOT 
• Obscure the original entry by scribbling it out 
• Try to correct/ modify the original entry 
• Use correction fluid 
 
Dates and Times 
Complete all dates as day, month, year i.e. 13/05/2008. Partial dates should be 
recorded as NK/05/2008. 
 
All times are to be recorded in 24 hours format without punctuation and always use 4-
digits; i.e. 0200 or 2130. Midnight is recorded as 0000. 
 
Storage 
CRF documents should be stored in a locked, secure area when not in use where 
confidentiality can be maintained.  Ensure that they are stored separately to any other 
documents that might reveal the identity of the participant. 
 
 
 
 
 
 
 
 
 
 
 
Participant initials       
Study code     
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Baseline (T0) CRF template 
 
Date of Assessment:  __ __ / __ __ / __ __ __ __                              
                           (DD  /   MM      / YYYY) 
 
Informed Consent 
Date that participant signed written consent 
form:  
__ __ / __ __ / __ __ __ __              
(DD   /   MM         / YYYY)    
  
Name of person taking informed consent:  
__________________________________________________ 
 
Demographic Data 
Date of Birth: __ __ / __ __ / __ __ __ __                                  
 (DD  /   MM  / YYYY) 
estimated age: _______ 
Gender  o Male 
o Female              
Weight  ________ kg 
Waist circumference (cm) ________ cm 
 
Past Medical History 
1. When did you diagnosed with MS? ___________ years ago 
2. Have you experience any MS attack(s) 
in the last 6 months?  
 
o Yes    when? ___________ 
o No  
3. When was your last MS attack? ________________________ 
4. Do you have a history of any of the 
following: 
Cardiac problem: 
o Yes   when? ___________          
o No  
Renal problem:     
o Yes   when? ___________         
o No 
Liver disease: 
o Yes   when? ___________ 
o No  
Participant initials       
Study code     
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5. Do you have any history of the 
following in the last 6 months: 
Lower limb fracture 
o Yes   when? ___________ 
o No  
Ankle sprain: 
o Yes    when? ___________ 
o No   
Cancer:  
o Yes   when? ___________   
o No  
If YES, are you under medication? 
______________ 
 
 
Range of motion (ROM) 
 R L 
Plantar flexion    
Dorsiflexion    
 
 
Skin condition  
 
Skin condition in both limb area is mainly: 
 
R L 
 
+ - + - 
Dryness      
Pigmentation     
Fragility     
Redness     
Warmth     
Cellulitis     
Fungal infection     
Scars, wounds and ulcers     
Stemmer sign     
Tissues in the affected area are mainly: soft / firm  
Sensory changes: 
 
 
 
 
 
 
Muscle strength  
 
R L 
Plantar flexion 
  
Dorsiflexion 
  
Participant initials       
Study code     
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Pitting oedema test (p=pitting, NP=none pitting) 
         
Location  R L 
Toes   
  
  
Leg   
  
Thigh    
  
 
Lower Limbs circumference  
Instruction on how to make the lower limb 
circumference: (Moffatt et al. 2006) 
• Ask the patient to stand or sit with both feet firmly on the 
ground 
• On the medial aspect of the leg* measure with a ruler and 
record the distance from the floor to 2cm above the middle 
of the medial malleolus†. Mark this point on the patient. This 
determines the starting point 
• Mark the same point on the contralateral leg 
• Seat patient on a chair with bottom as close to the edge as 
possible, or seat on a couch with the leg straight lie a ruler 
along the medial aspect of the leg and mark the limb at 4cm 
intervals from the starting point to 2cm below the popliteal 
fossa for swelling below the knee 
• If swelling extends above the knee, ask the patient to stand 
or to lie on a couch. 
• Continue the marks at 4cm intervals above the knee to 2cm 
below the gluteal Crease with the limb in a relaxed position, 
measure the circumference at each mark, placing the top 
edge of the tape measure just below the mark 
• Note measurements above the knee in the correct section of 
the paper or electronic recording form 
• Repeat the process on the other limb. Ensure there are the 
same number of measurements for both legs 
Document the position the patient was in when 
measurements were taken   
 Lower limb 
R L 
Foot circumference 
(cm) 
  
  
Starting point (cm)   
Below knee (cm)   
  
  
  
  
  
  
  
Above knee (cm)   
  
  
  
R L 
Participant initials       
Study code     
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Calculating one Repetition Maximum (1RM) 
In this part, 
the participant 
will select the 
starting weight  
Planter flexion Dorsiflexion Rest 
between 
attempts 
Number 
of 
attempts  
Note 
R L R L 
Final weight  Kg kg Kg kg   Started weight: 
 
Participant’s PRE programme for 12 weeks 
 1-RM 40% 1-RM 50% 1-RM 60% 1-RM 70% 1-RM 
R  L  R  L  R  L  R  L  R  L  
Planter flexion           
Dorsiflexion            
 
Week 
number 
Session 
number 
% of 1RM Repetitions  sets Rest 
between 
sets 
Note 
Week 1 Session 
1 
 
R  
PF 40%=          kg 
 
L  
PF 40%=         kg 10 3 min  
 
 
 
DF 40%=         kg 
 
DF 40%=         kg 
 
Principal Investigator’s Name:                                                                               Principal Investigator’s Signature: 
                                                         
CLLO & MS  13-Feb-21 
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Appendix 11: Case report form (follow-up template) 
 
 
 
 
 
 
CASE REPORT FORM 
Follow-up template 
 
Chronic Lower Limb Oedema in a Population of Saudi Arabian 
Residents with Multiple Sclerosis:  Evaluation of Progressive 
Resistance Exercise 
 
 
 
 
 
 
 
 
 
 
Principal Investigator:  
Name of Site:   
 
  
           
 
 
 
 
 
 
 
Participant initials       
Study code     
Follow-up template  
 
                                    
CLLO&MC  13-Feb-21 
Participant initials       
Study code     
308 
Appendices 
Follow-up Template  
 
Date  Week 
number 
Session 
number 
% of 1RM Repetitions  sets Rest 
between 
sets  
Note  
 
Signature  
 
Week 1 Session 2 40%=         
kg 
10 3  
        min 
 
 
 
 
 
Week 2 Session 3 40%=         
kg 
10 3   
 
 
 
 
Session 4 40%=         
kg 
10 3   
 
 
 
 
Week 3 Session 5 50%=         
kg 
10 3   
 
 
 
 
Session 6  50%=         
kg 
10 3   
 
 
 
 
Week 4 Session 7 50%=         
kg 
10 3   
 
 
 
 
Session 8 50%=         
kg 
10 3   
 
 
 
 
Follow-up template  
 
                                    
CLLO&MC  13-Feb-21 
Participant initials       
Study code     
309 
Appendices 
Date  
Week 
number 
Session 
number 
% of 1RM Repetitions  sets Rest 
between 
sets  
Note  
 
Signature  
 
Week 5 Session 9 50%=         
kg 
06 4   
 
 
 
 
Session 10 50%=         
kg 
06 4   
 
 
 
 
Week 6 Session 11  50%=         
kg 
06 4   
 
 
 
 
Session 12 50%=         
kg 
06 4   
 
 
 
 
Week 7 Session 13 60%=         
kg 
06 3   
 
 
 
 
Session 14 60%=         
kg 
06 3   
 
 
 
 
Week 8 Session 15  60%=         
kg 
06 3   
 
 
 
 
Session 16 60%=         
kg 
06 3   
 
 
Follow-up template  
 
                                    
CLLO&MC  13-Feb-21 
Participant initials       
Study code     
310 
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Date  
Week 
number 
Session 
number 
% of 1RM Repetitions  sets Rest 
between 
sets  
Note  
 
Signature  
 
Week 9 Session 17  60%=         
kg 
04 4   
 
 
 
 
Session 18  60%=         
kg 
04 4   
 
 
 
 
Week 
10 
Session 19 60%=         
kg 
04 4   
 
 
 
 
Session 20 60%=         
kg 
04 4   
 
 
 
 
Week 
11 
Session 21 70%=         
kg 
04 3   
 
 
 
 
Session 22 70%=         
kg 
04 3   
 
 
 
 
Week 
12 
Session 23 70%=         
kg 
04 3   
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Appendix 12: Case report form (discharge template) 
 
 
 
 
 
 
CASE REPORT FORM 
Discharge Template  
 
 
Chronic Lower Limb Oedema in a Population of Saudi 
Arabian Residents with Multiple Sclerosis:  Evaluation of 
Progressive Resistance Exercise 
 
 
 
 
 
 
 
 
 
 
Principal Investigator:  
Name of Site:   
 
 
 
 
 
 
Participant initials       
Study code     
 
Participant initials       
Study code     
 
CLLO&MC  13-Feb-21 312 
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Discharge (T1) Template  
 
Discharge (T1) Template  
 
Date of Discharge Assessment:  __ __ / __ __ / __ __ __ __                              
                                          (DD     /      MM  /     YYYY) 
 
Week 
number 
Session 
number 
% of 1RM Repetitions  sets Rest 
between 
sets 
Note  
Week 1 Session 
1 
 
R  
PF 40%=          
kg 
 
L  
PF 40%=         
kg 
10 3 min  
 
DF 40%=         
kg 
 
DF 40%=        
kg 
 
 
Demographic Data 
Weight  ________ kg 
Waist circumference (cm) ________ cm 
    
Range of motion (ROM) 
 R L 
Planter flexion    
Dorsiflexion    
 
Skin condition  
 
Skin condition in both limb area is mainly: 
 
R L 
 
+ - + - 
Dryness      
Pigmentation     
Fragility     
Redness     
Warmth     
Cellulitis     
Fungal infection     
Scares, wounds and ulcers     
Stemmer sign     
Tissues in the effected area are mainly: soft / firm  
Sensory changes: 
 
Muscle strength 
 
R L 
Planter flexion 
  
Dorsiflexion 
  
 
Participant initials       
Study code     
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Discharge (T1) Template  
Pitting oedema test (p=pitting, NP=none pitting) 
         
Location  R L 
Toes   
  
  
Leg   
  
Thigh    
  
 
Lower Limbs circumference  
Instruction on how to make the lower limb 
circumference: (Moffatt et al. 2006) 
• Ask the patient to stand or sit with both feet firmly on the 
ground 
• On the medial aspect of the leg* measure with a ruler and 
record the distance from the floor to 2cm above the middle 
of the medial malleolus†. Mark this point on the patient. This 
determines the starting point 
• Mark the same point on the contralateral leg 
• Seat patient on a chair with bottom as close to the edge as 
possible, or seat on a couch with the leg straight lie a ruler 
along the medial aspect of the leg and mark the limb at 4cm 
intervals from the starting point to 2cm below the popliteal 
fossa for swelling below the knee 
• If swelling extends above the knee, ask the patient to stand 
or to lie on a couch. 
• Continue the marks at 4cm intervals above the knee to 2cm 
below the gluteal Crease with the limb in a relaxed position, 
measure the circumference at each mark, placing the top 
edge of the tape measure just below the mark 
• Note measurements above the knee in the correct section of 
the paper or electronic recording form 
• Repeat the process on the other limb. Ensure there are the 
same number of measurements for both legs 
Document the position the patient was in when measurements 
were taken   
 Lower limb 
R L 
Foot circumference 
(cm) 
  
  
Starting point (cm)   
Below knee (cm)   
  
  
  
  
  
  
  
Above knee (cm)   
  
  
  
 
 
 
 
 
R 
 
Participant initials       
Study code     
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Discharge (T1) Template  
Study completion  
 
Did participant complete the trial? o Yes  
 
o No, Please provide date of 
withdrawal and complete below: 
 
     __ __ / __ __ / 2 0 __ __ 
Early Withdrawal: please provide the reason(s) of participant’s early 
withdrawal: 
 
 
Principal Investigator’s Name: 
 
 
 
Date of Signature:  
        __ __ / __ __ / 20 __ __ 
          
Principal Investigator’s Signature: 
 
 
ONCE SIGNED, NO FURTHER CHANGES CAN BE MADE TO THIS CRF 
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Appendix 13: Arabic version of short form of the McGill pain questionnaire  
                       (SF-MPQ) 
 
 
 الصيغة الموجزة مكجيل الستبيان اآللم
 رونالد ميلزاك 
 
 
ــ                         اسم المريض: ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ          التاريخ: ــــــــــــــــــــــــــــــــــــــــــــــــ
 
 
 مرتفع  متوسط  خفيف  ال يوجد 
 الم نابض 
    
 الم شديد 
    
 الوخز 
    
 حار 
    
 التشنج 
    
 القضم 
    
 حرق شديد 
    
 مؤلم 
    
 ثقيل 
    
 رقيق
    
 انشطار 
    
 تعب. انهاك 
    
 الغثيان 
    
 الخوف 
    
 الم قاس للغايه
    
 
 
 ـــــــ| أسوء ألم ممكن|ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــال يوجد ألم 
 
 مقدار األلم حاليا: 
  ال يوجد ألم  ٠
  خفيف  ١
  مزعج ٢
  مقلق  ٣
  مخيف  ٤
  موجع  ٥
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Appendix 14: Arabic translation of quality of life measure for limb  
                       lymphoedema (LYMQOL) tool (lower limb part) 
 
LYMQOL LEG 
 
 
 أداة نوعية الحياة لمرضى الوذمة اللمفية 
م هذا االستبيان وتم التحقق من صحته للمرضى الذين يعانون من  في إحدى الساقين أو  تورم او انتفاخ مزمنُصمَّ
 كلتيهما لقياس نوعية الحياة. 
 يُرجى وضع عالمة في المربع الذي يوفر أفضل وصف لما تشعر به بشأن كل سؤال من األسئلة. 
 
 ………………………  المستشفى:……………………        رقم االسم: …………………
 التاريخ: …………………………
 
 ساقك المتورمة على األنشطة التالية؟ ( ما مدى تأثير ١)س 
ك، يُرجى كتابة ال في حالة عدم انطباق أي عنصر على حالت 
 ينطبق في مربع )مربعات( اإلجابة ذي الصلة. 
 
 
                      ( هل يؤثر التورم في أنشطتك الترفيهية/حياتك االجتماعية؟٢)س 
 يُرجى ضرب أمثلة على ذلك 
 
 ........................................................................................................... .......................................................... 
 
 ............................................................................................................................................ .................. 
 
 
 
 ما مدى حاجتك لالعتماد على أشخاص آخرين؟ ( ٣)س
 
 
 
 
 
 
 
على  ال تؤثر
 اإلطالق 
 إلى حد  قليالا 
 بعيد
ا   كثيرا
a)  قدرتك على المشي 
     
b)  قدرتك على االنحناء، على سبيل المثال. لربط أربطة الحذاء أو قص
 أظافر أصابع القدم 
    
c)  قدرتك على الوقوف 
    
d)  قدرتك على النهوض من وضع الجلوس على كرسي 
 
    
e)  عملك 
    
f)  قدرتك على أداء الواجبات المنزلية 
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 في األسبوع الماضي….
 ( بوجه عام، كيف تقيم نوعية حياتك في الوقت الحاضر؟ ٢٢)س
 
 ال يحدث 
 على اإلطالق 
 إلى حد  قليالا 
 بعيد
ا   كثيرا
 ( ما مدى شعورك بأن التورم يؤثر في مظهرك؟ ٤)س
    
 ( ما مدى الصعوبة التي تواجهها للعثور على المالبس ٥)س
 المناسبة؟        
    
  ( ما مدى الصعوبة التي تواجهها للعثور على المالبس التي ٦)س
 تحب أن ترتديها؟        
    
 العثور على األحذية المناسبة؟( هل تجد صعوبة في ٧)س
    
 ( هل تجد صعوبة في العثور على الجوارب / الرداءات المحكمة ٨)س
 الجوارب النسائية المناسبة؟ /         
    
 ( هل يؤثر التورم في شعورك بنفسك؟٩)س
    
 ( هل يؤثر في عالقاتك مع اآلخرين؟ ١٠)س
    
 شعورك باأللم؟ ( هل تتسبب الوذمة اللمفية في ١١)س
 
    
 ( هل تعاني من أي تنميل في ساقك )ساقيك( المتورمة؟ ١٢)س
 
    
 ( هل تشعر بوخز "دبابيس وإبر" أو وخز في ساقك )ساقيك( ١٣)س
 المتورمة؟            
    
 ( هل تشعر بضعف في ساقك )ساقيك( المتورمة؟ ١٤)س
    
 المتورمة؟( هل تشعر بثقل في ساقك )ساقيك( ١٥)س
    
 
ال على 
 اإلطالق 
ا  إلى حد بعيد  قليالا   كثيرا
 ( هل واجهتك مشاكل في النوم؟١٦)س
    
 مثل القراءة؟ ( هل واجهت صعوبة في التركيز على األشياء، ١٧)س
    
 ( هل شعرت بالتوتر؟١٨)س
    
 ( هل شعرت بالقلق؟ ١٩)س
    
 بالتهيج؟ ( هل شعرت ٢٠)س
    
 ( هل شعرت باالكتئاب؟٢١)س
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 يُرجى وضع عالمة على درجتك على المقياس التالي:          
 
 
١٠ ٩ ٨ ٧ ٦ ٥ ٤ ٣ ٢ ١ ٠ 
 ممتاز          ضعيف 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ا لك إلكمال هذا   النموذج. شكرا
 إذا كانت لديك أي تعليقات أو استفسارات حول هذا الموضوع، فيُرجى مناقشتها مع ……………
 . EORTCبإذن من  21إلى  16تم نسخ األسئلة من 
ا من استبيانتعد هذه األسئلة   C30-QLQ جزءا
 
 Ref  LEG V II  2007حقوق الطبع والنشر نوفمبر 
استخدام هذا المستند أو استنساخه بحرية شريطة أن يظل بيان حقوق الطبع هذا سليًما، وأن يُعترف بالمصدر، جميع الحقوق محفوظة. يمكن 
فوان كيلي،  وأن يقوم المستخدم بالتسجيل، وأال تتم أي تغييرات دون إذن المؤلف. يجب تقديم طلب اإلذن والتسجيل كتابة إلى الدكتور
 ,  DE22 3NE  توكستر، دربي ، طريق أوالملكي  ديربي اللمفية، مستشفى  استشاري الطب التلطيفي، عيادة الوذمة
 
